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ABSTRACT
Globoid cell leukodystrophy (GLD) is a rare lysosomal storage disorder (LSD) due to 
the deficiency of the lysosomal enzyme Galactocerebrosidase (GALC). The enzymatic 
deficiency results in intracellular storage of undegraded metabolites in the nervous system, 
leading to progressive dysmyelination. We are testing the feasibility and efficacy of a gene 
therapy strategy based on hematopoietic stem/progenitor cells (HSPC) and lentiviral 
vectors (LV) in the murine model of GLD. Differently from what observed with other 
lysosomal enzymes, GALC gene transfer and expression in HSPC causes apoptosis and 
functional impairment of the transduced cells due to an inbalance of the intracellular 
content in bioactive sphingolipids consequent to de novo enzyme expression. Differentiated 
cells of the myeloid and lymphoid lineages are not affected by GALC expression, 
suggesting a unique sensitivity of HSPC to enzyme toxicity.
To overcome this issue, we explored strategies aimed at de-targeting vector expression 
from HSPC, while permitting GALC over-expression in differentiated cells. The first 
approach aims at a transcriptional regulation of GALC expression by the 
microglia/macrophage specific promoter CD lib . The second strategy exploits endogenous 
microRNAs for post-transcriptional regulation of GALC expression. The use of LV 
containing the target sequence of miRNA126, expressed only in HSPC, allows expressing 
GALC only in the differentiated progeny of transduced HSPC. Although these two 
approaches proved to be very promising in protecting HSPC from enzyme toxicity both in 
vitro and in vivo in heterozygous GLD mice, gene-corrected HSPC failed to repopulate 
lethally irradiated homozygous GLD mice. This poor result might be explained by the 
existence of a niche defect in homozygous GLD mice, which might hamper the 
engraftment of HSPC.
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1. Globoid Cell Leukodystrophy
1.1 Lysosomal Storage Disorders
Lysosomal storage disorders (LSDs) are a group of inherited disorders caused by 
defects in the genes which control the lysosomal degradation of naturally occurring 
proteins, glycoproteins, sphingolipids, glycosaminoglycans (GAGS) and carbohydrates, 
and the transport of certain smaller molecules from lysosomes. The likelihood of an 
individual being affected with an LSD is estimated to occur in about 1 in 5000-8000 
births in the United States and Europe \  The majority of LSDs are caused by mutations 
in the genes coding for lysosomal enzymes and most are inherited in an autosomal 
recessive manner. Depending on the specificity of the enzyme and the nature of the 
mutation, there will be one or more substrates whose catabolism is affected by the 
deficiency. Tissues with no naturally present substrate will have little or no pathology, 
while the accumulation of undegraded material in cells where the substrate is 
physiologically present, usually results in cellular pathology. In addition to the 
pathology caused by engorging the lysosomes with undegraded storage products, 
possibly disrupting normal lysosomal functions, some undegraded products may be 
toxic to other organelles leading to the death of certain cell types.
Although the majority of LSDs are caused by defects in the lysosomal enzymes 
directly involved in catabolism, some LSDs are due to defects in the sphingolipid 
activator proteins, saposins which are required for interactions between sphingolipid 
substrates and the enzyme. In addition, a few other LSDs are caused by defects in the 
enzymes involved in post-translational modification of lysosomal enzymes.
1.2 Globoid Cell Leukodystrophy: clinical manifestation
Globoid Cell Leukodystrophy (GLD), or Krabbe disease, is an autosomal recessive 
LSD caused by deficiency of the lysosomal enzyme Galactocerebrosidase (GALC) 
which catalyzes the catabolism of galactosylceramide (GalCer). It is a rare LSD, with an 
incidence of 1 in 100,000 live births worldwide. GLD was first described in children as 
a syndrome that began during infancy and was characterized by tonic spasms, 
nystagmus, muscular rigidity, progressive quadriplegia and early death 2 3. It affects both 
the central nervous system (CNS) and the peripheral nervous system (PNS) and the 
typical neuropathological finding includes generalized brain atrophy with the central 
white matter being replaced by gliotic tissue. Postmortem examination of affected 
individuals reveals loss of myelin, degeneration of long spinal tracts, gliosis and 
infiltration of characteristic globoid cells of macrophage-microglia origin. The prognosis 
is severe, leading to death a few years after diagnosis. Clinically, GLD is classified 
according to the patient’s age at onset. Different forms of GLD exist: early infantile (El), 
late infantile (LI), juvenile (J) and adult (AD). The most severe variant is the one with El 
presentation, which accounts for over 90% of patients, becoming manifest within six 
months of age in most cases 4 and developing in four stages 3:
Pre-symptomatic stage: infants are able to fix and follow visual targets and can 
reach for objects.
Stage 1 (3 to 4 months): photic and auditory sensitivity, extreme irritability, 
neurogenic fever, developmental arrest followed by regression and tonic spasms.
Stage 2: tonic flexion of arms and extension of legs, loss of all previously acquired 
skills, seizures, optic atrophy and blindness.
Stage 3 (before 12 months): immobile, decerebrate and unable to feed.
The LI variant is much less common and begins between 19 months and four years 
of age 5. These patients have only moderate mental retardation during the first years, but 
gradually develop ataxia, and spasticity. Peripheral neuropathy is severe. Disease
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progression is slower than in El manifestation, with visual loss, mental regression, 
seizures and deafness. The prognosis is severe, leading to death 5-7 years after 
diagnosis.
The late-onset variants are the J (onset at 4 to 19 years) and the AD forms (>20 
years). These are characterized by a slowly progressive tetraplegia, sensor-motor 
demyelinating neuropathy and preserved mental function; survival into the seventh
vr 7
decade is possible
1.3 GALC: the gene and the enzyme
The GALC gene was mapped in 1990 by restriction fragment length polymorphism 
(RFLP) studies: it lies at 14q31 and spans 17 exons over a 60 kb interval8. The 5’ UTR 
region, considered as the promoter region, contains 13 GGC sequences and binding sites 
for SP1, YY1, E2F and AP3 trascription factors 9. CAAT sequences or TATA box, 
present in the promoter regions of other lysosomal enzymes, are absent in the GALC 
promoter. At the 5’ end of the first intron, 6 binding sites for Spl, 1 for API and 8 for 
AP2, were found. The presence of an inhibitory region, from 800 bp to 300 bp upstream 
of the start codon, together with a sub optimal transcription start site and the general 
weakness of the promoter, could explain the low level of the GALC enzyme detected in 
all tissues examined so far (i.e. fibroblasts, leukocytes). GALC is also expressed at a low 
level in the nervous system, where the first substrate of GALC, GalCer is present in high 
concentration 10.
The GALC cDNA, encodes a 669 residue protein of about 80 kDa with a 26 amino 
acid leader sequence 4. In the lysosome, this pro-enzyme is further cleaved to a 50 kDa 
amino terminal and a 30 kDa carboxy terminal subunits. These subunits associate to 
form the functional enzymatic complex n .
GALC works within the lysosome at low pH (between 4 and 4.4), together with
1 9activators such as Saposine A and C . The main substrates of GALC are GalCer and
12
Psychosine (Psy): GalCer is hydrolyzed to ceramide (Cer), while Psy is hydrolyzed to 
Sphingosine (So). Other substrates of GALC are Monogalactosyldiglyceride (MGD) and 
Lactosylceramide (LacCer) 13 (Figure 1).
Plasmatic
-membrane
ER
Lysosome
GALC
Figure 1. G A L C  pathw ay. G alactocerebrosidase (G A LC ) catalyzes the hydrolysis o f  
G alactosylceram ide to C eram ide in the lysosom e. C eram ide is also produced at the level o f  
plasm atic m em brane (de-novo biosynthesis), w hile it is converted  to G alactosylceram ide by 
C eram ide-galactosyltransferase (CG T) in the endoplasm ic reticulum  (ER). GLUC: 
G lucocerebrosidase; SM ase: Sphingom yelinase; SPH-K: Sphingosine kinase; ARSA:
A rylsufatase A; SGT: Sphingosine-galactosyltransferase; G A LC II: G alactocerebrosidase II.
The most relevant o f these substrates is GalCer, produced from Cer by Ceramide- 
Galactosyltransferase (CGT) in the endoplasmic reticulum and from sulfatide by 
Arylsulfatase A (ARSA) in the lysosome. GalCer and sulfatides represent one third of 
the whole lipidic myelin mass 14. Moreover, GalCer is implicated in the transduction of 
signals for oligodendrocytes differentiation and in axon-glia interaction at paranode 
level 15 16. Although GalCer is the first substrate o f GALC, it does not accumulate in 
GALC deficient tissues, likely due to the activity of a different galactocerebrosidase (see 
paragraph 1.4). GALC deficiency is actually responsible for Psy accumulation, up to 10- 
20 times normal levels in human infants and animal models. This toxic storage has been
shown to kill oligodendrocytes by an apoptotic mechanism, resulting in a greatly 
diminished amount o f myelin and astrocytic gliosis and the production of the 
characteristic globoid cells (for details, see paragraph 1.4).
As shown in figure 1, Cer, the first product of GALC, can be considered to be a 
metabolic hub since it occupies a central position in sphingolipid biosynthesis and 
catabolism. Cer and other molecules o f this pathway, such as So and Sphingosine-1- 
Phosphate (SIP), are considered “bioactive sphingolipids” : they act as signals regulating 
a vast number o f cellular processes. Cer has been implicated in differentiation, cell cycle 
arrest and senescence in several cell types, but the most studied function is its role as a 
pro-apoptotic molecule 17 18. An accumulation o f Cer has been observed prior to the
19 20 21activation of execution caspases but downstream of initiation caspase . So has also 
been demonstrated to have a pro-apoptotic activity in a Cer-independent manner, while 
SIP  promotes proliferation, survival and inhibition o f apoptosis 22. In addition to the 
vast number o f processes that sphingolipids are associated with, further levels of 
complexity arise from the metabolic interconnection o f bioactive lipids.
1.4 Pathogenetic mechanism
1.4.1 Accumulation o f Psychosine
After GALC was identified as the gene responsible for GLD 23, the lack of 
accumulation o f GalCer in the white matter o f GLD patients and the observation of Psy 
storage was an unexpected finding. It was first hypothesized that this could be due to the 
early death o f accumulating oligodendrocytes 24. Subsequently, several hypotheses were 
formulated:
• GalCer might be converted to Psy by N-Deacilase, but the existence of this
25alternative pathway has never been demonstrated (figure 1).
14
• Psy is also obtained through galactosylation o f sphingosine by UDP-
9 f\Galactose:sphingosinel-|3-Galactosyltransferase . In physiological conditions, 
GALC converts Psy to sphingosine and hydrolyzes GalCer to Cer; in the absence 
of GALC, GalCer could be hydrolyzed by Galactosylceramidase II. This 
enzyme, deficient in GM1 Gangliosidosis, has a low affinity for Psy, which is 
not metabolized and accumulates in the white matter and, to a lesser extent, in 
other tissues 27 (Figure 1).
1.4.2 Toxic effects o f Psychosine storage
Since sphingolipids and Psy precursors are abundant in myelin, the accumulation o f 
Psy mainly affects myelin forming cells, such as oligodendrocytes and Schwann cells. In 
affected subjects these cells are rapidly lost; in early onset-forms this loss occurs mainly 
during the early stages o f brain development. Although the toxic effect of Psy storage 
has been studied in depth, it is still not fully understood. Psy acts mainly in 
mitochondria, both by a specific inhibition o f cytochrome C oxidase and the aspecific 
alteration of mitochondrial membranes 28. In vitro studies on oligodendrocyte progenitor 
cells have demonstrated that caspases 8, 9 and 3 are involved in Psy-induced apoptosis 
29. Further studies have shown that Psy-induced cell death also involves the activation of 
secretory phospholipase A2 (sPLA2), which generates lysophosphatidylcholine and 
arachidonic acid. sPLA2 activation also leads to oxygen-reactive species (ROS) 
production and oxidative stress 30. As well as the activation o f oxidative stress and 
apoptotic oligodendrocyte cell death, Psy down-regulates survival pathways including 
nuclear factor-kB and PI3K-Akt.
Several studies have reported the expression o f pro-inflammatory cytokines and 
chemokines in cell cultures from GLD patients and twitcher mice, a murine model of 
GLD (see paragraph 1.6). Moreover, expression of iNOS and glial fibrillary acidic 
protein (GFAP) in activated astrocytes in the CNS of GLD patients, indicates the
15
involvement o f an inflammatory process in the pathogenesis o f GLD. In astrocytes, Psy 
maintains the production of inflammatory mediators by inducing the nuclear 
translocation o f the transcriptional factor C/EPB, which, in turn, stimulates the 
production o f IL-6, IL-1|3 and TN F-a 30. Further studies have shown that Psy mediates 
the inactivation o f AMP-activated protein kinase (MAPK): this results in an alteration of
30 31 32lipids both in astrocytes and oligodendrocytes and in up-regulation o f C/EPB ’ .
Psy also induces alterations at the level o f peroxisomes, involved in the biosynthesis 
o f plasmalogens (important constituents of myelin), in |3-oxidation of fatty acids and in 
detoxification from H2O2 . Indeed, Psy acts by up-regulating sPLA2, which results in the 
down-regulation o f PPAR-a, a factor involved in the transcriptional regulation of
32peroxisomal proteins
Psy also accumulates into microglia, leading to the formation o f globoid cells (GC). 
GC have mainly been observed in less recent CNS lesions of GLD patients 33: these cells 
o f the monocytic lineage, are positive to PAS-staining and display microglia-specific 
markers, such as vimentin and ferritin 34. In the CNS of GLD patients, the presence of 
pro-inflammatory cytokines secreted by astrocytes, together with the debris o f dead 
oligodendrocytes, contribute to the generation o f a neuroinflammatory environment and 
the activation o f microglia. Activated microglia engulf dead cells and Psy but are unable 
to metabolize this toxic molecule due to the GALC deficiency. The origin of GC seems 
to be caused by the effect o f Psy on the cell cycle regulation: Psy inhibits cytokinesis 
without inhibiting cell division 35, leading to the formation of giant GC, filled with non­
metabolized m ateria l36 which impairs their scavenger activity. As a direct consequence,
37 38the cellular debris cannot be cleared, thus further worsening neuroinflammation 
(Figure 2).
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Figure 2. Form ation o f globoid cells. Inflam m atory  cytokines secreted by astrocytes and 
cellu lar debris activate resting m icroglia. A ctivated m icroglia en g u lf dead cells and Psy, w hich is 
stored in toxic deposits and leads to globoid  cell form ation.
The role of Psy in the occurrence of inflammation and immune activation of 
peripheral blood mononuclear cells (PBMC) has recently been demonstrated. PBMC 
from GLD patients show a basal pro-inflammatory pattern and an increased production 
o f pro-inflammatory cytokines, which seems to be induced and amplified by Psy upon in 
vitro administration 39. The Psy-induced pro-inflammatory response has been also 
observed in the liver of twitcher mice. Although the level o f Psy accumulation in the 
liver is lower than that found in the nervous system, the toxic metabolite storage can 
trigger the induction o f an inflammatory response which in turn, increases expression of 
pro-inflammatory cytokines, such as TN F-a and IL-6. Moreover, although the storage of 
Psy per  gram o f liver tissue is low, given the large size o f the liver itself, this organ may 
represent an important Psy reservoir 40.
1.5 Diagnosis
1.5.1 Clinical features that suggest an LSD
The diagnosis o f a patient with an LSD, initially requires a physician to consider 
whether the individual’s clinical features are suggestive o f this possibility. LSDs should
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be considered in any individual experiencing developmental delay, loss of learning 
skills, ataxia, seizures and dementia, in the presence or absence of hepatosplenomegaly 
and other somatic changes. This is especially true if  the individual is regressing after a 
period o f relatively normal development and if  the disease seems progressive. It should 
be remembered that most LSDs are progressive and early diagnosis is o f the utmost 
importance, both for genetic counseling purposes and consideration for treatment. 
Neurological symptoms, in the absence of additional findings, could signal GLD, 
metachromatic leukodystrophy (MLD), neuronal ceroid lipofuscinoses or Schindler’s 
disease. Patients with mild to severe neurological symptoms who are also o f short 
stature and have evidence of coarse facial features, hepatosplenomegaly, corneal 
clouding and /or unusual skin findings, require a larger battery of tests which include 
analysis for mucopolysaccharidosis (MPS) and Gaucher disease, so as to arrive at a 
definitive diagnosis (Table 1).
Nam e o f disease Defective protein Initial signs and sym ptom s
Metachromatic 
leukodystrophy (M LD)
Arylsulfatase A
LI: weakness, hypotonia, 
developmental delay, genu 
recurvatum
JU: weakness, ataxia, behaviour 
changes
AD: pyramidal or cerebellar signs, 
psychoses, behaviour changes, 
dementia
Globoid cell leukodystrophy 
(GLD)
Galactocerebrosidase
EI-LI: spasticity, irritability, 
hypotonia, fisting, developmental 
delay
JU-AD: spastic paraparesis, 
weakness, burning paresthesia, ataxia, 
vision loss
M ucopolysaccharidosis type 
I Hurler (MPS I)
a-L-iduronidase
Coarse facial features, developmental 
delay, dysostosis multiplex, mental 
retardation, hearing loss, comeal 
clouding, hernias
Gaucher disease types II 
and III
Glucocerebrosidase
Hepatosplenomegaly, developmental 
delay, strabismus, seizures, 
m yoclonus, horizontal supranuclear 
gaze palsy
Table 1. E xam ples o f  LSD with neurological sym ptom s (M LD  and G LD) or with  
n eurological, v isceral and skeletal m anifestations (M PS I and G aucher disease).
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1.5.2 Diagnostic instrumental evaluation of GLD
A patient suspected of having GLD, according to neurological symptoms, should 
have a magnetic resonance imaging (MRI) scan to evaluate the white matter: infants 
with El and LI GLD have abnormal T1 and T2 intensity, indicating a loss of myelin in 
the posterior limb of the internal capsule. As the disease progresses, gray matter atrophy 
and abnormality of cerebellar white matter and pyramidal tracts develop 41 42. With the 
progression o f GLD, all white matter structures become abnormal, with a high signal in 
T1-weighted images in the thalamus, suggesting a paramagnetic effect due to the 
presence of hydrophilic material. At postmortem, these regions show an abundant 
infiltration of GC and macrophages and severe demyelination. JU and AD GLD can 
present with relatively mild changes in the posterior corpus callosum and parieto-
• • 1 1 - 43 44 45occipital white matter
Electrophysiological studies and electroencephalograms (EEG) are helpful in 
evaluating nerve conduction and monitoring disease progression. The severity of the 
abnormalities detected by electrophysiological testing (slow nerve conduction), usually 
correlates with the severity o f the abnormalities on MRI scans. EEG is usually normal at 
the early stages of the disease, but generalized slowing and multifocal epileptic spikes 
are observed in the later stages 46.
1.5.3 Enzymatic activity and genetic diagnosis
The accurate diagnosis of patients, especially those early in the course of their 
disease, is a challenge for both the clinician and the laboratory performing diagnostic 
testing. As clinical features frequently overlap. Between different LSDs as well as other 
genetic and non-genetic disorders, a wide range o f tests may be indicated after 
examination of a patient. Testing of most LSDs usually entails the measurement of 
enzymatic activities, using synthetic or natural substrates in easily obtained tissue
19
samples, detection o f an abnormal level of a metabolic product in cells or urine, or 
identification o f a known mutation in certain families or within certain ethnic groups.
1.5.3.1 Enzymatic activity
Most LSDs can be diagnosed by measuring the activity of selected enzymes with 
commercially available synthetic or radiolabeled natural substrates, using an appropriate 
sample sent to a laboratory. Typically, the finding of low activity for one lysosomal 
enzyme and normal values for others, results in a diagnosis. The specific test to confirm 
the diagnosis o f GLD, is the measurement of GALC activity in serum, leukocytes or 
fibroblasts, using a 3H-GalCer. W hile normal values range between 0,9-4,4 nmol/h/mg 
47, in GLD patients the average o f measured GALC activity is 0,07 nmol/h/mg 48. The 
reduction of GALC activity can be further confirmed by repeating the same test on 
cerebrospinal fluid.
1.5.3.2 Molecular analysis
Over 40 different genes are involved in LSDs and most are inherited in an 
autosomal recessive manner. Many disease causing mutations and polymorphic changes 
have been identified in these genes and many patients are compound heterozygotes, 
having two different mutations in the two copies o f the same gene. This results in the 
wide range of clinical features that is characteristic o f most LSDs and is responsible for 
the difficulty in predicting the clinical course of newly diagnosed patients, especially 
those with J and AD onset. The use o f molecular analysis may be beneficial once 
diagnosis has been made, to aid carrier screening of family members.
Since defects in Saposine A (SapA), the activator o f GALC, may also cause GLD 49, 
genetic testing is the definitive test for GLD diagnosis. In SapA -/- patients, the reduced 
GALC activity is not due to a defect in the GALC gene, but to the loss of function of 
Sap A, which is essential for GALC functionality. Seventy-eight variants o f the more
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common GALC sequence have been identified to date (The Human Gene Mutation 
Database at the Institute o f Medical Genetics in Cardiff -  update: December 2007). 
Among these variants, over 60 mutations affecting GALC are associated with GLD, 
including base transitions, single amino acidic substitutions and deletions. A 30 kb 
deletion, from the intron 10 to the 3 ’ end of the gene, is present in 40-50% of cases of El 
and LI GLD in Europe 8 50. This allele frequently carries a polymorphism present in 4% 
of the population, a C to T transition at position 502. Most o f the mutations found in 
patients with the El and LI GLD, are located in the region encoding for the 30 kDa 
subunit o f the enzyme, suggesting a critical role of this subunit for the functionality of 
the enzyme 4. AD cases are frequently characterized by heterozygosity for a 502/del 
mutation, but many other mutations, mainly in the region encoding for the 50 kDa 
subunit, have been found 44 51 45.
When a patient is diagnosed with an LSD, the first question is what clinical course 
lies ahead for the patient. This is important, in order to select those patients who would 
benefit most from aggressive therapy. Many authors have analyzed GALC mutations to 
establish a correlation between genotype and phenotype, but neither the specific 
mutation nor the residual enzymatic activity are definitively predictive o f disease 
progression. From experiences with patients affected by the late-onset form o f GLD, it is 
clear that there is tremendous variability even between siblings with the same genotype 
for the GALC gene 13.
1.5.3.3 Prenatal diagnosis and newborn screening fo r  LSDs
Many LSDs are severe, resulting, as in the case o f GLD, in early death a few years 
after diagnosis. However, the success o f most treatments, such as hematopoietic stem 
cell transplantation (HSCT), depends on the accurate diagnosis of patients before 
symptoms, especially those affecting the nervous system, become overwhelming. The
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identification o f a patient at birth would result in careful clinical observation and 
treatment could begin when deemed appropriate (Figure 3). The initial promise of LSD 
screening using the ‘generic’ lysosomal storage disease proteins, lysosomal-associated 
membrane protein (LAMP-1) 52 and saposins, has not been realized in prospective 
studies. Prenatal diagnosis is extremely accurate using a direct chorionic villus sample, 
cultured trophoblasts and cultured amniotic fluid cells. There are two different 
approaches currently used for screening: measurement o f lysosomal protein activity 53 54, 
or of protein amount 55 56. Both use multiplex assays and usually do ‘second-tier’ testing 
on the same initial sample. A third method for newborn screening has recently been 
developed, based on the quantification o f enzyme activity by tandem mass spectrometry 
on dried blood spots. Previous studies have shown that lysosomal enzymes are active in 
dried blood spots 55. Li and colleagues reported that it is possible to incubate rehydrated 
dried blood spots from newborn-screening cards with buffer containing substrates for 
five lysosomal enzymes and to use tandem mass spectrometry for the multiplex 
detection of all five enzymatic products that are relevant to the diagnosis o f Fabry,
cn
Gaucher, Krabbe, N iem ann-Pick and Pompe diseases . While conventional methods o f 
quantifying enzymatic activity rely on the incorporation of a chromophore or 
fluorophore into the substrate, in this new procedure, substrates are synthetic 
sphingolipids containing N-linked fatty acyl chains that are shorter than the typical 
natural substrates. The corresponding products are non-natural ceramides, which are 
differentiated in the mass spectrometer according to the length of the fatty acyl chains.
In addition to the development of reliable and easy assay for prenatal diagnosis and 
newborn screening, the development o f prevention programs for the detection of 
heterozygotes o f relatively prevalent autosomal recessive diseases, such as LSDs, is a 
relevant issue for various ethnic groups. A screening prevention program has become 
available in recent years in Israel. The aim o f the program is to determine high-risk 
couples prior to the birth o f affected offspring. This is performed by a population-
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screening program which addresses the specific needs and requirements o f various
58population groups in Israel .
An experimental newborn screening program for GLD has been active in New York 
since 2006. In the first stage of screening, GALC activity is measured using tandem 
mass spectrometry on rehydrated dried blood spots from newborn-screening cards, as 
described above. Samples with less than 10% o f normal activity values are considered 
positive and DNA analysis for GALC mutations starts. In order to avoid false positive 
screening, GALC deficiency is confirmed by a second assay performed on blood. When 
the diagnosis is confirmed, the infant is referred for consideration of a cord blood (CB) 
transplant. Currently, the transplant center with the most experience o f neonatal GLD is 
Duke University Medical Center (North Carolina).
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1.6 Animal models of GLD
Before the biochemical defect was identified in human patients in 1970, a canine 
model o f GLD was described 59 (Figure 4). Affected Cain and West Highland White 
terriers present characteristic pathological features of GLD, such as weakness and 
tremor, a severe deficiency o f GALC activity and progressive accumulation of Psy in the
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brain. In 1996 the canine cDNA was cloned and the mutation causing GLD in Cain and 
West Highland White terriers was identified60.
In 1980, a murine model of GLD, called twitcher (twi) was identified at the Jackson 
Laboratory 61 (Figure 4). These mice of the C57BL/6J strain, present no GALC activity, 
Psy accumulation in the CNS and PNS and develop clinical signs at approximately 20 
days, with twitching and hind leg weakness. Neurological deterioration both in CNS and 
in PNS is very fast, leading to a progressive hind leg paralysis. They also lose weight as 
a result o f their inability to feed and drink and die by about 40 days of age.
The mapping of the disease to mouse chromosome 12 was very useful in mapping 
the human disease to human chromosome 14. The miss-sense mutation responsible for 
the disease in twi mice is a G ^ A  transition at position 1017 o f the cDNA, which results 
in a mutation o f a Tryptophan codon to a stop codon.
In 2001 a new transgenic mouse model o f GLD was obtained by homologous 
recombination (trs mouse) 62. The miss-sense mutation responsible for the disease results 
in a substitution of a Cysteine with a Histidine. W hile this mutation in humans decreases 
GALC activity to only 80% of normal values, in the mouse it results in  a more severe 
reduction of GALC activity (10 to 20% o f normal values). Trs mice present a phenotype 
similar to the one observed in twi mice, but with a delayed onset o f about 10 days: 
twitching and tremors start around day 30 and the life span is about 50 days.
More severe murine models than the twi have been generated, such as the twi IL-6 - 
/ - 63 or the twi mouse with the mixed background C57BL/6-129SvEv 64. A milder mouse
ASmodel o f GLD was obtained by breeding twi mice with CAST/Ei mice . The synthesis 
of GALC substrates in these mice, characterized by a low cholesterol and phospholipids 
turnover, is lower. C57BL/6x CAST/Ei twi mice have an increased life span (about 62 
days), a delayed onset of tremor and a delayed decline of walking abilities, compared to 
C57BL/6 twi mice.
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A murine model resembling the phenotype observed in the late-onset forms of GLD, 
was obtained by Cre/lox knock out of Sap A. SapA-/-mice develop a slowly progressive 
hind leg paralysis, with clinical onset at about 70 days and survival up to 5 months.
In 1989 the first monkey with pathological signs consistent with a diagnosis of GLD 
was described 66 (Figure 4). These Rhesus monkeys present a tremor o f the head and 
limbs, deterioration o f walking abilities and ataxia. W ith disease progression, the 
animals also display a decreased nerve conduction velocity, severe demyelination in 
both CNS and PNS, accumulation o f globoid cells in the white matter and severe gliosis. 
The life span is around 22 months 67. In 1997, the GALC cDNA o f the rhesus monkey 
was cloned and a two-base-pair deletion in exon 4 was found in the affected animals. 
This mutation is responsible for a frameshift that generates a stop codon after 46 
nucleotides 10.
Figure 4. A nim al m odels o f G L D . (a) Tw itcher m ouse in C57B16/J background, (b) Cain and 
W est H ighland W hite terriers, (c) Rhesus m onkey.
1.7 Treatment of LSDs
1.7.1 Cross correction
Currently available treatment options for LSDs are based on cross-correction. This 
phenomenon was first observed on fibroblasts from patients affected by MPS I and II: 
the metabolic defect o f these cells was corrected by providing “factors” secreted by wild 
type cells 68. Furthermore, the “corrective factor” was clarified as being the functional 
enzyme secreted by wild type cells, up-taken and sorted to the lysosomal compartment 
of the deficient fibroblasts through the mannose-6-phosphate receptor (M6P-R) pathway 
69. This phenomenon is unique of lysosomal enzymes, as MP6 groups are added 
exclusively to the N-linked oligosaccharides o f these soluble enzymes as they pass 
through the cis Golgi network. After being modified, the lysosomal enzyme binds the 
M6P receptor in the trans Golgi network (TGN) and is sorted to the late endosomes to 
reach the lysosome. About 40% of the enzyme escapes this pathway and is secreted in 
the extra-cellular space: this enzyme can then bind the M6P-R on the membrane to the 
producer cell or surrounding cells and can be endocytosed and sorted to the lysosome 70 
(Figure 5). Many therapeutic approaches for LSDs are based on cross-correction: in 
enzyme replacement therapy (ERT), the enzyme, administered through intra-venous
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injections, can reach the affected tissues with blood, while in HSCT, the lysosomal 
enzyme is provided by normal cells of donor origin.
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Figure 5. C ross-correction  o f  defective cells by wild type cells. The lysosom al enzym e is 
released in the extra-cellu lar space where it is up-taken by defective cells through the M 6P-R  
and sorted to lysosom es.
1.7.2 Enzyme Replacement Therapy
ERT consists of the parenteral administration o f the recombinant or purified enzyme 
and is aimed at reducing the storage of the substrate responsible for the disease. ERT is 
now available or under investigation for a number o f LSDs, including Gaucher disease, 
Fabry disease, MPS I, II, IVB, VI and VII and Pompe disease 71 72. ERT started more 
than 15 years ago with the large-scale isolation o f glucocerebrosidase from human 
placentas for the treatment of Gaucher disease 72. The treatment o f non-neuronopathic 
forms o f Gaucher disease with this original source o f enzyme and the later recombinant
I'X
form, has been very successful . In particular, the largest experience with ERT is in the 
treatment of Gaucher disease type I, caused by (3-glucocerebrosidase deficiency. In this 
LSD, the accumulation o f lipids within tissue macrophages leads to hepatomegaly, 
splenomegaly, anemia, thrombocytopenia and bone involvement 74. ERT significantly
75alleviates hepatosplenomegaly and hematological manifestations .
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In order to develop an efficacious ERT for LSDs, the differences between the 
affected tissues should be taken into consideration. Various cell types express different 
receptors for the uptake o f lysosomal enzymes: the hepatocyte membrane contains 
galactose receptor, macrophages require mannose residues for uptake, whereas most 
cells bind exogenous enzymes via the M6P-R. Moreover, diversity in the membrane 
density of the M6P-R of different cells and tissues has been observed: the highest 
concentration o f receptors was found in the heart and kidneys, the lowest in muscles and 
the brain 76. Therefore, since successful ERT requires targeting o f multiple cell types, 
the ideal drug may be one which includes enzymes with various sugar residues and 
isoforms, so as to take advantage o f the many cellular receptors involved in endocytosis.
Recombinant enzymes are currently obtained from cultures o f over-expressing
77 78Chinese Hamster Ovary (CHO) cells or human fibroblasts . The genes for almost all 
o f the lysosomal enzymes have been cloned and theoretically their encoded proteins 
could be produced in large quantities. Despite this possibility, the small number o f 
patients affected, makes the pharmacological development o f ERT likely to be 
unprofitable to produce and test the protein for most LSDs.
In spite o f pressure from concerned families and healthcare providers, significant 
problems still remain before ERT can be successfully applied to most LSDs. A major 
limitation of ERT is the inability o f the enzyme provided, to efficiently cross the blood- 
brain barrier (BBB), with a consequent ineffectiveness of this treatment for LSDs with 
severe CNS involvement 79. Recent experimental evidence has shown a reduction of 
substrate storage in the CNS of many animal models o f LSD, in the presence of high 
quantities of enzyme in the plasma 80 81. The mechanism by which the enzyme could 
reach the brain is still not fully elucidated, but it was hypothesized that monocytes and 
macrophages could uptake the circulating enzyme, cross the BBB and release the 
enzyme in the CNS 80. Based on these results obtained in animal models, a phase 1 
clinical trial o f ERT was started recently for the treatment of Metachromatic
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Leukodystrophy (MLD), an LSD caused by ARSA deficiency and characterized by a 
severe CNS involvement, but the effectiveness of the therapy on CNS is still unknown. 
Similarly, little is known about the possible benefits o f ERT in GLD, which has a 
substantial CNS component. Pre-clinical studies examined the effect o f peripheral 
GALC injections in the twi mouse. Even though immunohistochemical and biochemical 
analyses have demonstrated GALC uptake in multiple tissues, including the brain and a 
consequent decrease in Psy accumulation, only a slight increase in the life span of 
treated animals was observed .
Pre-clinical studies are currently directed at promoting transport o f the administered 
enzyme across the BBB. Among the recently explored strategies are the conjugation of 
the enzyme with molecules recognized by a specific BBB carrier, such as IGF-2, the Fc 
fragment of antibodies, ApoB, or the TAT protein transduction domain. In one example 
o f these strategies tested for MPS I in Rhesus monkeys, ot-L-Iduronidase (IDUA) was 
fused with a monoclonal antibody directed against the insulin receptor expressed by 
brain endothelial cells. After intravenous administration, the enzyme was able to reach 
the CNS. Other approaches being developed to improve the transport across the BBB 
aim to extend the circulating half-life o f the administered enzyme, such as by removing
83M6P residues and thus inhibiting uptake via M6P receptor by peripheral organs .
Another limitation of ERT is the frequent occurrence o f immune responses against 
the injected protein. In LSDs characterized by a complete absence of the enzyme, 
parenteral administration could result in the recognition o f the protein as a non-self 
antigen, thus triggering a humoral response with IgG production. As a consequence, 
alteration of the pharmacokinetic, hypersensitivity and very occasionally, neutralization 
o f the administered enzyme, were observed 84 85.
Finally, the high cost o f the recombinant enzymes, the need for life-long treatment 
and the frequency o f injections are significant issues for many patients and their 
families.
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1.7.3 Hematopoietic Stem Cell Transplantation
1.7.3.1 Hematopoietic Stem Cells
Hematopoietic Stem Cells (HSC) are somatic stem cells that give rise to all blood 
cell lineages, including lymphoid (T and B) and myeloid cell lineages. In the adult, HSC 
mainly reside in the hematopoietic niche of bone marrow (BM). In the niche, HSC are 
closely associated with stromal cells, which support the maintenance o f stem cells and 
hematopoiesis both by the secretion of factors and by cell-cell interactions. In order to 
generate mature blood cells, HSC differentiate towards multi-lineage progenitors, which 
undergo expansion and further commitment steps that restrict their developmental 
potential. This differentiation process ends up with the generation o f terminally 
differentiated progeny (Figure 6).
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Figure 6. H em atopoietic stem  cell differentiation. H em atopoietic  stem  cells differentiate 
tow ards m ultilineage progenitors, w hich undergo further d ifferentiation  processes to produce 
lym phocytes, N K  cells, m onocytes, granulocytes, p latelets and red blood cells.
1.7.3.2 Characterization o f  Hematopoietic Stem Cells
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Human HSC can be isolated mechanically from the BM, where they reside, or from 
peripheral blood upon mobilization. An alternative HSC source is cord blood (CB). The 
HSC pool is generally identified through the expression o f the surface marker CD34 86 
87, but selection using this marker provides a heterogeneous population containing only a 
minority o f primitive self-renewing stem cells (long term -  LT-HSC) among a mixture 
o f multipotent and oligopotent progenitors (MPP) which have lost their self-renewing 
ability and acquired differentiation and proliferation capacity 8S.
The most accurate definition of HSC is according to their function, measured as 
their ability to repopulate the hematopoietic system o f a myeloablated host. The most 
primitive human stem/progenitor cells identified so far in experimental models have 
been called SCID repopulating cells (SRC) for their ability to engraft an
89immunodeficient murine recipient (for detailed description of xenograft models see ) 
while long-term providing differentiated progeny 90. Long-term culture-initiating cells 
(LTC-IC) have a poorer self-renewal ability than SRC and are identified through a 5- 
week in vitro proliferation assay on a stromal layer 91. Colony form ing  cells (CLC) are 
the progenitor fraction already committed toward the lymphoid, myeloid or erythroid 
lineage and proliferate extensively during a 2-week culture 92. Unlike SRC, LTC-IC and 
CFC are unable to efficiently engraft SCID mice.
1.7.3.3 Maintenance o f  Hematopoietic Stem Cells
The ability of HSC to differentiate w ithout exhausting the pool o f HSC, relies on the 
ability o f stem cells to perform both symmetrical and asymmetrical divisions. 
Symmetrical divisions give rise to two daughter cells with the same potential o f the 
dividing cell, whereas asymmetrical divisions give rise to: I) a cell with the same 
potential o f the dividing cell; II) a progenitor that has a higher degree o f commitment, 
lower self-renewing and proliferative potential and which will generate the differentiated 
progeny. Thus, symmetrical mitoses are responsible for the maintenance and expansion
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o f the HSC compartment, while asymmetrical mitoses are responsible for both self­
renewal and differentiation. To sustain the hematopoietic system without undergoing 
exhaustion, HSC must be tightly regulated, both by intrinsic and extrinsic signals. 
Intrinsic signals converge at the level of gene expression and have been better 
characterized in the developmental pathways of HSC than in the homeostatic 
maintenance o f HSC in their adult state. On the other hand, extrinsic signals are those 
provided by the BM microenvironment: in the BM niche. HSC interaction with stromal 
cells and extracellular matrix through adhesion molecules profoundly influence HSC 
fate.
1. 7.3.4 Hematopoietic Stem Cell Niche and Homing
The hematopoietic niche comprises HSC and their microenvironment, which is 
defined as the cells adjacent to, or surrounding, the stem cells (Figure 7). The 
microenvironment o f the BM is fundamental for HSC maintenance, self-renewal and 
differentiation 93. Stem cells represent a very small fraction o f the niche in which they 
are contained, as most niche cells are non-hematopoietic and most niche-associated 
hematopoietic cells are committed progenitors or differentiated cells. The 
microenvironment is composed o f endosteal osteoblasts and progenitor cells 94 95, 
mesenchymal stem cells (MSC), fibroblasts and the peri- and endothelial cells o f bone 
marrow capillaries. Moreover, the niche contains extracellular factors produced by these 
cells, such as Stromal cell Derived Factor 1 (SDF-1), osteopontin, fibronectin, collagen, 
vitronectin and tenascin 96. The generation o f mature blood cells requires a close 
interaction between HSC and their niche and pathological conditions responsible for 
alteration o f the niche microenvironment could result in hematopoietic defects. In 
particular, the sympathetic nervous system seems to play an important role in 
maintaining the trophism o f the endosteal niche. Katayama and colleagues have recently
32
reported that aberrant nerve conduction is responsible for a dysregulation of HSC
97attraction to their niche, leading to a severe lymphopenia in CGT knok- out mice .
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F igure 7. T he stem  cell n iche. The hem atopoietic  niche com prises HSC and their 
m icroenvironm ent, including m esenchym al stem cells and strom al cells such as osteoblasts, 
fibroblasts and adipocytes.
Since in physiological conditions, HSC reside in the BM niche, in an HSC 
transplantation setting (HSCT), transplanted HSC must migrate through the blood, cross 
the vasculature and seed in the niche. This migration requires an active process called 
homing. Like other HSC features, homing is regulated by factors expressed in the niche 
microenvironment, such as adhesion molecules and hematopoietic cytokines. The 
interaction between SDF-1, expressed by endo-osteal osteoblasts, stromal and 
endothelial cells and CXC chemokine receptor 4 (CXCR4), expressed by HSC, has been 
proposed as a fundamental axis regulating retention, migration and mobilization of HSC 
during homeostasis and stress 98 " .  Adhesion molecules, such as integrins and selectins, 
mediate rolling and adhesion of homing cells before extra-vasation. Very late antigen 4 
(VLA-4) and VLA-5 integrins have been found to participate in HSC homing 9 .
1.7.3.5 H e m a to p o ie t ic  Stem Cell T ra n sp la n ta t io n  in LSDs
An increasing number o f patients with LSDs are undergoing HSC transplantation 
(HSCT) in an attempt to slow the course of the disease, prevent the onset o f clinical 
symptoms and improve some pathological findings. The most promising results are 
obtained when HSCT is performed in pre-symptomatic patients, identified in the uterus 
or at birth because o f family history.
The rationale for the use of HSCT to treat LSDs is the reconstitution o f recipient’s 
macrophage and microglia populations by functional cells of donor origin (Figure 8). 
Animal studies have shown that donor-derived cells of the monocytic lineage infiltrate 
different tissues including the CNS of the recipient, replacing the local macrophage 
population. These cells are not only the major effectors contributing to the clearance of 
the stored material throughout the tisses, but also act as mini-pumps synthesizing and 
secreting a portion o f their lysosomal enzymes which can be taken up by neighboring 
cells 100 101. Those lysosomal enzymes, endocytosed by the M6P-R-mediated pathway, 
localize in the lysosomes and hydrolyze the stored substrate.
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Figure 8. M icroglia  reconstituton upon H SC T . Upon HSCT, cells o f  donor origin differentiate 
and reconstitu te m icroglia in the host CNS.
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W hile the reconstitution of visceral organ macrophages by donor-derived cells has 
been clearly demonstrated, a substantial debate exists on the occurrence o f CNS 
microglia replacement by the progeny of the transplanted donor HSC. In particular, 
factors affecting microglia replacement following HSCT have been identified in pre- 
clinical models. The replacement o f brain microglia by donor-derived macrophages is 
favored in LSDs characterized by neuroinflammation or neurodegeneration 102 103 104 105, 
106. In fact, microglia recruitment could be enhanced by both pro-inflammatory 
cytokines and an increased BBB permeability 107. For this reason, the myeloablative 
conditioning regimen applied before HSCT, might also play a fundamental role in the 
timing and extent o f reconstitution. Irradiation promotes microglia reconstitution by 
increasing the permeability of the BBB; however, when myeloablation is obtained by 
administering chemotherapic agents such as busulphan, the replacement o f host 
microglia with cells of donor origin might be enhanced by the production o f pro- 
inflammatory cytokines triggered by the neurotoxic effect of the drug 108-110 11 Recent 
studies demonstrated that the reconstitution o f brain microglia upon HSCT may also be 
influenced by the characteristics o f the transplanted HSC. In particular, the mechanical 
flushing of femurs and tibiae used in pre-clinical studies to collect HSC, could damage 
the BM niche, thus allowing microglial progenitors to enter in circulation and possibly 
cross the BBB. In physiological conditions, these cells should not be able to leave the
bone marrow and enter into circulation 110 108. In any case, microglia replacement
112following HSCT might take many months or even years to accomplish in humans 
Therefore HSCT may not be beneficial for rapidly progressing LSDs or for symptomatic 
patients.
HSCT is associated with a fairly high morbidity and mortality which limits its use to 
conditions that are themselves essentially life-threatening. Major causes o f morbidity
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and mortality are engraftment failure, regimen-related toxicity, graft-versus-host disease 
(GvHD) and sepsis.
Engraftment failure is the inability of the transplanted HSC to engraft and 
repopulate the recipient. This inability might be related to HSC or to the recipient. 
Several studies analyzed the risk factors related to engraftment failure and o f particular 
interest is a study performed on a cohort of MPS I-Hurler patients transplanted between 
1994 and 2004 113. This study observed that the percentage o f engrafted patients after
113one HSCT was only 56% going up to 81%, after one to three transplantations 
Among the factors analyzed, T cell depletion was found to increase the risk of graft 
failure. HLA disparity was found to be a risk factor in 1994-1998 but not after, probably 
thanks to improvements in supportive care. Moreover, an HLA mismatch exerts a 
different effect depending on the source of HSC. In fact, a less mixed chimerism was 
observed in patients transplanted with CB HSC, in comparison to patients receiving cells 
from BM or PBMC. These differing outcomes might be due to the higher HLA 
mismatch o f CB cells which could exert a stronger graft-versus-marrow (GvM) effect 
114 The GvM is associated with a subclinical GvHD, likely since CB cells have a more 
naive phenotype. This might make the marrow more sensitive to GvM in comparison to 
the known target organs o f GvHD. Another explanation for the higher engraftment of 
CB cells could be the increased pluripotential capability and the higher proliferative 
potential of these cells in comparison to BM HSC 115.
The application o f  a myeloablative regimen is necessary prior to HSCT to allow 
engraftment o f HSC. Unfortunately, the myeloablative action o f the chemotherapic 
regim en is often accompanied by a toxic effect on different tissues. As mentioned above, 
while the neurotoxic effect o f busulphan might enhance microglia reconstitution on the 
one hand, it could result in seizures and other neurological symptoms following 
conditioning, on the other.
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GvHD is an inflammatory disease, unique to allogeneic transplantation. It is an 
attack o f the donor’s immune cells against the recipient's tissues. This can occur even 
when the donor and the recipient are HLA-identical, because the immune system still 
recognizes other differences between their tissues. Acute GvHD typically occurs in the 
first three months after transplantation and may involve the skin, intestine, or the liver. 
Chronic GvHD is the major source of late complications.
A fter myeloablation and prior to engraftment, patients may go for several weeks 
without appreciable numbers of white blood cells to help fight infection. This puts a 
patient at risk o f infections, sepsis and septic shock, despite prophylactic antibiotics. The 
immunosuppressive agents employed in allogeneic transplants for the prevention or 
treatment of GvHD further increase the risk o f opportunistic infection.
In order to optimize transplant procedures, recent HSCT protocols use CB as a 
source o f HSC. Banked CB is prospectively HLA typed, screened for infections and 
other risk factors and readily available for transplantation. In a disease where the time 
from diagnosis to definitive treatment represents a crucial period for the prevention o f 
further disease progression, a readily available source of HSC is extremely desirable. 
The incidence o f acute GvHD is usually lower in HSCT from CB compared to when 
HSC are derived from BM, and the hematopoietic reconstitution is faster 116 117. The use 
of CB HSC greatly has influenced the outcome o f HSCT in LSDs. When allogeneic 
HSCT is performed using BM HSC, the donor is usually a sibling and often he/she is a 
carrier o f LSD. On the one hand, this means that the time to find a suitable donor is 
reduced, but, on the other, that the amount of enzyme provided by donor cells is lower 
than normal levels, thus compromising the positive outcome of the treatment. 
Transplantation o f CB-derived HSC, increases the number o f available donors since a 
lower standard o f histocompatibility between donor and recipient, is acceptable. In 
addition, HSC would not come from LSD carriers but from healthy donors and thus 
supply a normal level o f therapeutic enzyme.
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HSCT was initially considered as a therapeutic option for those LSDs involving BM 
and hematopoiesis and was then applied to those LSDs also involving CNS. The results 
obtained following successful engraftment in transplanted MPS I-Hurler patients, have 
been gratifying. Treated subjects showed a restored enzymatic activity and resolution of 
cardiac pathology 117 118. Allogeneic HSCT has also proved to be effective for patients 
affected by the cerebral form of Adrenoleukodystrophy (ALD) 119,120. The data to date 
clearly shows that the degree o f disease correction is dependent on the symptomatic 
stage at the time of treatment: the cerebral outcomes are superior following engraftment 
at an earlier stage of the disease compared to later stages. This could be explained by the 
ratio between disease progression and the rate of microglia reconstitution from donor- 
derived cells, which changes according to the time when treatment is applied.
Despite the promising results obtained in the above-mentioned LSD, HSCT showed 
a poor outcome when applied to MLD patients. Failure to obtain an improved, or even 
stabilized quality of life and to halt disease progression was reported. The majority of 
treated patients displayed a continuous decline in their neurological performance,
despite full donor engraftment and restoration o f enzymatic activity to normal in
121peripheral blood mononuclear cells
In order to increase the effectiveness of HSCT in LSDs, transplantation has been 
associated with ERT in recent phase I clinical trials for MPS I Hurler. The enzyme 
Laronidase® was administered 11-14 weeks before HSCT and 8 weeks after HSCT, by 
parenteral infusion. All patients engrafted with more than 90% donor hematopoiesis, 
thus demonstrating that ERT does not affect the engraftment o f donor cells and could be 
used to stabilize patients while waiting for HSCT 122.
1.7.3. 6 Hematopoietic Stem Cell Transplantation in GLD
HSCT was initially tested on twi mice. Transplanted mice displayed a sustained 
increase o f GALC activity in the CNS, a stabilization o f Psy storage and a reduction in 
both the number o f globoid cells and demyelination 123 124 125 126 10 \  Preliminary 
evidence has shown that HSCT could be effective for patients affected by the infantile 
form o f GLD, if  applied within the first months of life. W hen the disease is diagnosed 
early and when an HSC donor is available, HSCT can delay the onset o f GLD and halt 
its progression. Pre-symptomatic and symptomatic children with the infantile form of
197GLD have been successfully transplanted with HSC from unrelated CB . Preliminary 
results have shown a positive effect if  patients have been transplanted very early in life 
before the onset of symptoms. In such patients, the progression o f the disease has been 
slowed and their phenotype seems milder compared to untreated controls. However, in 
patients transplanted at a symptomatic stage, disease progression has been shown to be 
as fast as in non transplanted children. Good results were also obtained when HSCT was
128 129performed in patients affected by the late-onset form (J and Ad) o f GLD 
Transplanted patients showed an improvement in CNS functions as well as an increase 
in nerve conduction velocity, thus confirming the therapeutic potential o f HSCT for the 
treatment o f GLD 121.
1.7.4 Substrate reduction therapy
In cases wherein mutant cells express residual enzyme activity, metabolic 
homeostasis may be restored or maintained in diseased cells by limiting the amount of 
intra-lysosomal substrate build-up, by inhibiting the number o f precursors synthesized 
13°. This approach, called substrate reduction therapy (SRT), seeks to strike a balance 
between the amount o f substrate that ultimately needs to be degraded and the mutant 
cells intrinsically low enzyme activity. This could be accomplished by compounds such 
as L-cycloserine, which inhibit a very early step in the synthesis o f sphingolipids. Pre-
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clinical studies demonstrated that administration o f L-cycloserine to twi mice, from both 
C57BL/6 and B6; CAST/Ei background, resulted in a longer life span and a delayed 
onset of clinical manifestations 131 132. SRT could also be combined with HSCT to 
enhance its efficacy, thus increasing the number of patients who could benefit from the 
treatment. Studies on twi mice demonstrated that SRT combined with HSCT resulted in 
a greater benefit than either treatment alone 65.
There were legitimate concerns that treatments based on the use o f substrate 
synthesis inhibitors might influence the presence and distribution o f sphingolipids which 
play a number of important functions in cellular metabolism, including signal 
transduction, cell adhesiveness and nerve impulse transmission 133 thus adversely 
influencing cell growth and differentiation. To some extent these concerns were 
mitigated by the availability o f authentic animal models and pre-clinical studies 
performed in twi, Sandhoff and Niemann-Pick type C (NPC) mice, which revealed that 
SRT delayed the onset of symptoms, improved behavior and prolonged survival 134 135. 
The lack of any significant deleterious effects in the mice exposed to the drug, may 
reflect the fact that the inhibition o f substrate synthesis is a partial, rather than a full or 
complete block. However, the “genetic” substrate reduction in CGT-/- twi-/- double ko 
mice led to unexpected findings 136. In this mice GG are not present at any age, while a 
progressive neuronal pathology was observed in the brainstem and spinal cord after 45 
days. This new disease phenotype, different both from the twi and the CGT single ko 
phenotype, is similar to the one observer by Suzuki in twi mice that had received bone 
marrow transplantation treatment (unpublished data). This finding might suggest that 
either some unknown substrates o f GALC are synthesized in the absence of CGT or 
some of the usual CGT products can be synthesized by other enzymatic mechanism.
SRT has been successfully applied to patients affected by type I Gaucher disease. 
Oral administration of a glucosylceramide synthesis (N-butyldeoxynojirimycin) 
inhibitor, proved to be effective in reversing clinical symptoms in these patients, with
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mild to moderate disease manifestations 137. Clinical trials that should reveal the value 
o f substrate reduction for the treatment of neuronopathic variants of Gaucher disease, 
NPC, late-onset Tay-Sachs disease and Sandhoff disease, are under way.
2. Gene Therapy
Gene therapy is the delivery of genetic material into an individual's cells and tissues 
with the aim o f curing a disease or at least improving the clinical status of a patient. It 
could be used to treat both inherited or acquired diseases, or for prophylactic purposes
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Depending on the target of gene transfer, gene therapy may be classified into the 
following types:
I. Germ line gene therapy, germ cells, i.e., sperm or eggs, are modified by the 
introduction o f functional genes, which are ordinarily integrated into their genomes. 
Therefore, the change due to therapy would be heritable and would be passed on to later 
generations. Theoretically, this new approach should be highly effective in 
counteracting genetic disorders. However, this option is prohibited for application in 
human beings, at least for the present, for a variety o f technical and ethical reasons.
II. Somatic cell gene therapy: the gene is introduced only into somatic cells, 
especially for those tissues where expression o f the gene concerned, is critical for health. 
Expression o f the introduced gene can relieve/eliminate symptoms o f the disorder, but 
this effect is not heritable as it does not involve the germ line. At present, somatic cell 
therapy is the only feasible option and clinical trials addressing a variety o f conditions 
have already begun.
Referring to the aim and the genetic material used, gene therapy could be defined as 
follows:
Replacement therapy, a functional gene is provided or inserted into the genome to 
replace the function o f an endogenous defective one. The most common method is the
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insertion of the functional gene into a non-specified location within the genome. An 
alternative method is to “correct” the mutant gene through homologous recombination.
Addictive: a DNA or RNA portion is transferred into the patient’s cells, in order to 
provide a supplementary biological function (i.e. resistance to viral infection).
Ablative: patient’s cells are provided with genetic material which can down-regulate 
or suppress the expression of a target gene (i.e. miRNA, siRNA and antisense 
oligonucleotides could be used to interfere with mRNA maturation and translation).
Gene transfer can be obtained using an in vivo or ex vivo procedure. The in vivo 
method inserts genetic material directly into the patient’s target tissues. This procedure 
is, in theory, easier and once optimized, could be applied to a great number o f patients. 
However, it is an invasive procedure which might lead to inadvertent gene transfer into 
tissues and cell types that are not the proper target (Figure 9).
In Vivo Gene Therapy
Tissue 
injection '
* Recombinant 
virusliposome
Biolistic gene gun
Systemic
infusion
plasmid DNA
Figure 9. In vivo G ene T herapy. G enetic m aterial (D N A  liposom es, viral vectors or plasm ids) 
is inserted directly into the patient.
In the ex vivo method, tissue is removed from the patient, target cells are isolated 
and genetically modified before returning them to the patient. This procedure is less 
invasive and the time in which the target cells are exposed to the vector used for gene 
transfer, is limited. However, in vitro manipulation could modify the treated cells,
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possibly impairing their functionality or engraftment potential. Moreover, some tissues 
are difficult to remove for ex vivo manipulation (Figure 10).
Ex Vivo Gene Therapy
Fibroblast cells
Figure 10. Ex vivo G ene T herapy. Target cells are iso lated  and genetically  m odified  before 
returning them  to the patient.
2.1 Non-viral vectors
Several gene transfer methods have been developed. Non-viral approaches take 
advantage o f physical delivery methods (i.e. direct DNA injection, electroporation, 
nucleofection, gene guns) and chemical approaches (i.e. liposomes) to transfer the 
genetic material into target cells or tissues 115 139 140 141. The efficiency o f gene transfer 
by non-viral approaches is generally low, particularly in non-dividing cells, due to the 
inability of liposomes, gene gun complexes or nude DNA to enter the nuclear membrane 
when it is not disrupted, such as during cell division. Moreover, upon in vivo 
administration, non-viral vectors bind negatively-charged plasmatic proteins, thus 
greatly decreasing the amount of vector available for target cells 142. A new non-viral 
approach based on a transposon system (i.e. sleeping beauty transposon) has recently 
been developed; although it should ensure integration of the genetic material into the 
target cell chromatin, the efficiency and safety of this system still need to be evaluated 
(for a review see 143). The application o f gene transfer by non-viral approaches, has been 
limited by its poor efficiency, mostly to pre-clinical studies, with some phase I clinical 
trials 144 145.
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2.2 Viral vectors
The basic concept of viral vectors is to harness the innate ability of viruses to deliver 
genetic material into the infected cell. A vims (from the Latin virus meaning "toxin" or 
"poison"), is a sub-microscopic infectious agent that is unable to grow or reproduce 
outside a host cell. In general, the major occupation o f viruses is to replicate and 
produce copious amounts o f progeny. Many viral infections lead to deleterious effects 
on the host, accompanied by destmction o f infected host cells. Damaging effects can be 
caused by induction of genes whose products are hazardous to the host. The basic 
principle of turning these pathogens into delivery systems, relies on the ability to 
separate the cis-acting sequences o f the viral genome that act on the same sequence 
during the infection cycle from the trans-acting sequences that encode for viral structural 
and non-stmctural proteins. Next, dispensable genes are deleted from the viral genome to 
reduce replication and pathogenicity, as well as expression o f immunogenic viral 
antigens. This procedure generates enough space into the viral genome to insert the 
expression cassette, made up o f a transgene and transcriptional regulatory elements 
sequences. The recombinant vims is generated by supplying in trans the gene products 
required for virion production 146. Since viral methods are usually more efficient than 
non-viral methods, they have been widely studied as tool for gene transfer. Moreover, 
some viral vectors allow for stable integration into the cell chromatin. Nevertheless, 
concerns about the safety o f the viral sequences contained within the gene transfer 
vector, the risk of insertional mutagenesis and the potential immunogenicity of the 
vector particles, have been raised.
The more widely used viral approaches are based on Adenovims, Adeno-Associated 
vim s, Herpes Simplex vims and Retrovirus 147. In particular, Retrovims-based vectors 
(RV) are highly relevant for gene therapy, given their ability to efficiently transduce a
45
wide spectrum of target cells, including hematopoietic cells and to integrate their 
genome into the host chromatin. Retroviruses are RNA viruses, whose replication 
strategy is based on an intermediate DNA form (provirus), which stably integrates into 
the infected cell chromatin. Retroviruses possess two copies o f RNA genome, a proteic 
core (capsid) and a lipidic envelope derived from the infected cell, into which the viral 
glycoproteins are inserted (Figure 11).
g lycopro tein  41 
g ly copro te in  120 pro tein
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m em b ran e  en v elo p e  
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Figure 11. Structure o f a R etrovirus. R etroviruses are m ade up o f  a lipidic envelope, 
containing the viral g lycoproteins gp 41 and gp 120, a proteic capsid and a proteic core 
containing copies o f  RNA.
The viral RNA contains three essential genes, gag , po l and env and  is flanked by 
long terminal repeats (LTR). The gag  gene encodes for the core proteins capsid, matrix 
and nucleocapsid, which are generated by proteolytic cleavage of the gag  precursor 
protein. The p o l gene encodes for the viral enzymes protease, reverse transcriptase and 
integrase, which are usually derived from the gag-pol precursor. The env gene encodes 
for the envelope glycoproteins, which are inserted into the lipidic envelope, involved in 
the virus entry.
This family o f viruses has been divided into three subfamilies: Gamma 
retroviruses (or Oncoviruses), Lentiviruses and Spumaviruses. Oncoretroviruses are 
simple viruses encoding only the structural genes: gag, po l and env, whereas lentiviruses
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and spumaviruses have a more complex genome organization and encode for additional 
viral proteins.
The production o f all RV relies on the supply o f all the structural proteins by 
separate plasmid(s) 138. This strategy can be based on either co-transfection procedures 
or transfection of the transfer vector into packaging cell lines stably producing the viral 
proteins. In both cases, the structural proteins needed for vector production are 
expressed only in the producer cells. In fact, in the vector transduced cells, the sequences 
encoding for viral proteins will be absent, because they lack the signals for encapsidation 
and thus replication o f the vector will be inhibited, unless recombination events occur 
between the vector genome and the viral genes to reconstitute a functional viral genome. 
Since the tropism  o f the RV is dictated by the envelope glycoproteins, the choice of the 
suitable envelope should be performed according to the target cells. The process of 
exchanging the wild type envelope proteins o f RV with other envelope proteins, thus 
modifying the tropism  of the vector, is known as pseudotyping  148 149 150 151. According 
to the envelope selected, different procedures o f  vector production and concentration are 
applied.
2.2.1 Oncoretroviruses and derived vectors.
The vast majority of RV is based on the M oloney murine leukemia virus (MLV), a 
member of the oncoretroviruses family. MLV-derived vectors (MoRV) can package up 
to 10 kb o f foreign genetic material 138. In vivo transplantation studies established 
M oRV’s ability to transduce HSC, an important target for gene therapy 152 153. Given 
this ability, many phase I-II clinical gene therapy trials for several genetic diseases, such 
as Adenosine Deaminase Severe Combined Immunodeficiency (ADA SCID), X-linked
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Severe Combined Immunodeficiency (X-linked SCID) and Chronic Granulomatous 
Disease (CGD), have been performed or are currently ongoing 154 155 156.
The limitations o f MoRV are mainly related to their inability to transduce quiescent 
cells, since they require nuclear membrane disruption and thus mitosis, to gain access to 
the chromatin 157. Given that HSC are mostly non-proliferating cells, all protocols 
developed for retroviral vector-mediated HSC gene transfer, involve prolonged in vitro 
manipulation and/or cell cycle entry induction 90 158 159 160, thus increasing the risk of 
compromising H SC ’s long-term repopulating ability.
Another limitation of utilizing MoRV in gene therapy is related to the risk o f vector 
integration, since insertional mutagenesis leading to leukemia, has occurred in recent 
clinical trials 161 162 163 (see paragraph 2.2.4).
2.2.2 Spumaviruses and derived vectors.
The Spumavirus genome encodes for structural proteins common to all retroviruses 
and for a set o f regulatory and accessory proteins. Despite the name o f the Spumavirus 
prototype, Human Foamy Virus (HFV), spumaviruses are not endemic in human 
populations 164. This, coupled with their non-pathogenicity in natural hosts (non-human 
primates), has supported the development o f HFV-derived vectors (FVV) for gene 
therapy. In addition to safety considerations, the broad host and tissue tropism of 
spumaviruses 165 and the ability o f FVV to package up to 9.2 kb o f foreign genetic 
material 166, have made FVV promising gene transfer tools. Recently, it has been shown 
that FVV ultimately require mitosis for transgene expression, but the transduction
1 filintermediate is stable and persists in non-dividing cells for some days . Investigation 
continues as to whether these vectors can permit transgene expression in quiescent cells 
such as more primitive HSC, which are possibly non-proliferating during transduction 
and will not divide soon after.
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2.2.3 Lentiviruses and derived vectors
Lentiviruses are the most complex family among retroviruses. In addition to gag , 
pol and env, lentiviruses encode for three to six additional viral proteins, which 
contribute to virus replication and persistence of infection (Figure 12). The most 
studied lentivirus is the human immunodeficiency virus 1 (HIV-1).
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Figure 12. S tructure and genom e o f a lentivirus (H IV -1). T he RN A  viral genom e is flanked  
by LTR sequences (m ade up o f U 3-R-U 5) generated  during retro-trascription. R region: 
te rm in a lly  redundant sequence; U5: unique 5 ’ sequence; U3: unique 3 ’ sequence. V if, vpu, 
vp r, nef, ta t, rev: reg u la to ry  genes. RT: re tro tra sc r ip ta se ; IN T : in tegrase.
HIV regulatory proteins are Tat and Rev. Tat is a potent trans-activator of 
transcription which, through binding to the TA R sequence in the U3 LTR region, 
activates the transcription of the HIV genome. Alternative splicing o f the full-length 
transcript generates the array of mRNAs required for expression of all viral genes. The 
full-length transcript itself also serves as a translational template, as well as being a 
source of new viral genomes. Thus, the un-spliced genome, which constitutes the 
genome of new virions, must be transported from the nucleus to the cytoplasm, an event 
that ordinarily does not occur in the cell. This problem is overcome by Rev, which binds 
the RRE sequence o f the transcribed genome and allows nuclear export of the un-spliced 
RNA. Since Tat induces a number o f potentially detrimental cellular responses 169, it has 
been deleted from the design of the latest generation lentiviral vectors (LV). This is
possible if  the U3 region o f the 5 ’ LTR in the transfer vector construct, is replaced by 
constitutively active promoter sequences, thus rendering Tat dispensable. REV is the 
only regulatory/accessory protein that has been maintained in the design of the latest 
generation LV. In fact, its activity is required to express the transfer vector RNA.
HIV accessory proteins are Vif, Vpr, N ef and Vpu. V if is incorporated in the virion 
and is required for replication in “nonpermissive” cells, which include the natural targets 
o f H IV -1 (lymphocytes, monocytes, dendritic cells and brain microglia). In “permissive” 
cells (most HIV-l-infectable cell lines), V if is completely dispensable. In
170“nonpermissive” cells, Vif-defective HIV is unable to complete reverse transcription 
Vpr is present in the viral particle and increases virus production by delaying infected 
cells at the G2 phase o f the cell cycle 171. N ef helps the budding o f the virus from 
infected cells and protects infected cells from being recognized and killed by cytotoxic T 
lymphocytes 172. Furthermore, N ef enhances virion infectivity, likely because it is 
involved in the uncoating and reverse transcription processes 173 174. Vpu mainly 
facilitates virus release. It down-regulates CD4 expression in the ER to prevent 
interaction with HIV-1 envelope proteins during virus budding and stimulates the 
release o f virions, possibly by acting as an ion channel 175. All the HIV accessory 
proteins have been deleted in the latest generation o f LV designs.
2.2.3.1 Lentivirus life cycle
A major difference between lentiviruses and oncoretroviruses is the ability of the 
former to cross the intact nuclear membrane and integrate into the chromatin of non­
proliferating cells 176 177. To better understand the reason for this important difference, it 
is necessary to look at the lentiviral life cycle.
The main stages of lentivirus life cycle are: entry, uncoating, reverse transcription, 
nuclear import, integration, transcription and production of viral proteins, assembly of
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new viruses and release o f viruses (Figure 13). After retro transcription, the dsDNA 
proviral genome, flanked by the LTR regions, and together with other molecules, forms 
a pre-integration complex (PIC). The composition of PIC is still not fully understood, 
mainly because of technical limitations in the isolation o f the particles. However, the
1 78complexes isolated by most protocols retained the po l encoded proteins . To reach the 
nuclear membrane, PIC must travel through the cytoplasm exploiting the cellular 
cytoskeleton 179. After reaching the nuclear envelope, HIV PIC is translocated through 
the nuclear pore, most likely by relying on the cellular nuclear import machinery. 
Although there is no agreement about the viral components needed for nuclear 
translocation, it is likely to be mediated by the im portin/karyopherin cellular machinery 
18°. After entering the nuclear membrane, the viral DNA integrates into the host genome. 
This process is carried out by the viral integrase protein. For a long time, the integration 
o f lentiviruses and more generally all retroviruses, was believed to occur randomly into 
the host chromatin. Nevertheless, recent reports indicated specific biases for integration 
into transcriptionally active genes 181 182, (see paragraph 2.2.4).
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Figure 13. Lentivirus life cycle Entry: the  en v e lo p e  g ly co p ro te in s  bind to  specific  recep to rs  
on  th e  cell m em brane and th e  virus en te rs  the cell th rough  m em brane  fusion. T he  in itia l 
binding is betw een th e  viral g ly c o p ro te in  g p l2 0  and CD4; th e n  g p l2 0  binds to  a co -re c ep to r
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(CCR5 o r C X C R 4) 1X3 to  allow  the fusion betw een  virus and cell m em brane. Uncoating: the  
v ira l core  is re leased  in to  th e  target cell cy to p la sm  and undergoes a progressive disassem bly. 
T h e  RN A  viral genom e is released in th e  cy to p lasm . Retrotranscription: the  viral RN A  
genom e is re tro tran sc rib ed  in to  double stranded  D N A  by the  v iral reverse  tran sc rip tase . Two 
LTR  sequences are generated. Nuclear import: double stranded viral D N A  form s a p re­
in tegration com plex (PIC #168) w ith cellu lar proteins and enters the nuclear m em brane. 
Integration: H IV  in teg ra tes  in to  the  host c h ro m a tin . Transcription and production o f  viral 
proteins: R N A  p o ly m erase  II transcribes the  in teg ra ted  prov irus. O nce in the cytoplasm , 
transcribed R N A  is translated to new  viral proteins or is inserted into new  viral particles l84. 
Assembly o f  new viruses: th e  viral p ro te in s  M A  (fo r th e  m a trix ) , CA (capside) and NC 
(nucleocapside) are required. Virus release: new  v irio n s budding from  cell m em brane. D uring 
th is  p ro cess  th e  en v e lo p e  is acquired.
2.2.3.2 Lentiviral vectors
The first LV was developed from HIV-1 185. Starting with initial constructs, which 
contained all HIV-1 sequences, several studies were performed to limit viral 
sequences/proteins without losing transduction efficiency. The state o f the art HIV-1 
derived vectors are made o f a packaging system consisting of at least four plasmids, in 
which all the accessory proteins have been deleted, and a Self-Inactivating (SIN) 
transfer vector (Figure 14) 186 187.
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Figure 14. T hird generation plasm ids. (A dapted from  (Dull, et al. 1998). pM D L.G : 
packaging plasm id  encoding for viral enzym es and structural proteins. pREV: p lasm id used in 
th ird  generation  LV, codifying for rev. pV SV -G : p lasm id encoding for viral glycoproteins. 
PR R L-SIN : transfer plasm id, containing the expression cassette (transgene and internal 
prom oter).
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The first construct (pMDL.G) is the packaging plasmid, containing gag  and pol, 
which encode for viral enzymes and structural proteins. The second plasmid (pVSV-G) 
expresses the glycoprotein o f the envelope, which determines the tropism o f the virus; in 
order to broaden the host range o f lentiviral vector, they can be pseudotyped with the
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vesicular stomatitis virus glycoprotein (VSV-G) env . Other viral glycoproteins have
189also been used to pseudotype lentiviral vectors and provide alternative cell tropism 
190. The third plasmid (pREV), used in third generation vectors, expresses the Rev 
protein. The fourth construct is the transfer plasmid: it contains the expression cassette 
for the transgene and the essential cis-acting sequences, such as if to allow the 
encapsidation of the virion. The four plasmids are co-transfected into 293T cells, where 
they are transcribed. As a result, viral particles containing RNA sequence encoding for 
the transgene instead of the viral genome, are released into the medium by producer 
cells. These LV are harvested from the supernatant and those pseudotyped with VSV-G 
can be concentrated by ultracentrifugation to produce high-titer preps. Particle titer can 
be determined using assays which measure the amount or activity o f proteins 
incorporated in the vector particles, such as the p24gag ELISA assay (see method 
section) 146.
In this design, the dispensable viral genes and the sequence homologies between the 
different plasmids are greatly reduced, making recombination and production of 
replication-competent lentiviruses very unlikely to occur 191. The first generation 
packaging vectors, contain all the viral proteins except env, which is provided in trans by
1QO 1 QTanother plasmid . In this plasmid the encapsidation signal is deleted, the 5 ’LTR is 
replaced by an heterologous promoter and the 3 ’LTR is replaced by an heterologous 
polyadenilation signal of the SV40 virus 194. In the second generation packaging vectors, 
vif, vpu and vpr genes are deleted, while in third generation vectors, two constructs are
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used: the first is a second generation plasmid, in which tat and rev genes have been 
deleted; the second plasmid provides the rev gene 186 195.
In order to increase the safety and the efficiency o f LV, transfer vectors have also 
been improved. In the first transfer constructs, a sequence spanning from gag  to env is
1 RSdeleted, thus removing all the regions encoding for viral genes . The SIN design of the 
transfer vector, where the enhancer/promoter sequence (U3) o f HIV-1 has been deleted, 
has greatly improved safety. In fact, the SIN-Long Terminal Repeat (SIN-LTR) cannot 
initiate transcription o f the vector genome and, thus, should not permit mobilization of 
the vector, for instance following superinfection by HIV. Finally, the SIN design has 
improved vector performance, allowing for the use of internal promoters, which can be 
selected according to the application.
In addition, more elements such as cPPT (central poly-purine tract) were added into 
the transfer vector, which, together with CTS (central termination site), increase the 
efficiency o f the vector by promoting the provirus entry into the nucleus. The level of 
transgene expression was also improved by the WPRE (woodchuck hepatitis post- 
transcriptional regulatory element) 196 197 (Figure 15).
cPPT-CTS
| TransgenePromoter WPRE
Figure 15. Schem e o f last generation  transfer plasm id. SD: Splicing D onor site; SA: Splicing 
A cceptor site; cPPT: central poly-purine tract; CTS: central term ination site; W PRE; w oodchuck 
hepatitis post-transcrip tional regulatory  elem ent.
2.3 Gene transfer into hematopoietic stem cells
HSC are attractive targets for gene therapy in a variety of inherited and acquired 
genetic diseases, including immunodeficiencies and metabolic disorders. These 
disorders have been treated for some time by allogeneic bone marrow transplantation. 
However, the development o f GvHD in transplanted patients is a frequent and life- 
threatening complication so the higher than normal levels o f expression o f the functional 
gene in autologous HSC and their progeny, might improve the therapeutic 
potential/outcome of HSC transplantation. For this reason, the transplantation of gene 
corrected, autologous HSC has been proposed as an alternative therapy. HSC can be 
supplied with the therapeutic gene by ex vivo transduction and then be re-infused into 
the donor. If  gene transfer occurs in primitive HSC and the genetic material is inserted 
into the target cell chromatin in order to be maintained during HSC proliferation and 
differentiation processes, transplanted HSC will self-renew and generate large numbers 
o f gene corrected, differentiated progeny, theoretically for the lifespan of the host. 
Moreover, the use o f vectors capable o f higher than normal levels o f expression o f the 
functional gene in HSC and their progeny, might improve the therapeutic benefit of 
HSCT.
W hen a protocol for in vitro culture and transduction o f HSC has to be defined, 
critical issues are related to the maintenance of HSC sternness and homing capacity. The 
development o f protocols that maintain HSC in culture without affecting their biological 
properties, is closely linked to the knowledge of extrinsic signals regulating HSC in 
vivo. Since the majority o f  these stimuli still need to be elucidated, the specific 
combination o f the most suitable factors for in vitro culture and gene transfer, has yet to 
be determined. Moreover, the use of different vectors for HSC gene transfer poses 
diverse requirements for cell stimulation. Since MoRV have been the most exploited 
vectors for HSC gene transfer, the majority of designed protocols include several days of 
cell stimulation, to induce cell proliferation. The main issue is to induce HSC
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proliferation without impairing their clonogenic potential, keeping ex vivo manipulation 
time to a minimum. Several studies have addressed this issue with the most studied 
factors for HSC stimulation being IL-6, IL-3, SCF, Flt3L and TPO which have been 
shown to preserve function, allow moderate expansion and aid in transduction o f HSC
198 199 200
Since supporting niche cells act on HSC through specific molecular interactions, 
promoting either their quiescence or expansion according to physiological needs, an 
alternative approach could be to mimic these interactions in vitro. The strategy that was 
first exploited to recreate the natural condition o f HSC, was to grow them on a layer of 
BM stromal cells, which would provide physiological amounts of cytokines and trophic 
factors to cultured cells 201. Nevertheless, this procedure presents technical limitations. 
Firstly, it is very difficult to standardize this kind o f culture. Furthermore, its clinical 
application is challenging given the need to either harvest autologous stromal cells 
weeks before the HSC harvest 159, or to introduce foreign human or animal antigens, 
when using heterologous stromal cells. In order to provide support for HSC in culture 
and overcome the limitations of stromal cells, fibronectin (FN) has been widely used to 
coat culture dishes or bags. FN is abundantly expressed in the BM microenvironment, 
where it plays an important role in cell-cell and cell-matrix interaction. It has been 
proved that cells cultured on FN, show an increased survival and better maintenance of 
clonogenic capacity during ex vivo culture compared to those grown on a stromal layer 
or in suspension 159. Moreover, by allowing co-localization of RV and target cells, FN 
increases the HSC transduction rate 202 203.
Beyond the choice o f which are the best factors for maintaining HSC, another issue 
that has been investigated in the gene transfer field is the period of cell culture. Since 
MoRV have been the most exploited vectors for HSC gene transfer, most designed 
protocols included several days of cell stimulation, to induce cell proliferation 204 205. 
Some o f  these trials have already given encouraging results in terms o f efficacy, but
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only long-term analysis o f the patients’ graft will determine whether transduced cells 
were short-term or long-term progenitor HSC. Additional studies are currently ongoing 
in an attempt to further increase transduction efficiency and evaluate the safety and 
repopulation potential o f transduced HSC. Xenotransplant studies performed in 
NOD/SCID models, showed that 4 days in culture greatly reduced HSC engraftment 
ability in a competitive setting 206, supporting the idea that minimal HSC manipulation 
should be preferred.
Even in the best cases reported, SRC transduction with MoRV never reached 
sustained levels, likely due to the need for cycling cells. This issue has been markedly 
improved using LV, which efficiently transduce HSC without extensive manipulation. 
Nevertheless, in apparent contrast with the lack o f LV requirement for target cell 
proliferation, a significant enhancement in gene transfer in the presence o f a
150 207combination o f early-acting cytokines was found
The therapeutic potential o f LV-mediated ex vivo gene transfer has been 
demonstrated in murine models o f MLD 208, (3-thalassemia 209, sickle cell anemia 21°, 
W iskott-Aldrich syndrome 211 and Chronic Granulomatous Disease 212. Clinical trials on 
(3-Thalassemia and X-linked ALD are currently ongoing 213.
2.4 Safety of integrating vectors
Integration of a transgene into the cell chromatin may ensure stable expression o f 
the gene product in the target cell and its progeny. For this reason, integrating vectors, 
such as retrovirus-based vectors, have been the preferred choice for gene delivery into 
HSC. On the other hand, vector integration may significantly affect the expression of 
cellular genes consequently altering cell growth control and eventually triggering cell 
transformation.
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2.4.1 Adverse events in gene therapy
Given their ability to achieve high expression levels in the hematopoietic system, 
MoRV carrying wild type LTRs have been largely and in some cases, successfully used 
in gene therapy for blood disorders since 1991. These vectors were considered relatively 
safe, since integration was thought to be randomly distributed in the genome and the 
chance o f accidentally disrupting or activating a gene was considered remote. This 
assumption was reconsidered when a lymphoproliferative disorder was reported in one 
patient treated for X-SCID with M oRV-transduced HSC 162. Mapping o f MoRV 
integrations in the predominant T-cell clone revealed a single pro viral insertion within 
the LMO-2 locus, associated with up-regulation of transcript and protein levels. A 
similar complication was reported in three more patients enrolled in the same clinical 
study 163 and in another patient recruited in an independent X-SCID trial 161. These five 
adverse events have remarkable features in common: all but one malignant clone hosted 
at least one MoRV insertion near to the proto-oncogene L M 02, resulting in LM 02 
protein over-expression and leukemia developed 2 to 5 years after gene therapy 
treatment. This observation led the scientific community to reconsider both the 
assumption o f random distribution o f retroviral integration in the genome and the risks 
associated with retroviral gene transfer in human beings.
2.4.2 Insertional mutagenesis
Upon integration upstream from a gene in a tandem orientation, the proviral LTR 
can generate transcripts that read through and form chimeric transcripts including all, or 
part o f the coding sequences o f the downstream gene. Such read-through transcription 
occurs because the polyadenylation sites within the R region of the LTR are relatively 
weak and inefficient. If  the vector genome contains an active splice donor (SD) site, 
aberrant splicing can lead to a truncated transcript that is missing a portion o f the 5' 
mRNA sequences. As a result, such a read-through transcription can increase the amount
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of the normal gene product or, alternatively, lead to the generation o f a truncated 
protein, which may have adverse effects (Figure 16). Alternatively, the proviral genome 
could integrate in any orientation upstream, within, or downstream of a gene, interacting 
with its cellular promoter. The activity o f viral LTR enhancers on the cellular promoters 
might increase the expression level of genes found within a genomic region of up to 300 
kb flanking the vector integration site. A third possibility is intragenic integration. 
Proviral integration might interrupt gene expression, either by inducing premature 
polyadenylation at a site within the vector genome or by triggering aberrant splicing 
which eliminates or alters the gene product. This mechanism becomes relevant for 
somatic genes only if  the insufficient haploid state is associated with a potentially 
deleterious effect.
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fo llow ing retroviral integration. (A) R ead-through transcrip tion  o f  a dow nstream  gene. U pon 
in tegration upstream  from  the gene in a tandem  orientation, the proviral LTR  can generate 
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the LTR  and the cellular prom oter. (C) D ecreased gene expression secondary to intragenic 
insertion  o f  a proviral genom e. The potential m echanism  w hereby proviral integration  m ay 
in terrupt gene expression is illustrated.
2.4.3 Pattern o f integration
Recent reports have also challenged the notion that retroviral integration occurs 
randomly in the target cell chromatin and have indicated specific biases for integration 
into transcriptionally active genes, for both MoRV and HIV 182 214 181. These recent 
findings have prompted the scientific community to study and compare integration site 
selection among different integrating vectors in greater depth, in order to evaluate the 
risk-benefit ratio in gene therapy applications and to develop safer vectors. In our lab, 
the use o f a tumour-prone mouse model, allowed us to demonstrate a dose-dependent 
acceleration o f leukemia/lymphoma onset triggered by M oRV upon HSC gene transfer 
and tranplantation. By contrast, tumorigenesis was unaffected by SIN-LV 215. The 
different integration site selection patterns of the two vectors and the lack of 
transcriptionally active LTRs in the LV design were recently shown to contribute to the 
low genotoxicity of LV observed in this model (Montini et al, JCI, in press). Recent 
studies confirmed the different integration pattern o f LV, which unlike MoRV, rarely 
integrate in proximity to expressed genes 182
3. Gene therapy for LSDs
LSDs are excellent candidates for gene therapy. Firstly, they represent generally 
well-characterized, single gene disorders and secondly, a partial reconstitution of
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enzyme activity is usually sufficient for clinical efficacy
3.1 In vivo gene therapy for LSDs
3.1.1 Systemic vector administration
In vivo gene therapy in LSDs is usually designed to establish a sustained source of 
therapeutic enzyme within the body for metabolic correction. Intravenous delivery of 
viral vectors may represent an effective strategy to target gene transfer to tissues, which 
are readily accessible from the bloodstream and may thus become efficient sources of 
systemic enzyme distribution. It has been shown that intravenous administration of 
Adenoviral vectors (AdV) 217, Adeno-associated vectors (AAV) 218 219 220? RV 221 222 223 
and LV 194 224 leads to efficient liver cell transduction. By using these different 
approaches, the liver can produce large amounts of therapeutic enzyme, thus becoming a 
depot organ. The efficacy o f this strategy has been evaluated in several LSD animal 
models. Neonatal intravenous MoRV gene therapy has been evaluated in mice and dogs. 
Newborn mice affected by MPS I, caused by IDUA deficiency, were intravenously 
injected with MoRV expressing canine IDUA. Treated animals achieved stable 
expression o f IDUA in serum, a reduction o f storage material in tissues and a reduction 
o f some major clinical manifestations. Interestingly, these results were not observed in
mice treated with a lower dose o f vector, suggesting that a high expression of the
222transgene is required for gene therapy to be effective . Similar results were obtained in 
dogs affected by MPS VII and injected with MoRV expressing the canine b-
glucuronidase (GUSB). Treated animals displayed stable levels o f GUSB in serum, at or 
above the heterozygous levels, an absence of major clinical signs o f the disease such as 
cardiac abnormalities and a marked amelioration of the skeletal, cartilage and synovial
9 9 9  9 9 9disease . AAV were also successfully used for systemic gene delivery in LSDs. 
Mice affected by MPS II caused by iduronate 2 sulfatase (IDS 2), were injected 
intravenously with AAV2/8 expressing IDS 2. Treatment resulted in the full clearance of 
storage substrate and restoration o f IDS 2 activity in plasma and tissues 225.
Despite encouraging pre-clinical data, this approach reveals some relevant 
limitations when considering clinical translation: i) the occurrence o f immune responses
directed towards the vector or the novel therapeutic protein can lead to clearance of the
226transduced cells and/or loss o f enzyme activity ; ii) poor therapeutic potential in LSDs 
with CNS involvement, since the secreted enzyme is unable to cross the BBB, thus 
limiting the benefit to peripheral organs, without correcting nervous system 
manifestations; iii) the safety and toxicity of parenteral vector administration and the 
possible risk o f inadvertent gene transfer to the gonads and germ-line transmission o f the 
vector will have to be established.
The development o f immune responses may be reduced by the use of liver-specific 
promoters capable o f restricting transgene expression to parenchymal cells o f the liver, 
thereby reducing the expression within antigen-presenting cells 227. Moreover, the 
residual off-target expression o f the transgene has been recently prevented by using 
microRNA regulation: Brown et al. demonstrated that transgene expression could be 
inhibited in antigen presenting cells by microRNA-regulated LV and allow establishing
9 98stable long-tenn therapeutic gene transfer in the liver . These novel approaches are 
currently being tested in vivo, for therapeutic efficacy in LSD models.
3.1.2 Direct CNS gene delivery
To overcome the issue o f poor BBB permeability for lysosomal enzymes, delivery 
systems have been developed for direct in vivo gene transfer into the CNS. Efficient 
transduction o f the neurons o f adult rodent brains was observed with all generations of
9 9 Q o  9  n  1 Q 9  9  9 1LV and effective gene transfer was also observed in the neurons o f non­
human primates 232. The main cellular target of LV in the CNS are neurons (over 90% of 
transgene-expressing cells after administration of VSV-pseudotyped LV), while glial 
cells are transduced in vivo to a lower efficiency. Pre-clinical studies have been 
performed on animal models for several LSDs. LV encoding the lysosomal ARSA 
enzyme were stereotactically injected into the brains o f mice affected by MLD. Treated 
animals displayed a significant improvement o f disease-associated neurological and 
behavioral symptoms 233. Similar results were obtained by injecting AAV coding for a- 
iduronidase into the brains o f murine and canine MPS I models: the procedure prevented 
the accumulation o f gangliosides and allowed for clearance of the storage material
9 9<1 9  9  Spresent at the time o f treatment . Stereotactical injections of AAV were also
performed on small and large animal models with late infantile neuronal ceroid 
lipofuscinosis (LINCL), an LSD caused by tripeptidyl peptidase 1 (TPP1) deficiency. 
LINCL mice that received intracranial injection o f AAV2 and AAV5, showed a marked 
reduction in stored material and neurological abnormalities, but motor neuron function
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was preserved only when gene therapy was performed in a pre-symptomatic stage . In
a related study, this group demonstrated a reduction o f storage material, but significant 
recovery did not occur when the treatment was applied after the onset of symptoms 237. 
Given these encouraging results, a clinical protocol for CNS-directed gene therapy has 
been approved for LINCL patients’, where an AAV2 encoding for TPP1 is administered 
directly into the brain 238. Preliminary data showed a modest diffusion of the enzyme in 
the CNS and disease progression was reported to be slowed. Unfortunately, serious 
adverse events were also observed: one patient died after developing epileptic seizures,
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while another showed a humoral response against the transgene 239. A clinical protocol 
o f CNS-directed gene therapy has also been approved for Canavan disease 24°. In this 
LSD the deficiency o f the lysosomal enzyme aspartoacylase (ASPA) is responsible for 
toxic accumulation o f substrates in the CNS, leading to myelination impairment and 
spongiform degeneration o f the brain. Patients treated with intracranial infusions of 
recombinant AAV2 expressing ASPA showed minimal systemic signs o f inflammation. 
Three out of 10 patients developed a low level o f neutralizing antibodies. This data 
suggested that intraparenchymal administration o f AAV2 is relatively safe, while the 
efficacy of this treatment will be evaluated in phase II/III trials.
In summary, in vivo gene therapy approaches for LSDs have demonstrated up to 
date satisfactory safety and efficacy. The effective correction o f disease manifestations 
throughout large sectors o f the brain despite the focal vector administration has been 
shown to be due to the transduction o f neurons, which, through their projections, could 
distribute the enzyme into the CNS 241 236. Nevertheless, the invasiveness o f the gene 
transfer procedure and the adverse events described in the LINCL clinical trial caution 
for further development o f this approach. Ongoing pre-clinical studies in primates and 
upcoming clinical trials will clarify the tolerability and therapeutic potential o f direct 
CNS gene transfer by different vectors.
3.2 Ex vivo gene therapy for LSDs
3.2.1 HSC-based ex vivo gene therapy
Based on the positive clinical experiences with HSCT in some LSDs, HSC-mediated 
gene therapy has been considered as an attractive alternative for the treatment of LSDs. 
Importantly for LSDs characterized by a severe involvement o f the nervous system (see 
paragraph 1.6.3), HSC progeny might contribute significantly to the turnover of CNS
102 242microglia , which play a major role in the pathogenesis o f CNS involvement in
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many LSDs, including GLD 243 244 Gene transfer strategies aimed at correcting the 
genetic defect in HSC may have significant advantages when compared with 
conventional allogeneic HSCT protocols. Because autologous cells are used, transplant- 
related mortality and morbidity are reduced. Moreover, genetically modified cells may 
express higher levels o f the therapeutic enzyme, thus becoming more effective than wild 
type cells.
Several pre-clinical studies have been performed on murine models o f LSDs. In the 
case of MLD, LV-mediated transduction of HSC allowed a supra-physiological 
expression o f the lysosomal enzyme ARSA. M ajor disease manifestations were 
prevented in mice transplanted with ARSA-transduced HSC when treated in a pre- 
symptomatic stage and pre- established neurophysiological and neuropathological 
damage was corrected when transplanted in a symptomatic stage 208 102. The efficacy o f 
HSC gene therapy has also been demonstrated in MPS I mice. Transplantation o f 
MoRV-transduced HSC allowed for the reduction o f stored toxic material in the liver, 
spleen, kidney, choroid plexus and thalamus 245. This result was likely due to the 
reconstitution o f peripheral macrophages by cells o f donor origin, over-expressing the 
therapeutic enzyme. The level of enzyme over-expression required to achieve 
therapeutic efficacy could vary for different diseases. LSDs characterized by CNS 
involvement or by bone alterations might require a higher enzyme expression, compared 
to those characterized by visceral manifestations. In order to achieve high enzyme 
activity and therapeutic efficacy, a high level o f transgene expression by HSC and their 
progeny may be required. High transgene expression relies on multiple vector 
integration into HSC, a condition that might increase the risk o f integration-dependent 
adverse events (see paragraph 2.4).
In HSC gene therapy, as in the case of allogeneic HSCT, CNS inflammation might 
enhance the efficacy o f the treatment by accelerating the rate o f microglial 
reconstitution. This phenomenon has been observed in the murine model of
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gangliosidosis GM-1: upon transplantation o f HSC transduced with MoRV coding for 
lysosomal p-Galactosidase, animals showed correction of disease phenotype 107. These 
results highlighted the concept that therapeutic HSCT actually corrects a nervous system 
damage-response pathway which is defective in LSDs. Vector-mediated over-expression 
o f the therapeutic enzyme in macrophages/microglia may serve to enhance the 
corrective potential of this pathway.
3.2.2 Neural stem cells-based ex vivo gene therapy
In 1992, Reynolds and Weiss were the first to isolate neural progenitor and stem 
cells from the striatal tissue, including the sub ventricular zone -  one o f the neurogenic 
areas - o f adult mice brain tissue. Neural stem cells (NSC) are the self-renewing, 
multipotent cells that, in vitro, generate the main phenotypes of the nervous system: 
neurons, astrocytes and oligodendrocytes. Since then, neural progenitor and stem cells 
have been isolated from various areas o f the adult brain, including non-neurogenic areas, 
such as the spinal cord and from various species including humans 246.
NSC-based ex vivo gene therapy exploits the engraftment potential and the 
multipotency o f NSC. The identification and mapping of persistent NSC and progenitor
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cells in the CNS highlight the potential o f neuroplasticity in adulthood and
emphasized the possible role of NSC and progenitors in the treatment o f LSDs. In many 
metabolic myelin disorders, such as GLD, oligodendrocytes are killed by toxic 
metabolites; the engraftment of glial progenitor cells is associated with astrocytic and 
oligodendrocytic production, while undifferentiated NSC can migrate widely throughout 
the CNS and can, to some extent, differentiate and integrate in a regionally appropriate 
fashion. As such, both glial progenitors and NSC seem to be promising vehicles for the 
distribution o f enzyme-producing cells throughout the brain parenchyma. Lacorazza and 
colleagues reported the expression o f |3-Hexosaminidase upon engraftment of 
transduced NSC into recipient mice 249. Similar results have been obtained in a murine
model of MPS VII: upon implantation o f MoRV or LV-tranduced NSC into the CNS, 
high levels of therapeutic enzyme and correction o f brain disease manifestations have 
been observed 250 251.
3.3 Gene therapy for GLD
The first gene transfer studies on GLD were performed on fibroblasts. Gama Sosa 
and colleagues demonstrated that retroviral-mediated gene transfer o f human GALC 
cDNA into twi fibroblasts and primary human fibroblasts from a patient with juvenile- 
onset GLD, was able to correct the GALC-deficient phenotype o f the disease, reaching a 
supra-physiological level o f GALC activity 252. Furthermore, the cross-correction 
mechanism was demonstrated in fibroblasts and oligodendrocytes cultured in 
conditioned medium from transduced cells 253 254 Rafi and colleagues transduced 
primary cultures of fibroblasts, obtained from a GLD patient, with a MoRV containing 
the human GALC cDNA. Transduction permitted over-expression o f GALC up to 100 
times the normal value. Moreover, untransduced GLD fibroblasts cultured in the 
conditioned medium o f transduced cells, displayed a reconstitution of enzymatic 
activity, thus confirming that GALC could be secreted and internalized by neighboring 
cells. Further analysis confirmed that GALC was correctly sorted to lysosomes of cross­
corrected fibroblasts 254. Although fibroblasts could be useful for basic studies, they do 
not have abnormalities related to sphingolipid accumulation. Therefore, enzyme 
reconstitution following transduction and cross-correction was evaluated in 
oligodendrocytes. Luddi and colleagues transduced twi oligodendrocytes with a MoRV 
expressing GALC. In transduced cells GALC activity was increased to heterozygous 
levels and correction o f morphology was observed. In this study, GALC expression 
following transduction was lower in respect to that observed in transduced fibroblasts. A 
possible explanation could be the poor transduction efficiency o f MoRV on slowly 
dividing cells, such as oligodendrocytic precursors. Further experiments demonstrated
that transduced oligodendrocytes are able to secrete GALC into the culture medium and
253untransduced oligodendrocytes are able to uptake the enzyme as well
These results have been the background for further pre-clinical studies. Most 
strategies that have been developed and that involve AdV, AAV, MoRV or LV, are in 
vivo gene therapy approaches. In 2001, the first case of gene delivery directly to the 
CNS in GLD models, was reported. AdV coding for the human GALC was intra- 
ventricularly injected into 0 day-old or 15 day-old twi mice. The treatment, when 
performed at birth, resulted in increased GALC activity and partial correction o f the 
pathology in the brain, but without a significant improvement o f the phenotype. 
Moreover, pathology correction was not observed when twi mice were treated at 15 
days, suggesting that the timing o f intervention should be precocious 255. Similar studies 
further demonstrated that in vivo approaches targeting the CNS only, are not able to 
correct the disease. Intraventricular injection of AAV1 in twi and in trs mice (see 
paragraph 1.6) achieved a prolonged lifespan and a correction of pathologic signs of 
disease, but treated animals died with the same disease manifestation as controls 256. 
Comparable results were obtained with intracranial injections of AAV2 or AAV2/5 
expressing murine GALC, performed on twi mice 257 at 3 days of age. In general, 
intracranial injection of viral vectors expressing GALC, resulted in high levels of 
enzyme activity in the brain. However, this supraphysiological level o f GALC activity 
resulted only in a slowing of disease progression, with minimal improvement of 
phenotype and lifespan. Moreover these results were obtained only when treatment was 
performed at a pre-symptomatic stage. The major limitation of this approach is the lack 
o f efficacy at the level of the PNS. For this reason, the combination with a systemic 
approach, such as ERT or HSCT, which could provide the enzyme to the PNS, might 
give better results. Lin and colleagues combined CNS gene delivery with HSCT 258. Twi 
mice were injected with AAV vector expressing GALC in the CNS and underwent 
HSCT from wild type donors. Treated animals showed a significant reduction in
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demyelination, astrocytosis and macrophage infiltration. Their survival was longer, not 
only in respect to untreated controls, but also compared to that obtained with either 
single treatment, thus suggesting a synergy between the two therapies. Interestingly, the 
increase of GALC activity in the tissues o f mice that received the combination 
treatment, was higher compared to either therapy alone and even higher than the sum of 
the activity from the individual treatments. This finding enforced the hypothesis o f a 
synergistic effect o f AAV injection in the CNS and HSCT.
Besides direct CNS gene delivery, cell-based gene therapy strategies have also been 
tested. Pellegatta and colleagues engrafted twitcher mice with cultured LV-transduced 
NSC 259. Although the engrafted GALC-over-expressing cells did not survive well in the 
highly inflammatory twitcher brain, they migrated appropriately to active sites of 
demyelination, in a manner similar to the one observed in adult mice by 260 261. The 
therapeutic effect o f the treatment was modest, due to the clearance of transduced cells, 
likely due to the activated microglia. The hypothesis that the CNS of twi mice could be a 
non-permissive environment for transplanted cells was also investigated by Snyder’s 
group. The inflammatory milieu o f twi CNS was not found to be a limiting factor for 
NSC engraftment, but, rather, it appeared to serve as a tropic factor, drawing 
transplanted NSC towards damaged areas. Moreover, they investigated the sensitivity of 
NSC to the toxic storage of Psy, present in the CNS o f two mice. NSC showed an 
increased resistance to the detrimental effect of Psy, if  compared to more differentiated 
cells, such as oligodendrocytic progenitors 262. Therefore, in order to develop an 
effective cell gene therapy strategy for the treatment o f GLD, the sensitivity of 
transplanted cells to the toxic environment where they are transplanted, should be 
considered. This issue could also be relevant for developing HSCT-based gene therapy 
strategies. Previous studies demonstrated that Insuline-Like Growth Factor 1 (IGF1) is 
involved in survival pathways of different cell types and could rescue oligodendrocytes
9 0from apoptosis induced by the toxic effect of Psy accumulation . The usefulness of
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IGF 1 in helping to improve HSCT has recently been tested. In vitro stimulation with 
IGF I,- before transplantation, resulted in an increased engraftment o f HSC and 
prolonged survival o f transplanted mice 263. Overall, these findings suggest that gene 
therapy for a complex disease like GLD should consider different aspects, including the 
level o f enzyme expression required, the characteristics o f transplanted cells and the 
permissiveness o f the environment where cells are transplanted or where viral vectors 
are injected.
AIM OF THE WORK
First aim o f this work was to develop a gene therapy approach for the treatment of 
GLD, based on HSPC and LV. From the experience with MLD, we learned that for HSC 
gene therapy to be efficacious in LSD, effective gene transfer and enzyme over­
expression in HSPC must be obtained. First, we tested the feasibility of GALC over­
expression in HSPC upon GALC.LV transduction. Then, we set up a transplantation 
protocol in twitcher mice. Unfortunately, our work showed that transduction with GALC 
encoding LV affects the functionality o f HSPC, which become unable to repopulate 
lethally conditioned twitcher mice, For this reason, we then attempted to evaluate the 
safety o f GALC over-expression in HSPC. We studied the maintenance of the functional 
properties o f HSPC upon GALC over-expression both in vitro, evaluating their 
clonogenic potential by CFC assay, and in vivo, evaluating their repopulation potential 
by HSCT in mice. Moreover, we verified whether transduction affected HSPC survival, 
by monitoring the occurrence o f apoptosis by TUNEL assay and annexin V staining at 
different time points after gene transfer. Indeed, we demonstrated that GALC expressing 
HSPC undergo a rapid and massive apoptosis, associated to a functional impairment 
both in vitro and in vivo. The mechanism responsible for this overt toxicity observed in 
HSPC upon GALC de novo expression was further investigated. We performed a 
sphingolipid profile o f GALC.LV transduced HSPC, and demonstrated that ceramide 
and sphingosinelP accumulation is likely to be responsible for the observed acute 
apoptosis.
Third aim of the work was to overcome the limitation o f GALC de novo expression 
toxicity in HSPC in order to develop HSC gene therapy for GLD. First, we evaluated the 
sensitivity to GALC toxicity o f differentiated hematopoietic cells and in cells of other 
lineages. Since microglia and macrophages, the effector cells of HSC gene therapy, were 
not affected by GALC de novo expression, we tested two new strategies to restrict
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transgene expression to differentiated hematopoietic cells. The first strategy was based 
on myeloid-specific promoters (transcriptional regulation), in order to allow GALC 
expression only in microglia and macrophages, the effector cells o f HSC gene therapy. 
The second strategy exploited microRNA-based post-transcriptional regulation to 
repress transgene expression only in HSC and not in differentiated cells. Although these 
two approaches proved to be very promising in protecting HSPC from enzyme toxicity 
both in vitro and in vivo in heterozygous GLD mice, gene-corrected HSPC failed to 
repopulate lethally irradiated homozygous GLD mice. This poor result might be 
explained by the existence o f  a niche defect in homozygous GLD mice, which might 
hamper the engraftment of HSPC.
METHODS
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1. Reagents and suppliers
1.1 Chemicals
All chemicals were obtained from FLUKA or Sigma-Aldrich. Other chemicals used 
during the study were obtained from the following sources:
Lymphoprep:
CH296 (retronectin): 
Metaphor agarose: 
Fluorsave Reagent: 
Papain:
EDTA:
Axis-Shield PoC AS 
Takara BIO 
BMA
Calbiochem
Worthington
ProLabo
1.2 Enzymes and buffers
All DNA modification enzymes and buffers were obtained from Roche. All 
restriction enzymes and buffers were obtained from either Roche or New England 
Biolabs.
GoTaq polimerase enzyme was supplied by Promega.
1.3 Bacterial strains
The Top 10 bacterial strain was supplied by Invitrogen (code number 44-0301).
1.4 Cell culture
Cells were incubated at 37°C in a 5% CO incubator. All tissue culture plastic ware 
(tissue culture plates and tubes) was obtained form BD Falcon.
74
Trypsin-EDTA solution: Phosphate Buffered Saline 0,05% trypsin, 4mM EDTA pH
7.3.
Media, sera and supplements:
IMDM: Sigma-Aldrich
RPMI: 1640 Euroclone
DMEM: Euroclone
StemSpan SFEM: Stem Cell Technologies
Cell Gro: Cell Genies
MethoCult H4434: Stem Cell Technologies
MethoCult M3434: Stem Cell Technologies
Foetal Bovine Serum (FBS) BioSera
Trypsin: Invitrogen
L-Glutamine: Invitrogen
Penicillin/Streptomycin: Invitrogen
Polybrene: Sigma-Aldrich
Cytokines: Peprotech
PBS: Sigma-Aldrich
Matrigel: Beckton Dickinson
2. Plasmids
LV were produced by co-transfection o f 4 plasmids: transfer construct, packaging 
construct, Rev-encoding construct and envelope construct. All the plasmids contain the 
gene encoding for Ampicillin resistance.
Transfer constructs:
pCCLsin.PPT.hPGK.eGFP.pre 186 264 187 
pCCLsin.PPT.hPGK.eGFP.142mirTag.pre
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pRRLsin.PPT.hPGK.GALC.pre
pRRLsin.PPT.hPGK.GALC.HA.pre
pRRLsm.PPT.hPGK.GALC.142mirTag.pre
pRRLsin.PPT.CDl lb.GALC.pre
pCCLsin.PPT.hPGK.ARSA.pre 102
pCCLsin.PPT.hPGK.IDUA.pre
pCCLsin.PPT.hPGK.DNGFR.pre
Packaging constructs:
pCMVAR8.74 186 was used in the production of second generation vectors.
pMDLg/pRRE 186 was used to package third generation vectors.
Rev-encoding construct: pRSV-REV 186
Envelope constructs: pMD2.VSV-G 186
3. Transformation of competent bacteria and plasmid 
preparation
Plasmid DNA (0.5-10ng) to be transformed was mixed with 50pl of chemically 
competent Top 10 cells prepared specifically for the heat shock mediated transformation 
method. The mix was incubated on ice for 30 minutes, then 1 minute at 42°C, and then 
returned to ice for a further 5 minutes. The mix was then plated onto Luria Bertani (LB) 
agar plates, containing lOOpg/ml ampicillin and placed overnight in a 37oC bacterial 
incubator. The following day, colonies were picked and placed into 2 ml o f Terrific 
Broth (TB) media for GALC-plasmids, or LB media for all other plasmids containing
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carbenicillin (ampicillin homologue), and grown over day with agitation at 37°C. 10 pi 
of the over day culture were placed in 200ml of TB or LB media containing 
carbenicillin, and grown overnight shaking at 37°C. The following day, cell suspension 
was measured by spectrophotometer analysis (k^OOnm) to check for optimal cell 
density (about 1-1.5 O.D.) and subjected to large-scale plasmid DNA preparation. 
Plasmid DNA preparation was performed using High Purity Plasmid Purification 
Systems (Marligen Biosciences). This system is based on alkaline lysis, followed by 
DNA purification on an anion exchange resin. After elution, plasmid DNA was then 
desalted and concentrated by alcohol precipitation washed in 70% ethanol and 
resuspended in TE buffer (lOmM Tris-HCl pH 8.0, 0.1 mM EDTA).
4. Vector production
4.1 Transfection
Reagents:
2X HBS: 281mM NaCl, lOOmM HEPES, 1.5mM Na2H P 0 4, pH 7.12, 0.22pM 
filtered, stored at -20°C  or -80°C .
2.5M CaCl2: tissue culture grade, 0.22pM filtered, stored a t-20°C .
0.1X TE buffer: lOmM Tris (pH 8.0), ImM  EDTA (pH 8.0) diluted 1:10 with dH20 , 
0,22pM  filtered, stored at 4°C.
dH20 : endotoxin-free, tissue culture grade (Sigma-Aldrich).
Vector stocks were prepared by calcium phosphate transfection and concentrated by 
ultracentrifugation. Vectors were produced by transfection o f human embryonic kidney 
293T cell line (containing the mutant gene of SV40 Large T Antigen, see paragraph 5. 
Cell lines), because these cells are optimal DNA recipients in transfection procedures 
and the backbones o f the vector construct contain SV40 origin o f replication. 9x106
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293T cells p er  dish were seeded and incubated in 15 cm dishes, 24 hours before 
transfection in IMDM, 10%FBS, Penicillin (25U/ml), Streptomycin (25U/ml). Two 
hours before transfection medium was replaced. To produce LV, plasmid DNA mix was 
prepared by mixing (per dish):
9pg pM D2-VSV-G
16,25pg pCMVAR8.74 or 12,5pg pMDLg/pRRE 
6,25 pg pRSV-REV 
32pg transfer construct
The plasmid solution was made up to a final volume o f 1125pl with 0. lXTE/dBhO 
(2:1) in a 15 ml polypropylene tube. Finally 125pl o f 2.5M CaCh were added. The 
precipitate was formed by drop wise addition o f 1250pl 2X HBS solution to the 1250pl 
DNA-TE-CaCl2 mixture while vortexing at full speed. The precipitate was added to 
293T cells immediately following addition of the 2X HBS and cells were incubated at 
37°C. 14-16 hours after transfection, medium was replaced. 30 hours after medium 
changing, supernatant was collected, filtered through 0.22pm pore nitrocellulose filter 
and ultracentrifugated at 19,500 rpm in SW32Ti rotor (Optima L-60 preparative 
Ultracentrifuge; Beckman) 2 hours at room temperature. Pellets containing the vector 
were resuspended in a volume of sterile PBS representing 1/500 of the starting medium 
volume, pooled and rotate on a wheel at room temperature for 1 hour. The concentrated 
vector preparation was then divided into small aliquots (20-50pl) and stored at -80°C .
4.2 Vector particle amount determination
Vector particle amount was determined by immunoenzymatic assay, using the 
Alliance HIV-1 p24 antigen ELISA kit (PerkinElmer), following m anufacturer’s 
instructions. Serial dilutions of the vector stock (see below vector titer determination) 
were plated in triplicate in microplate wells, which are coated with a highly specific
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mouse monoclonal antibody to the HIV-1 capsid protein p24, and vector particle 
envelope was lysed by 5% Triton X-100. The captured antigen was then complexed with 
biotinylated polyclonal antibody to HIV-1 p24, followed by a streptavidin-HRP 
(horseradish peroxidase) conjugate. The resulting complex was detected by incubation 
with ortho-phenylenediamine-HCl (OPD), which produces a yellow colour that is 
directly proportional to the amount o f HIV-1 p24 captured. The absorbance of each 
microplate well was determined using a microplate reader (Versa Max, Molecular 
Devices) (X 490nm) and quantity o f p24 protein was calculated using an HIV-1 p24 
antigen standard curve.
4.3 End-point titration
End-point titration is performed by transducing a permissive target cell line with 
serial dilutions of the vector preparation. 105 HeLa cells were plated per well in 3.5cm 
wells in 1 ml o f IMDM 10% FBS; 6 hours later, a vector aliquot was thawn and to 
prepare serial ten-fold dilutions o f 2X viral stock (from 10‘3 to 10'8) in IMDM 10% FBS. 
Medium of cells was replaced with 500pl of medium 16pg/ml polybrene (2X final 
polybrene concentration) plus 500pi of serial dilutions (one dilution p er  well). Cells 
were cultured in a 5% C 02  incubator at 37°C. 16 hours later the medium was replaced. 
After 7-10 days cells were harvested for expression titer (FACS analysis) or for 
integration titer (Real-time Quantitative-Polimerase Chain Reaction (Q-PCR) analysis). 
The titer is defined as number o f transducing units per milliliter (TU/ml) o f vector 
preparation. Expression titer is based on the assumption that a single vector copy 
integrated in the host genome will give a positive cell. Assuming that all the cells are 
equally susceptible to transduction, following Poisson distribution for random 
independent events, a single transduction event, and not more, has occurred in most 
positive cells, when the percentage o f positive cells in the total population is below 25%. 
It follows that expression titer must be calculated from a sample corresponding to a
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vector dilution where positivity o f cells ranges between 1% (to ensure an acceptable 
signal over the instrument noise) to 25%, in order not to underestimate the titer when 
multiple transduction events per cell have occurred. Integration titer must be calculated 
from a sample corresponding to a vector dilution where vector copies per  cells rages 
between 0.01 and 0.25. Proof o f linearity must be obtained showing that different 
dilutions in the optimal testing range yield linear increase in transduction frequency.
The equation to calculate expression titer is:
Titer (TU /m l) = (num ber o f  cells at the tim e o f  vector addition) X  (% transgene+ cells/100) X  
(dilution factor)
The equation to calculate integration titer is:
Titer (TU /m l) = (num ber o f  cells at the tim e o f  vector addition) X  (vector copies per cell) X  
(dilution factor)
For FACS and Q-PCR analyses see relative paragraphs below. Titers of vectors used 
in this project ranged between 109 and 1010 TU/ml (vector stock concentrated 500x).
4.4 Infectivity of the vector stocks
Infectivity is a reliable parameter to evaluate the quality o f the vector stock and can 
be defined as the transducing activity per  unit o f physical particle, where the first 
parameter is expressed as TU/ml, as obtained by end-point titration and the second as ng 
p24/ml, as determined by immunoenzymatic assay. Since one ng of p24 could 
theoretically contain 1.2 X 107 particles, if  all the particles in the vector stock were 
infectious, a titer o f 108 TU/ml would correspond to a p24 concentration of about 10 
ng/ml. Indeed, a concentration in the range o f 500-1000 ng p24/ml is more reasonably 
expected. This is due to two major reasons. The first reason is that end-point titer fails to 
estimate the real content o f infectious particles in a vector preparation, because vector 
particles move by Brownian motion in the medium and only a fraction of them has the
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chance to get in contact with a cell in the monolayer and transduce it in the time window 
of the assay. The second reason instead is crucially linked to the quality of the vector 
batch tested. In fact, the efficiency o f packaging o f infectious particles is lower than 
what is predicted by theoretical calculations, and a good fraction o f the total p24 protein 
is not assembled into infectious virions. Vector infectivity can be calculated by the 
following equation:
Infectivity = (TU/ml)/(ng p24/ml) = TU/ng p24 
Infectivities were 103-105 TU/ng p24 for all vector types.
5. Cell lines
HeLa (ATCC Number CCL-2), 293T (originally called 293tsA1609ne, and derived 
from 293 cells, a continuous human embryonic kidney cell line transformed by sheared 
Type 5 Adenovirus DNA, by transfection with the tsA 1609 mutant gene of SV40 Large 
T Antigen and the Neor gene of E. Coli - ATCC Number CRL-1573; cells were 
maintained in Iscove’s Modified Dulbecco’s M edium (IMDM) and U-937 (ATCC 
Number CRL-1593.2) in RPMI-1640, both supplemented with 10% foetal bovine serum 
(FBS), 100 IU/ml penicillin, 100 pg/ml streptomycin, and 2mM L-glutamine. To detach 
adherent cells PBS 0.05% trypsin, 4mM EDTA (pH 7.3) was used.
6. Mice studies
Twitcher (twi) mice were obtained from Jackson laboratories. Congenic 
FVB/N.B6Galc-(Pvz'/ftvz) (FVB/twi) mice were generated in our animal research facility 
by breeding Twi heterozygous (+/-) C57BL6 mice with wild type (+/+) FVB mice. Mice 
were screened as indicated in paragraph 6.1 and heterozygous offspring were 
intercrossed to obtain an inbred strain.
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Rag2-/-ychain -/- mice (Rag2yc) were obtained from Charles River laboratories.
Procedures were performed according to protocols approved by the Animal Care 
and Use Committee o f the Fondazione San Raffaele del Monte Tabor (IACUC #325) 
and communicated to the Ministry of Health and local authorities according to Italian 
law.
6.1 Genotyping of FVB/twi mice
Genotyping of FVB/twi mice was performed on DNA from tail biopsies. The 
sequence o f GALC containing the mutation was amplified by PCR and the product of 
amplification was digested by EcoRV endonuclease enzyme.
6.1.1 DNA extraction
Tail tissue was lysed by Proteinase K  (PK)(Roche) at the concentration of 1 mg/ml 
for 2 hours at 56 °C. The buffer used for PK lysis was TRIS 10 mM pH 7.2, EDTA 25 
mM, NaCl 10 mM, SDS 10%. After complete digestion, DNA was extracted through a 
salting-out method. The sample was spinned 5 minutes at 13200 rpm in a standard 
tabletop centrifuge to remove residues o f bones or fur. One volume of 
fenol/chloroform/isoamilic alcohol 25:24:1 was added to the sample, vortexed and 
spinned at 13200 rpm for 7 minutes. The upper phase was harvested and 10% volume of 
Sodium Acetate 3M pH 7.3 and 2 volumes of ethanol 100% were added. Sample was 
gently mixed and DNA flocculate was pellet by centrifugation at 12000 rpm for 5 
minutes. Pellet was washed with ethanol 70 % and resuspended in 100-200 pi o f sterile 
water.
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6.1.2 Amplification o f GALC sequence by PCR
Amplification o f GALC sequence was performed as described 265. The forward was 
designed on an intronic sequence 230 bp upstream the mutation site (TwF: 5 ’- 
CACTTATTTTCTCCAGTCAT). The reverse primer was designed on an esonic 
sequence immediately after the mutation site (TwR: 5 ’-
T AG AT GGCCC ACT GT CTT C AGGT GAT A ). The amplification generates in the 
mutant DNA a target sequence for the restriction enzyme EcoRV. Details o f PCR 
reaction are reported:
Buffer 5x (Promega) 5 pi step 1: 95°C 10’ 1 cycle
Primer F lOpM (Primm) 0.5pl step2: 95°C 30” 38 cycles
Primer R lOpM (Primm) 0.5pl 54°C 30”
dNTPs 10pM (Roche) 0.6pl 72°C 30”
Go Taq (Promega) 0.25pl step 3: 72°C 10’ 1 cycle
H 20 14,65pl
DNA 200ng
6.1.3 EcoRV restriction analysis
The 260 bp PCR product was digested by EcoRV in a final volume of 25 pi. 
Digestion o f one half o f PCR volume is enough to visualize the bands on gel. Details of 
reaction are reported:
Buffer B (Roche) 2.5 pi
EcoRV (Roche) 0.7 pi
h 2o 11.8 pi
DNA (from PCR) 10 pi
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Fragments obtained from EcoRV digestion were visualized on Metaphor 4% (BMA) 
agarose gel. EcoRV digestion o f wild type DNA results in the generation o f a band of 
260 bp; heterozygous restriction pattern shows 2 bands: one o f 260 bp (wild type allele), 
another o f 234 bp (mutant allele); homozygous restriction pattern shows only a band of 
234 bp.
7. Haematopoietic stem/progenitor cell (HSPC) enrichment
7.1 Human HSPC (hHSPC)
Cells from human subjects were obtained with informed consent according to the 
Declaration o f Helsinki, and to a protocol approved by the San Raffaele Scientific 
Institute Bioethical Committee. Mononuclear cells were obtained from human either CB 
or BM scheduled for discard by density separation, and CD34+ cells were isolated by 
positive selection. CB or BM were diluted 1:2 in PBS, stratified on half a volume of 
Lymphoprep and spinned at 1500 rpm in Heraeus Megafuge 1.0 (Kendro Laboratory 
products) 30 minutes at room temperature, w ithout brake. Plasma upper layer containing 
platelets was removed and the interphase between plasma and lymphoprep, containing 
PBMC, was transferred in a new tube and washed with PBS. Cells were then resuspend 
in 20ml MACS buffer (PBS pH 7,2, 0.5 % Bovine Serum Albumin -  BSA, Sigma- 
Aldrich - and 2mM EDTA). PBMC were then subjected to CD34 positive selection, by 
using the MACS Indirect CD34 Progenitor Cell Isolation Kit. The magnetically labelled 
cells were enriched on LS separation columns in the magnetic field o f the MidiMACS 
magnet (all M iltenyi Biotech), following m anufacturer’s instructions. Cells were
o
centrifuged at 1000 rpm  10 minutes at 4°C, resuspended in 300pl MACS buffer p er  10 
cells and incubated with 100 pi Fc receptors blocking reagent (to block aspecific binding
of the antibody) together with 100 pi apten-conjugated anti- CD34 antibody p er  10s cells 
20 min at 4°C. Cells were then washed with 20ml MACS buffer as above, resuspended 
in 400pl MACS buffer p er  108 cells and incubated with a secondary magnetic beads- 
conjugated anti-apten antibody 20 min at 4°C. Cells were washed again, resuspended in 
lm l MACS buffer p er  108 counted cells and subjected to two rounds of separation on LS 
columns. Flow through was discarded. CD34+ cells, recovered by removing the column 
from the magnetic field and by using the plunger, were then counted and either frozen in 
90% FBS, 10% Dimethyl Sulfoxide (DMSO) or used fresh.
7.2 Murine HSPC (mHSPC)
BM cells were harvested from FVBtwi mice o f 4-8 weeks and were subjected to 
negative selection by using the StemSep Mouse Hematopoietic Progenitor Cell 
Enrichment kit and the StemSep Magnet with StemSep 0.3" Negative Selection Gravity 
Columns (all Stem Cell Technologies), following manufacturer’s instruction. BM cells 
were harvested by flushing from femurs and tibias with PBS 2% FBS and counted in a 
Burker chamber. After spinning at 1500 rpm 5 min at room temperature, and cells were 
resuspended at a concentration of 5x l0 7cells/ml in PBS 2% FBS, 5% rat serum and 
incubated 15 min at 4°C to block aspecific binding o f antibodies. Cells were then 
incubated with 35pl/ml StemSep Enrichment Cocktail, which contains a combination of 
rat biotinilated monoclonal antibodies anti-mouse lineage specific markers (CD 5, 
C D llb , CD45R/B220, Gr-1, Neutrophils (7-4) and TER119) 15 min at 4°C. After 
washing with PBS 2% FBS, cells were resuspended at 5 x l0 7cells/ml in PBS 2% FBS, 
incubated with lOOpl/ml Anti-Biotin tetrameric antibody complexes 15 minutes at 4°C 
and then with 60pl/ml magnetic colloid 15 min at 4°C. Cells were then loaded on a 
primed and equilibrated column in the magnetic field. Flow though, which contains 
lineage negative (Lin-) cells, was harvested and cells were washed, resuspended in 
StemSpan medium and counted. mHSPC were used fresh for HSCT, for CFC assay or
were kept in culture in RPMI medium, 10% FBS, penicillin lOOU/ml and streptomycin 
100 pg/ml, L-glutamine 2 mM and cytokines (mSCF 50ng/ml, mFlt3L lOng/ml, mIL3 
lOng/ml, mIL6 20ng/ml).
7.3 Isolation of Seal- murine hematopoietic progenitors
BM cells were harvested from FVBtwi mice o f 4-8 weeks and were subjected to 
Seal positive cells depletion by using MACS S cal+  Progenitor Cell Isolation Kit 
(Miltenyi), following manufacturer’s instructions. BM Cells were centrifuged at 1000 
rpm 10 minutes, resuspended in 800 pi MACS buffer (see chapter 7.1) and incubated 
with 200 pi/ 108 cells of anti-Scal magnetic beads-conjugated antibody. After 20 
minutes at 4°C, cells were washed with 20ml MACS buffer, resuspended in 1ml MACS 
buffer per  108 counted cells, and subjected to one rounds o f  separation on LS columns. 
Scal+  cells were retained in the column, while S eal- progenitors were collected in the 
flowthrough.
8. Isolation of human lymphocytes
8.1 T lymphocytes
T lymphocytes were obtained from PBMC, isolated from buffy coat as described for 
CD34+ cell selection from CB. PBMC were cultured for 3 days at the concentration of 
lx l0 6 cells/ml in IM DM  5% human serum and PHA lpg/m l in order to stimulate T 
lymphocyte proliferation. Cells were then cultured in IMDM 5% human serum and IL-2 
300U/ml for at maximum two weeks.
8.2 B lymphocytes
B lymphocytes were obtained from PBMC, isolated from buffy coat as described for 
CD34+ cell selection from CB as described for CD34+ cell selection. PBMC were 
infected with Epstein-Barr virus (EBV) supernatant from B95.8 cells for 3 hours 266. 
After infection, cells were washed with PBS and cultured at the concentration o f 2 x l0 6 
cells/ml in IMDM 20% FBS, 100 IU/ml penicillin, 100 pg/ml streptomycin, and 2mM 
L-glutamine and PHA 2 pg/ml for 2 days. Medium was replaced twice a week (IMDM 
20% FBS, 100 IU/ml penicillin, 100 pg/ml streptomycin, and 2mM L-glutamine). B- 
lymphocytes were either frozen in 90% FBS, 10% DMSO or used fresh.
9. Primary cultures
9.1 Isolation of human monocytes
Monocytes were obtained from PBMC, isolated from buffy coat as described for 
CD34+ cell selection from CB. PBMC were washed with PBS and counted. PBMC were 
then subjected to CD 14 positive selection, by using the MACS CD 14 Isolation Kit. The 
magnetically labelled cells were enriched on LS separation columns in the magnetic 
field o f the MidiMACS magnet, following manufacturer’s instructions. Flow though was 
discarded. CD 14+ cells, recovered by removing the column from the magnetic field and 
by using the plunger, were then counted and plated on matrigel-coated cover-slips (for 
TUNEL assay) in RPMI supplemented with 10% FBS, 100 IU/ml penicillin, 100 pg/ml 
streptomycin 2mM L-glutamine and with GM-CSF 100 ng/ml, at the concentration of 
5x10s cells/ml. Alternatively, 2 .5x l06 CD 14+ cells were seeded in a 3.5 cm dish (for 
GALC activity assay). One half o f medium was replaced every 2 days.
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9.2 Isolation of murine peritoneal macrophages
Primary culture of murine macrophages were obtained through peritoneal wash with 
DMEM (8-10 ml/mouse). Cells were centrifuged at 1200 rpm 10 minutes and pellet was 
resuspended in DMEM supplemented with 10% FBS, 100 IU/ml penicillin, 100 pg/ml 
streptomycin 2mM L-glutamine. Cells were then counted and seeded at the 
concentration o f 4 x l0 6/ml in a 3.5 cm dish and cultured in incubator for 2 hours. After 
this time, medium containing non-adherent cells was removed and adherent cells were 
washed with PBS. The adherent fraction was cultured in DMEM 10% FBS, 100 IU/ml 
penicillin, 100 pg/ml streptomycin 2mM L-glutamine supplemented with GM-CSF 50 
ng/ml. One half of medium was replaced every 2 days.
9.3 Isolation of murine microglia
Primary cultures o f microglia were established from 2-day-old mice 267. Mice were 
sacrificed with a tribromoethanol injection and brains were removed and put in cold 
PBS for 15 minutes. Cortex was then dissected and disaggregated by incubation at 37°C 
20 minutes in EBSS with Papain 0.7 mg/ml, EDTA 0.2 mg/ml, L-Cysteine 0.2 mg/ml, 
DNAsel 10 pg/ml. After disgregation, cells were washed 3 times with DMEM and 
centrifuged at 1000 ref 10 minutes. Each time supernatant was removed and pellet was 
resuspended by carefully pipetting. Cells were then resuspended in DMEM 10% FBS 
100 IU/ml penicillin, 100 pg/ml streptomycin 2mM  L-glutamine, using a final volume 
of 12 ml o f medium to resuspend cells from 2 brains. After 7-10 days o f culture, 
microglia was separated from the mixed culture through one hour o f agitation at 195 
rpm at 37°C. Detached microglia was harvested, washed and counted. Cells were then 
plated on matrigel-coated coverslips (5x104 cells/ml) in DMEM 10% FBS 100 IU/ml 
penicillin, 100 pg/ml streptomycin 2mM L-glutamine.
9.4 Isolation of murine oligodendrocytes
Primary cultures o f oligodendrocytes were established from 2-day-old mice, as 
described for primary cultures of microglia. After one week of culture, microglia was 
separated from the mixed culture through one hour o f agitation at 195 rpm at 37°C, and 
was removed. Oligodendrocytes were detached through over-night agitation at 195 rpm 
at 37°C. Oligodendrocytes were then plated on matrigel-coated coverslips (5x104 
cells/ml) in chemically defined DMEM:F-12 1:1 medium 268 with FBS 2% and thyroid 
hormone T3 400 ng/ml.
10. Transduction
10.1 Human HSPC
10.1.1 CD34+ cells from CB
CD34+ cells from CB were incubated over-night at a concentration of lx lO 6 
cells/ml in Stem Span serum-free medium with 20 ng/ml recombinant human- 
Interleukin 6  (rh-IL6 ), 100 ng/ml rh-Stem Cell Factor (rh-SCF), 100 ng/ml rh-fms-like 
tyrosine kinase 3 Ligand (rh-FLT3L), and 20 ng/ml rh-thrombopoietin (rh-TPO). 
Transduction was carried out for 8  hours with 108 TU/ml (MOI 100) in the same 
medium 269. After the transduction period CD34+ cells were washed twice with PBS and 
maintained in IM DM  medium 10% FBS containing 20 ng/ml rh-IL 6 , 100 ng/ml rh-SCF, 
and 20 ng/ml rh-Interleukin 3 (rh-IL3) for suspension culture and/or plated for Colony 
Forming Cell Assay (see below).
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10.1.2 CD34+ cells from BM
CD34+ cells from BM were incubated in retronectin-coated plates at a concentration 
of lx l0 6 cells/ml in Cell Gro (Cell Genies) with IL-3 60ng/pl, TPO lOOng/pl, SCF 
300ng/pl, Flt3-L 300ng/pl) for 24 hours. After pre-stimulation, cells were transduced at 
MOI 100 for 12 hours. After transduction, cells were washed twice with PBS and 
maintained in IMDM medium 10% FBS containing IL-3 60ng/pl, IL - 6  60ng/pl, SCF 
300ng/pl for suspension culture and/or plated for Colony Forming Cell Assay (see 
below).
10.2 Murine HSPC
Lin- cells were incubated at a concentration o f lx l0 6 cells/ml in Stem Span serum- 
free medium in presence of mSCF 50ng/ml, mFlt3L lOng/ml, mIL3 lOng/ml, m IL 6  
20ng/ml (all from Peprotech) and transduced for 16 hours with 108 TU/ml o f LV (MOI 
100). After the transduction period cells were washed twice with PBS and maintained in 
RPMI medium 10% FBS containing mSCF 50ng/ml, mFlt3L lOng/ml, mIL3 lOng/ml, 
mIL 6  20ng/ml for suspension culture and/or plated for Colony Forming Cell Assay (see 
below).
10.3 Seal-m urine hematopoitic progenitors
Seal- murine hematopoitic progenitors were incubated at a concentration of lx lO 6 
cells/ml in Stem Span serum-free medium in presence of mSCF 50ng/ml, mFlt3L 
lOng/ml, mIL3 lOng/ml, mIL6  20ng/ml (all from Peprotech) and transduced for 16 
hours with 5x107 TU/ml of LV (MOI 50). After the transduction period, cells were 
washed twice with PBS and transplanted into mice.
10.4 U-937
U-937 cells were transduced in RPMI medium 10% FBS 100 IU/ml penicillin, 100 
pg/ml streptomycin 2mM L-glutamine at the concentration o f 6x105 cell/ml. 
Transduction was performed at MOI 50 and 100 for 12 hours.
10.5 T lymphocytes
T lymphocytes were seeded in IMDM 5% human serum and IL-2 300U/ml at the 
concentration of 106 cell/ml. Transduction was performed at MOI 200 for 12 hours. 
After the transduction cells were washed twice with PBS and maintained in IMDM 5% 
human serum and IL-2 300U/ml.
10.6 B lymphocytes
B lymphocytes were seeded in IMDM 10% FBS 100 IU/ml penicillin, 100 pg/ml 
streptomycin 2mM L-glutamine at the concentration o f lx l0 6 cell/ml. Cells were 
transduced with two hits o f 12 hours at MOI 100. After the first hit of transduction, B 
lymphocytes were washed with PBS and maintained in IMDM 10% FBS 100 IU/ml 
penicillin, 100 pg/ml streptomycin 2mM L-glutamine for 12 hours.
10.7 Microglia
Microglia was transduced after 2 days o f culture in DMEM  10% FBS 100 IU/ml 
penicillin, 100 pg/ml streptomycin 2mM L-glutamine at MOI 25 and 50 for 12 hours. 
After transduction, cells were washed with PBS and maintained in culture for not more 
than 5 days.
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10.8 Oligodendrocytes
Oligodendrocytes were transduced after 2 days of culture in DMEM:F-12 1:1 
medium 268 with FBS 2% and thyroid hormone T3 400 ng/ml at MOI 25 and 50 for 12 
hours. After transduction, cells were washed with PBS and maintained in culture for not 
more than 5 days.
10.9 Monocytes
After one week o f culture in RPMI 10% FBS, 100 IU/ml penicillin, 100 pg/ml 
streptomycin 2mM L-glutamine and with GM-CSF 100 ng/ml at the concentration of 
5x l0 5 cells/ml, human monocytes were transduced at MOI 200 for 16 hours. After 
transduction, cells were washed with PBS and maintained in culture for not more than 5 
days.
10.10 Macrophages
Murine macrophages obtained from peritoneal wash were transduced 2-3 days after 
establishment o f the culture. Transduction was performed at MOI 50, over-night, in 
DMEM 10% FBS, 100 IU/ml penicillin, 100 pg/ml streptomycin 2mM L-glutamine 
supplemented with GM-CSF 50 ng/ml.
11. Colony Forming Cell (CFC) Assay
CFC assay was used to assess clonogenic potential o f HSPC. After transduction, m- 
and hHSPC were washed, counted and seeded at a density o f 1000 cells/ml fpr hHSPC 
or 5000 cells/ml for mHSPC in semisolid medium (MethoCult). Cells were mixed with a 
syringe and 1,1ml o f cell suspension were plated in a 3.5cm dish. Each sample was
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plated in duplicate and dishes were put in a humid chamber in order to avoid drying of 
the semisolid medium. Cells were incubated for 10-14 days and then scored by light 
microscopy for number or plucked for quantitative PCR analysis.
12. HSCT in mice
12.1 HSCT in murine models of GLD
8 -days old FVB/Twi mice were lethally irradiated (850 rad) (Rad Gil EN 60601-1, 
Gilardoni) 4 hours before transplant. mHSPC were washed and resuspended in PBS at a 
density o f lxl07cells/m l approximately and were intra-peritoneally injected into 
recipient mice ( 1 0 6 cells/mouse).
12.2 HSCT in Rag2yc mice
Rag2yc mice at postnatal day (pnd) 2 were sub-lethally irradiated (550 rad splitted in 
2 doses) 24 hours before transplantation. hHSPC were washed and resuspended in PBS 
at a density o f 2 .5x l0 7cells/ml approximately and were injected into the temporal vein of 
recipient mice (2 .5xl0 5 cells/mouse). In the 2 weeks after HSCT Gentalin (Shering- 
Plough) was added to 200 ml o f drinking water for prophylactic purpose.
13. Anti-apoptotic treatment
Incubation with Insulin-like Growth Factor 1 (IGF1) was performed after 
transduction. mHSPC, washed after LV transduction, were treated in vitro with IGF1 50 
ng/ml in RPMI without serum at room temperature for 40 minutes. After incubation, 
mHSPC were washed twice with PBS and seeded for CFC assay or transplanted into 
recipient mice.
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14. GALC activity
GALC activity was determined using two alternative protocols:
14.1 GALC activity assay, method A
Cells were centrifuged and pellet was resuspended in Sodium Acetate 0.5 M pH=5 
at 4°C. After 2 hours, cells were sonicated, centrifuged and supernatant wash harvested 
for GALC activity quantification. N-lyssamine-rhodamine-galactosyl-sphingosine was 
used as substrate; products o f enzymatic reaction were loaded on a thin layer 
chromatography. Fluorescent Ceramide spots were visualized by using a UV lamp, 
scraped and quantified by using a spettrofluorimeter 270.
14.2 GALC activity assay, method B
Cell pellets were lysed in sodium phosphate buffer lOmM pH 6  0.1% (v/v) Nonidet 
NP40, sonicated, centrifuged and the supernatant was collected for GALC activity and 
protein quantification. 4-MU-b-D-galactoside 1.5mM, dissolved in citrate phosphate 
buffer pH4, in the presence o f A gN 03 llm M  (to inhibit b-Galactosidase activity), was 
used. Enzymatic reactions were performed using 2mg o f proteins (in 50pi) incubated 
with lOOpl o f substrate at 37°C and stopped by Glycine/NaOH 0.2M pH10.6. 
Fluorescence of 4-methylumbelliferone was measured on a Perkin Elmer LS3 spectro- 
fluorimeter (excitation: 360nm, emission: 446nm)(Tiribuzi et al., submitted for 
publication).
15. Analysis of sphingolipids on cell extracts
15.1 Internal Standards for Mass Spectrometry
Internal standards for the mass spectrometric analyses were obtained from Avanti 
Polar Lipids (Alabaster, AL); these were: C17-sphingosine (d l7 :l) , C17-sphinganine 
(dl7:0), C17-sphingosinel-phosphate, and C17-sphinganine-l-phosphate, C12-ceramide 
(N-dodecanoyl-sphingosine, d l 8 :1/12:0), C12-Ceramide 1-phosphate, C12- 
glucosylceramide, C12-lactosylceramide and C l2-sphingomyelin. The internal standards 
were prepared as 1 mM stocks in ethanol that were mixed to produce a cocktail that 
contained each compound at 50 pM.
15.2 Experimental Procedures
The sphingolipids were extracted and analysed as described 271 as described below:
Extraction o f  cells
To prepare the cells for extraction, the medium was removed, the dishes were 
washed twice with ice cold PBS to remove excess medium, then the cells were scraped 
from the dish in a minimum volume of PBS and transferred into 13 x 100 mm 
borosilicate screw cap test tubes with Teflon caps. To the cells was added 0.5 ml of 
methanol and the internal standards (in 10 pi). The cells were dispersed using a bath 
type sonicator (Bronson 1510 ultrasonicator) at room temperature for 30 s, 0.25 ml of 
chloroform added, and the capped tubes incubated at 48°C overnight in a heating block. 
After cooling, 75 pi o f 1 M KOH in CH3OH were added, mixed briefly by sonication, 
incubated in a heating block for 2 h at 37°C, and centrifuged to clarify. For analysis of 
sphingoid bases and related compounds, 0.4 ml was removed and transferred to a new 
test tube, the solvent was removed under vacuum at room temperature (in a Savant 
Speedvac), then the lipids redissolved in the LC mobile phase for reverse phase
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chromatography with sonication, centrifuged to clarify and transferred to autoinjector 
vials. The remainder of the extract was neutralized with 3 pi of glacial acetic acid, and 1 
ml o f CHCI3 and 2 ml o f H2O were added. The samples were mixed and then 
centrifuged, the lower layer was removed with care to recover the interface, transferred 
to a new test tube, and the solvent was removed under vacuum at room temperature (in a 
Savant Speedvac), then the lipids were redissolved in the LC mobile phase for normal 
phase chromatography with sonication, centrifuged to clarify and transferred to 
autoinjector vials.
Liquid Chromatography Electrospray Tandem Mass Spectrometry
Sphingoid bases and 1-phosphates (including ceramide 1-phosphate) were separated 
by reverse-phase HPLC using a binary system (Perkin Elmer Series 200 MicroPump) 
and a Supelco 2.1 mm i.d. x 5 cm Discovery C l8 column and a flow rate o f 1 ml/min. 
Mobile phase A consisted o f CH30F1:F[20 :H C 0 0 H  (58:41:1) (all mobile phase solvents 
are given in v:v); mobile phase B consisted o f CH3OH:HCOOH (99:1); both also 
contained 5 mM ammonium formate. For each analysis, the column was equilibrated 
with 60:40 (A:B) for 0.4 min, the sample was injected (50 pL by a Perkin Elmer Series 
200 Autosampler) and 60:40 (A:B) was continued for 0.5 min., followed by a 1.8-min 
linear gradient to 100% B, which was held for 5.3 min, then the column was re­
equilibrated at initial conditions for 0.5 min.
Complex sphingolipids (Cer, SM,) were separated by normal phase chromatography 
using a Supelco 2.1 mm i.d. x 5 cm LC-NFE column and a flow rate of 1.0 ml/min. 
Mobile phase A consisted o f CH3CN:CH3OH:CH3COOH (97:2:1); mobile phase B 
consisted o f CH30H :H 20 :C H 3(CH2)30H :C H 3C 0 0 H  (64:15:20:1); both also contained 5 
mM ammonium acetate. For each analysis, the column was equilibrated with 98:2 (A:B) 
for 0.5 min, the sample was injected, and 98:2 (A:B) was continued for 1.1 min, 
followed by a 0.2 min. linear gradient to 82% A. This state is held for 0.4 min, followed
by a 0.8 min linear gradient to 100% B, and re-equilibration o f the column at initial 
conditions for 0.5 min.
The mass spectrometry data was collected using a PE Sciex API 3000 triple 
quadrupole mass spectrometer equipped with a turbo ion-spray source. Dry N 2 was used 
as the nebulizing gas at a flow rate of 6 L/min. The ionspray needle was held at 5500 V, 
and the orifice and ring voltages were kept low (30-40 V and 180-220 V, respectively) 
to minimize collisional decomposition of molecular ions prior to entry into the first 
quadrupole, and the N 2 drying gas temperature was set to 500 °C. N 2 was used to 
collisionally induce dissociations in Q2, which was offset from Q1 by 30-40 V. Q3 was 
then set to pass molecularly distinctive product ions. The fatty acyl chain length 
variation was examined by product ion scans for m/z 264.4 through the ceramide and 
HexCer range and by precursor ion scans o f m/z 184.4 for SM subspecies.
16. Detection of apoptosis
16.2 Annexin V staining
To detect early apoptotic cells the “Annexin V-PE apoptosis detection kit” (Beckton 
Dickinson) was used. Annexin V is a Ca2+-dependent phospholipids-binding protein 
that has high affinity for phosphatidylserine, which is translocated from the inner to the 
outer leaflet o f the plasma membrane during the earliest stage o f apoptosis. Cell were 
washed twice with PBS and resuspended in Binding Buffer at the concentration of 106 
cells/ml and labelled following manufacturing protocol. Apoptotic Annexin V positive 
controls were obtained by an incubation with Camptothecin 5 pM  5 hours in the 
medium. Sample were analysed by flow cytometry (FACS CANTO, Beckton 
Dickinson) within 1 hour. 10,000-20,000 events were scored and results were analyzed 
by FlowJo 8.3 software.
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16.2 TUNEL assay
TUNEL (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling) 
assay allows in situ identification of apoptotic cells through the 
deossinucleotidiltransferase (TdT) -m ediated transfer of biotinilated dUTP to 3-O H  of 
DNA double strand fragments which are generated in late stages of apoptosis. 
Biotinilated dUTP are then recognised by TMR-red conjugated avidine. TUNEL assay 
was performed by using In situ Cell Death Detection Kit, TMR red (Roche) following 
m anufacturer’s instructions for adherent cells or for cell suspensions.
Adherent cells: Cover-slip were coated with Matrigel (BD M atrigel Matrix Growth 
Factor Reduced, BD Bioscences) 1:50 in IMDM 1 hour at 37°C, in order to increase 
adherence of cells and to minimize cell loss during the assay. M atrigel was removed and 
cells were seeded on cover-slip in their medium. Before performing the assay, cells were 
fixed with freshly prepared Paraformaldehyde 4% 1 hour at RT. Cells were then washed 
twice with PBS and labelled following the protocol for adherent cells. TUNEL positive 
cells were detected by confocal microscopy.
Cell suspensions: cells were resuspended in freshly prepared Paraformaldehyde 2% 
and incubated 1 hour at RT. Cells were then washed twice with PBS and labelled 
following the protocol for cell suspensions. TUNEL positive cells were detected by 
cytofluorimetry. Alternatively, cells were forced to adhere to a glass slide by a 
centrifugation at 800 rpm 5 minutes with a Cytospin (Cytospin3, Shandon). Cell spots 
were then air-dried, fixed with Paraformaldehyde 4% 1 hour at RT and labelled 
following the protocol for adherent cells. TUNEL positive cells were detected by 
confocal microscopy.
Apoptotic TUNEL positive controls were obtained by incubation with Camptothecin 
5 pM  5 hours in the medium. W hen samples were analyzed by microscopy, cells were 
also incubated 5 minutes at RT with ToProIII (Molecular Probes) diluted 1:1000 in PBS,
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in order to label nuclei. Samples were analyzed by confocal microscopy (Radiance 
2100; Bio-Rad) (^excitation = 488, 586, 660). Fluorescent signal was processed by 
Lasersharp 2000 software and analyzed by Adobe Photoshop CS 8.0 software.
17. Genomic DNA extraction and Real-time Quantitative-PCR 
(Q- PCR) analysis
In order to evaluate vector copy number p er  cell, Q-PCR was performed on genomic 
DNA extracted from transduced cells either grown in culture, from CFC or from mouse 
bone marrow. Cells in culture were grown for 10 days before analysis to exclude non­
integrated vector forms from the analysis.
17.1 Genomic DNA extraction
Genomic DNA extraction from BM or CFC samples was performed by using the 
Blood and Cell Culture DNA kit (Mini kit; Qiagen). This system is based on cell lysis, 
followed by DNA purification on an anion exchange resin.
Genomic DNA extraction from HeLa cells was performed by using DNA automatic 
extractor (Maxweel 16, Promega). Cultured cells were detached by trypsin-EDTA 
solution (for adherent cells) and washed with ice-cold PBS by spinning at 1000 rpm in 
Heraeus M egafuge 1.0 R (Kendro Laboratory products) 10 min at 4°C. Cell pellet was 
resuspended in 300 pi of PBS for a confluent 10 cm-dish and sample was loaded on 
Tissue DNA Extraction Cartridge. Genomic DNA was finally quantified by 
spectrophotometer analysis and run on a 0.8% agarose gel to check for possible RNA 
contaminations and degradation o f the sample. DNA was then stored at -20°C.
( 17.2 Real-time Q-PCR
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Q-PCR was performed in Optical 96-well Fast Thermal Cycling Plates (Applied 
I Biosystem) on ABI PRISM 7900 Sequence Detector System (Applied Biosystem), using
the following thermal cycling conditions: one cycle at 50°C for 2 min, one cycle at 95°C 
for 10 min, 40 cycles at 95°C for 15 seconds and 60°C for 1 min. For each sample, the 
Sequence Detector System 2.3 software provided an amplification curve constructed by 
relating the fluorescence signal intensity (Rn) to the cycle number. Cycle threshold (Ct) 
was defined as the cycle number at which the fluorescence signal was more than 10 SD 
of the mean background noise collected from the 3rd to the 15th cycle. Vector copy 
number was determined by using as standard curve serial dilutions (200ng, lOOng, 50ng, 
25ng and 12,5 ng for murine DNA; 200 ng, 40 ng, 8 ng, 1,6 ng for human DNA) of 
genomic DNA extracted from a transgenic mouse or from a human cell line clone stably 
containing a known number o f LV integrations (copy number o f the standard curve was 
previously defined by Southern Blot analysis). To determine vector copy number per 
cell, LV copy numbers were normalized to human DNA content, which was assessed by 
Q-PCR. Each sample was run in triplicate in a total volume of 25pl/reaction, containing 
12,5jitl TaqMan Universal Master Mix (4304437; Applied Biosystem), lOOng of sample 
DNA and one o f the following amplification systems at the following concentrations.
Human samples:
o hTERT (human Telomerase Reverse Transcriptase) forward primer: 5 ’- 
GGT GAA CCT CGT AAG TTT ATG CAA-3’ final concentration 300 
nmol
o  hTERT reverse primer: 5’-GGC ACA CGT GGC TTT TCG-3’ final
concentration 300 nmol 
o  hTERT probe: 5 ’-(VIC)-TCA GGA CGT CGA GTG GAC ACG GTG-
(TAM RA)-3’ final concentration 200 nmol
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o  HIV forward primer: 5 ’- TCT CGA CGC AGG ACT CG -3’ final 
concentration 300 nmol 
o  HIV reverse primer: 5 ’-TAC TGA CGC TCT CGC ACC-3’ final 
concentration 300 nmol 
o  HIV probe: 5 ’-(FAM)- ATC TCT CTC CTT CTA GCC TC-(M GB)-3’ 
final concentration 200 nmol 
VCN was determined by using the following formula:
absolute number of copies HIV/ absolute number o f copies hTERT x ploidy
(*)
(*) Ploidy o f HeLa cells is 4.
Murine samples:
o (3-actin forward primer: 5'-AGA GGG AAA TCG TGC GTG AC-3' final 
concentration 300 nmol 
o (3-actin reverse primer: 5'-CAA TAG TGA TGA CCT GGC CGT-3'fmal 
concentration 300 nmol 
o  [3-actin probe: 5'- (VIC) -A G C  TCT CTC GAC GCA GGA CTC GGC-
(MGB)-3'final concentration 200 nmol
o  PSI HIV forward primer: 5’-TAC TGA CGC TCT CGC ACC-3’ final 
concentration 300 nmol 
o  PSI HIV reverse primer: 5’- TCT CGA CGC AGG ACT CG-3’ final 
concentration 300 nmol 
o PSI HIV probe: 5 ’-(FAM)- ATC TCT CTC CTT CTA GCC TC-(M GB)-3’ 
final concentration 200 nmol
VCN was determined by using the following formula:
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ng DNA HIV/ng DNA (3-actin x standard VCN(*) 
(*) Standard VCN is 5.
18. Flow Cytometry
18.1 Expression titer
To determine expression titer, HeLa cells were detached by trypsin- EDTA solution, 
washed with PBS, fixed with PBS, 1% paraformaldehyde, 2% FBS (400pl/sample) and 
analysed by flow cytometry (FACS CANTO, Beckton Dickinson) for GFP expression. 
To assess transduction efficiency cells were grown for at least 5 days after transduction 
to reach steady state GFP expression and to rule out pseudotransduction (detection of 
GFP protein associated with the virus particles during vector production and transferred 
to the target cells during infection). Adherent cells were detached by trypsin-EDTA 
solution, washed with PBS and resuspended in PBS, 1% paraformaldehyde, 2% FBS. 
Untransduced cells were used as negative control to set parameters and gates. 10,000- 
20,000 events were scored. Results were analyzed by FlowJo 8.5.3 software.
18.2 Analysis of Rag2yc mice receiving HSCT
The engraftment of hHSC in Rag2yc mice was evaluated by flow cytometry.
Tissue processing: BM cells were harvested by flushing femurs and tibias with PBS 
2% FBS and counted in a Burker chamber. Splenocytes were obtained by mechanic 
disgregation o f spleen in RPMI 10% FBS, 100 IU/ml penicillin, 100 pg/ml streptomycin 
2mM L-glutamine supplemented with 2-mercaptoethanol 28.4 mM. Thymocytes were 
obtained by mechanic disgregation o f thymus in IMDM 20% FBS, 100 IU/ml penicillin, 
100 pg/ml streptomycin 2mM L-glutamine. After spinning at 1500 rpm 5 minutes at
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room temperature, 2.5x103 cells were resuspended in 50 pi of blocking solution (PBS 
1%BSA, 5%FBS).
Labelling procedure:
• Blocking: 20 minutes at 4°C in the dark
• Antibodies diluted 1:100 in blocking solution, 20 minutes at 4°C in the dark.
All the anibodies were from BD.
o  CD45 APC 
o  CD34 RPE 
o  CD 13R PE 
o  CD 19TC 
o  CD3 TC 
o  CD4 RPE 
o  C D 8TC  
o  C D llb R P E
Cells were then washed with PBS and centrifuged at 1500 rpm 5 minutes, 
resuspended in 300 pi of PBS, 1% paraformaldehyde, 2% FBS and analyzed by FACS 
CANTO. 10,000-20,000 events were scored. Results were analyzed by FlowJo 8.5.3 
software.
19. Immunofluorescence
Cells were seeded on M atrigel-coated coverslip and fixed with PBS 4% 
paraformaldehyde 20 minutes at RT. Cells were then washed twice with PBS and 
blocked with PBS 1% BSA, 5% goat serum 1 hour at RT. After blocking, cells wren 
incubated with the primary antibody diluted in PBS 10% goat serum, 0.3% triton 2 hours 
at RT or over-night at 4°C (for dilutions, see the list below). Samples were washed three 
times with PBS and were incubated 1 hour at RT with the secondary antibody
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conjugated with the fluorochrome (see the list below), diluted 1:500 in PBS 0.1% triton. 
Samples were washed three times with PBS, in the dark, and nuclei were labelled by 
incubation with ToProIII as described for TUNEL staining. Samples were mounted with 
Fluorsave Reagent (Calbiochem). Samples were analyzed by confocal microscopy 
(Radiance 2100; Bio-Rad) (Xexcitation = 488, 586, 660). Fluorescent signal was 
processed by Lasersharp 2000 software and analyzed by Adobe Photoshop CS 8.0 
software.
Primary antibodies:
• Ceramide (Alexis Biochemicals), 1:50
• Lam pl (abeam), 1:300
• NG2 (Chemicon, AB5320), 1:300
• Gal-Cer (Chemicon, MAB342), 1:200
• anti-HA High Affinity, rat monoclonal antibody (clone 3, Roche), 1:100
• F4/80 (MCAP497, Serotec), 1:200 
Secondary antibodies:
• Goat IgG anti-Rabbit Alexa Fluor 488 (green), Molecular Probes, 
A 11008, 1:500
• Goat IgG anti-mouse Alexa Fluor 633 (blue), Molecular Probes, A21050, 
1:500
• Goat IgG anti-Rat Alexa Fluor 546 (red), M olecular Probes, A11081, 
1:500
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20. Western Blot
15pg o f total cell protein/60pg o f total medium protein were re-suspended in sample 
buffer, heated for 5 minutes at 95°C and separated via SDS-PAGE under reducing
272conditions. W estern blotting was performed as previously described using the 
following primary antibodies: polyclonals raised against either precursor or mature 
protein forms of Cathepsin D (*=Santa-Cruz Biotechnology, USA) or anti-Caspase-9 
and anti-Caspase-3 (Cell Signaling Technology, MA-UK) or anti-PAR4 (*) and b-actin 
(*). Immunostaining was performed using the ECL kit from GE-Healthcare (UK). 
Quantification was assessed based on a protein standard included in each test.
RESULTS
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1. Forced GALC expression in HSPC
In order to assess the feasibility o f GALC over-expression in mHSPC, we isolated 
Lin- cells from FVB/twi (GALC -/-) mice. mHSPC were transduced at MOI 100 with 
GALC.LV in the presence o f an optimized cytokine combination 102. After transduction, 
cells were cultured 10-14 days in vitro to assess enzymatic activity and the vector copy 
number (VCN) by Q-PCR. We compared the expression level o f GALC with the over­
expression o f other lysosomal enzymes, Arylsulfatase A (ARSA) and a-Iduronidase 
(IDUA), obtained by transducing mHSPC with the control vectors ARSA.LV and 
IDUA.LV. All vectors expressed the transgene from the same expression cassette 
containing the human PGK promoter. Since our aim was to compare the enzyme over­
expression in transduced -/-HSPC with respect to physiological enzyme levels in wild 
type HSPC, mHSPC obtained from ARSA KO mice and from IDUA KO mice were 
used for ARSA.LV and IDUA.LV transduction, respectively. Transduction o f mHSPC 
reconstituted lysosomal enzyme activity in -/- cells and led to enzyme over-expression 
with respect to wild type levels in the cultured progeny of transduced -/- mHSPC 
(Figure 17A). However, the increase in GALC expression (2 fold above wild type) was 
significantly lower as compared to the increase in IDUA and ARSA obtained by 
IDUA.LV and ARSA.LV controls (320 and 5.6 fold over wild type, respectively), 
despite similar VCN.
A similar experiment was performed on human HSPC (hHSPC), isolated through 
CD34+ selection from CB obtained from normal donors (n.d.). hHSPC were transduced 
at MOI 100 with GALC.LV, ARSA.LV and IDUA.LV, using previously optimized 
transduction protocols 269. Similarly to mHSPC, we evaluated enzyme activity 
reconstitution and VCN upon in vitro culture o f the transduced cells. GALC.LV 
transduction o f HSPC from n.d. CB (n = 4) led to limited over-expression o f the enzyme
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in the cultured cell progeny as compared to IDUA.LV (n = 3) and ARSA.LV (n = 6) 
controls (Figure 17B).
2. Impaired in vitro function of GALC expressing HSPC upon 
LV-mediated GALC expression
2.1 Impaired in vitro function of murine HSPC
The effects of transduction and enzyme expression on mHSPC clonogenic potential 
were assessed by CFC assay. Equal number of GALC/GFP/ARSA.LV transduced 
mHSPC were seeded for colony assay. ARSA was chosen as control lysosomal enzyme 
since it was previously shown to not affect HSPC function . In 12 independent 
experiments GALC.LV transduced -/- and +/+ mHSPC gave rise to a significantly 
reduced number of colonies as compared to GFP.LV and ARSA.LV transduced cells 
(Figure 18A for G A LC -/- cells). Colonies from GALC.LV transduced mHSPC were of 
markedly reduced size as compared to controls (Figure 24B). These results suggested 
that GALC over-expression upon LV transduction impaired mHSPC clonogenic 
potential. The relative proportion of erythroid and myeloid colonies upon GALC.LV 
transduction was similar to controls (not shown), suggesting that enzyme expression 
impaired the different hematopoietic lineages to the same extent.
The reduced clonogenic potential o f GALC.LV transduced mHSPC could result 
from the death of highly transduced GALC over-expressing hematopoietic progenitors. 
In order to investigate the possible occurrence o f an in vitro negative selection of highly 
transduced mHSPC, we quantified the VCN of colonies by Q-PCR. Q-PCR was 
performed on DNA extracted from each pool of 4 colonies (pools were made in order to 
have a sufficient amount of material for the analysis). Colonies obtained from 
GALC.LV transduced mHSPC showed a significantly lower vector content when
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compared to controls (Figure 18A), suggesting the occurrence o f negative selection of 
highly transduced progenitors.
According to these data, we could not discriminate whether functional impairment 
and in vitro selection were due to a toxic effect o f transduction p er  se or to the presence 
o f contaminants released by vector-producer cells and co-purified with the vector. It 
must be mentioned that, during GALC.LV production, 293T cells detach from plates, 
suggesting that GALC expression is toxic also to these cells. For this reason, the 
incorporation of toxic molecules deriving from dead 293T cells into the vector 
preparation could not be excluded. To address this issue, we generated a control vector 
regulated by an hematopoietic-specific microRNA, GALCm irl42T.LV  22S. Four target 
sequences for the microRNA 142 incorporated downstream the transgene allow to 
suppress expression in mHSPC and in their progeny without impairing GALC 
expression in non-hematopoietic cells, such as 293T LV-producing cells. This 
technology is based on microRNA post-transcriptional regulation: microRNA 142, 
expressed only by hematopoietic cells, recognizes its target sequence downstream the 
transgene and inhibits the translation of the transcript and expression o f the transgene. 
As expected, transduction o f mHSPC with GALCm irl42T.LV was not associated to an 
increase o f GALC activity (Figure 18B). Moreover, mHSPC transduced with 
GALCmir 142T.LV (n = 6) showed unaffected clonogenic potential and similar vector 
content as compared to controls, thus confirming the previously observed impairment 
being dependent on de novo GALC expression (Figure 18A).
2.2 Impaired in vitro function of human HSPC
We investigated the effect o f GALC over-expression also on human HSPC. hHSPC 
were isolated from n.d. CB and BM and from the collected BM  of a GLD patient that 
was scheduled to be discarded. An equal number o f hHSPC were transduced with 
GALC.LV or ARSA.LV or GFP.LV control vectors were seeded for CFC assay, in 
order to assess the clonogenic potential o f transduced hHSPC. As in the case o f murine
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cells, GALC.LV transduced n.d. and GLD hHSPC showed an impaired clonogenic 
potential (Figure 19A). Colonies from GALC.LV transduced hHSPC showed a 
significantly lower vector content, when compared to controls, a reduced size and 
conserved erythroid-myeloid proportion, again suggesting negative selection of the 
highly transduced progenitors (Figure 19A). Also in this case, the control vector 
GALCmir 142T.LV was used to rule out an aspecific toxic effect o f transduction. As in 
the case of murine cells, GALCmir 142T.LV transduced hHSPC (n = 4) showed GALC 
activity and clonogenic potential similar to those observed in control cells (Figure 19A 
and B).
Overall these data indicate that forced GALC de novo expression upon LV 
transduction exerts a detrimental effect both on murine and human HSPC, leading to 
negative selection o f GALC over-expressing cells and to functional impairment.
3. Impaired in vivo function of HSPC upon LV-mediated 
GALC expression
We performed in vivo experiments with the aim o f assessing the repopulation 
potential o f m- and hHSPC upon GALC.LV transduction and GALC de novo 
expression. In vivo studies were performed on twi and FVB/twi mice for mHSPC, and 
on Rag2yc mice for hHSPC.
3.1 Engraftment failure of GALC.LV transduced cells in twi mice
Our initial experiments were performed on twi mice, a severe model of GLD, as 
described in the Methods section. A first set o f experiments was devoted to set the 
condition for HSCT in twi mice. Total BM transplantation from wild type donors was 
performed in these mice, resulting in a significant increase o f their lifespan up to 100 
days, as previously reported by 11 \  These preliminary experiments allowed defining the 
optimal irradiation dose. The use o f donor HSC carrying the CD45.1 allele allowed 
evaluating donor cell engraftment, since twi mice carry the CD45.2 allele. Because our 
goal was to transduce twi HSC., we tried to set up transplantation o f Lineage marker 
negative (Lin-) hematopoietic stem and progenitor cells (HSPC), in order to reduce the 
number of cells to be transduced and transplanted as compared to the use of total BM 
cells. HSPC from wild type (+/+) mice were transduced at MOI 100 with PGK_GFP.LV 
(GFP.LV), in the presence o f an optimized cytokine combination 102 (Figure 20A). After 
transduction, cells were transplanted into lethally irradiated 8 day-old twi mice or +/- 
controls. Control groups included also twi mice transplanted with wild type BM or Lin- 
cells. Surprisingly, and differently from control animals, HSPC-transplanted -/- twi mice
did not survive after lethal conditioning, thus suggesting that Lin- cells alone could not 
repopulate twi mice (Figure 20B).
W e thus decided to support GFP.LV transduced HSPC engraftment by co­
transplantation o f untransduced BM-derived hematopoietic committed progenitors, 
depleted o f HSC. These cells were obtained by magnetic depletion o f Scal+  cells from 
total BM of +/+ mice. Interestingly, twi mice transplanted with GFP.LV transduced +/+ 
Lin- cells and untransduced +/+ Seal- cells reached a survival similar to the one 
obtained with +/+ total BM transplantation (Figure 20B). The engraftment o f GFP.LV 
transduced HSPC was evaluated by flow cytometry on peripheral blood. Five-six weeks 
after transplantation, cytofluorimetric analysis revealed a high engraftment o f GFP+ 
HSPC-derived cells (Figure 20C). Thus, co-transplantation o f +/+ Seal- progenitors 
rescued the defective engraftment o f purified HSPC and allowed prolongation of 
lifespan and amelioration o f phenotype o f twi mice similar to those obtained with total 
+ /+ BM transplantation 111 273.
Once the transplantation procedures had been optimized with +/+ HSPC and 
GFP.LV, twi mice were transplanted with GALC.LV transduced -/- HSPC and with 
either +/+ or GALC.LV transduced -/- Seal- cells. Twi mice that received GALC.LV 
transduced -/- HSPC and +/+ untransduced cells survived significantly longer than mice 
transplanted with +/+ total BM or with +/+ HSPC and Seal- progenitors, and showed 
amelioration o f their phenotype and slower disease progression (Figure 20B). This data 
suggested that GALC over-expressing HSPC transplantation provides a unique 
therapeutic benefit as compared to conventional HSCT. However, when we evaluated 
the presence o f GALC.LV transduced cells in the BM of these mice by Q-PCR, we 
found a low Vector Copy Number (VCN), between 0.8 and 1, thus suggesting that only 
GALC.LV transduced cells with low VCN had been able to engraft.
Nevertheless, twi mice that received -/- Lin- and Seal- cells, both transduced with 
GALC.LV, died after lethal conditioning or had a lifespan similar to untreated mice.
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These results suggested that GALC.LV transduced progenitors failed to support HSPC 
engraftment, resulting in engraftment failure and autologous reconstitution o f 
hematopoiesis.
3.2 Engraftment failure in milder murine models
We decided to use FVB/twi mice instead o f the usual twi model o f GLD to take 
advantage from the slightly less severe model: previous experiments showed us that the 
successful transplantation o f Lin- cells without the need o f Seal- supporting cells was 
possible in this model. Moreover, FVB/twi mice have larger litters, thus allowing us to 
have a larger number of -/- mice to isolate mHSPC. Transduced mHSPC were 
transplanted into lethally irradiated 8 day-old FVB/twi -/- and heterozygous (+/-) 
recipients (Figure 21). In order to reduce biological variability, we transplanted -/- and 
+/- littermates. Mice o f the control group were transplanted with GFP.LV transduced 
+/+ cells. For this control group, the transduction efficiency was evaluated by 
cytofluorimetry 7 days after transduction on the in vitro culture, while the engraftment 
o f transduced cells was evaluated by cytofluorimetry on peripheral blood 6 weeks after 
HSCT. The transduction efficiency was very high, ranging between 75% and 93% of 
GFP+ cells. All the GFP-transplanted animals showed a high engraftment of 
transplanted cells (between 63% and 85%), and all the irradiation controls (lethally 
irradiated mice that did not received HSCT) died within 3 weeks after conditioning, thus 
confirming the correct setup o f HSCT conditions. -/- mice receiving GFP.LV transduced 
+/+ mHSPC achieved prolonged survival after lethal conditioning (up to 150 days), as 
compared to un-transplanted control mice. The survival o f the untreated and GFP- 
transplanted FVB/twi mice was longer with respect to that observed in the respective 
groups o f twi mice, thus confirming the influence of the genetic background on the 
severity o f the phenotype. The engraftment of transduced mHSPC was also evaluated by 
Q-PCR on DNA extracted from BM transplanted mice at sacrifice. A significant
engraftment of GFP.LV transduced mHSPC, measured as VCN per  genome, was 
observed (Table 2). Strikingly, both -/- and +/- mice transplanted with GALC.LV 
transduced -/- or +/+ mHSPC did not survive to lethal irradiation (death within 21 days, 
similar to that o f irradiation controls) (Figure 21 and data not shown). Q-PCR revealed 
very low to undetectable VCN in their BM (Table 2). These results indicated a 
functional impairment of GALC-transduced mHSPC, which became unable to 
repopulate a lethally conditioned host.
3.2 GALC.LV transduced hHSPC repopulate Rag2yc mice
The long-tenn repopulation potential o f GALC.LV transduced hHSPC was tested in 
Rag2-/-yc-/- mice. CB-derived hHSPC were prestimulated with a combination o f 
cytokines and transduced at MOI 100 with GALC.LV or with the control vector 
ARSA.LV. W e previously demonstrated that ARSA over-expression does not impair the 
viability and the function o f hHSPC 269. After transduction, cells were transplanted into 
sub-lethally irradiated neonate Rag2-/-yc-/-mice or seeded for CFC assay to confirm the 
results obtained in previous in vitro experiments. Five mice were transplanted with 
GALC.LV transduced hHSPC and four mice were transplanted with ARSA.LV 
transduced hHSPC. Mice were euthanized ten weeks after HSCT and BM, spleen and 
thymus were analyzed for human cell engraftment by flow cytometry (Figure 22). CD45 
positive human cells were present in all the hematopoietic tissues from both GALC and 
ARSA transplanted mice, except for one mouse transplanted with ARSA.LV transduced 
hHSPC, in which transplanted cells did not engraft. As expected, thymus was the organ 
with the highest engraftment (average o f CD45+cells in GALC group = 92.7%±6.1%); 
(average o f CD45+cells in ARSA group = 87.6%±8.1%), (Figure 22B). Engraftment of 
human cells in spleen was 7.8%±1.5% and 5%±1.9% for GALC and ARSA respectively 
(Figure 22C); engraftment of human cells in BM was 32%±3.9% and 29.7%±6.4% for 
GALC and ARSA respectively (Figure 22A). The differentiation potential o f the
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transduced hHSPC was evaluated by flow cytometry using specific human lineage 
markers. All the tissues analyzed showed multilineage differentiation o f transplanted 
hHSPC (Figure 21D-F), thus suggesting that GALC.LV transduction does not impair the 
differentiation potential o f hHSPC. Also in the thymus, human lymphocytes showed a 
normal differentiation pattern (Figure 22G) Finally, the long-term persistence of 
transduced hHSPC was evaluated on thymus, spleen and BM by Q-PCR, using the 
hTert-HIV system (see method section). Thanks to the specificity of this system for the 
human Telomerase Reverse Transcriptase, the number o f vector copies integrated into 
the genome was normalized to the content o f human DNA and not to the murine one. 
The average VCN was similar in the two experimental groups (VCN in thymus = 1±0.9 
for GALC and 2.5±2 for ARSA; VCN in spleen = 1.2±1.1 for GALC and 1.1±0.4 for 
ARSA; VCN in BM = 1.4±1 for GALC and 1.3±0.6 for ARSA), (Figure 22H). The 
results obtained with CFC assay were similar to the previous experiments, both in term 
o f VCN and number o f colonies (data not shown). Overall, these results demonstrate 
that, despite the clonogenic impairment and the negative selection observed in vitro 
upon GALC.LV transduction, GALC expressing CB-derived hHSPC are capable of 
long-term engraftment and multilineage differentiation when transplanted in Rag2-/-yc- 
/- mice. However, the VCN measured in thymus, spleen and BM was similar to what we 
found in the BM of FVB/twi mice transplanted with GALC.LV transduced -/- HSPC and 
+/+ progenitors.
4. Apoptosis of GALC expressing murine and human HSPC
Having detected a functional impairment of GALC.LV transduced HSPC, we 
evaluated whether this could be due to apoptosis of the transduced cells mediated by de 
novo GALC expression. The occurrence o f apoptosis was evaluated at two different time 
points, 2 and 5 days after transduction, when transgene expression presumably reaches 
steady state (see GFP expression in Figure 23B) by Annexin V staining and TUNEL 
assay. The first technique labels early apoptotic cells, and the second one late apoptotic 
cells, m- and hHSPC were transduced with GALC.LV and control GFP/ARSA.LV. 
After transduction and washing, cells were plated on matrigel-coated coverslips for 
TUNEL assay or cultured in usual plates and stained for Annexin V and TUNEL. At 
confocal microscopy, the large majority of GALC.LV transduced mHSPC were TUNEL 
positive and exhibited enlarged nuclei with condensed chromatin, demonstrating the 
widespread occurrence o f apoptosis at both time points (Figure 23A-B). On the contrary, 
ARSA/GFP.LV transduced cells were mostly TUNEL negative. Annexin V staining 
confirmed the occurrence o f apoptosis, showing a higher fraction o f apoptotic cells 
among GALC-transduced m- and hHSPC, as compared to controls (Figure 23C).
5. IGF1 rescues GALC expressing HSPC from apoptosis and 
functional impairment
The experiments presented above indicated that GALC de novo expression upon LV 
transduction triggered apoptotic cell death in cultured HSPC and likely explain the 
functional impairments observed in the biological assays. In order to further confirm the 
occurrence of apoptosis and support this causal relationship, and to develop a strategy 
aimed at overcoming this limitation, we tested in vitro and in vivo the anti-apoptotic 
activity of Insulin-Like Growth Factor 1 (IGF1). Several studies have implicated IGF1 
in preventing cell death due to the activation of the phosphatidylinositol-3 kinase 
(PI3K)/Akt signaling pathway 274 This pathway appears to be required for the survival
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of a number of cell types , including hematopoietic cells and oligodendrocytes . 
Cer, the first product o f GALC, acts on this pathway by inhibiting the phosphorylation 
o f Akt and Erkl/Erk2 (E rkl/2) 276 277. After transduction with either GALC.LV or 
GFP/ARSA.LV, mHSPC were washed and briefly (40 minutes) stimulated in vitro in the 
presence of IGF1. Similarly to the previous experiments, HSPC clonogenic potential 
was assessed by CFC assay, vector content was measured by Q-PCR on colonies, and 
apoptosis was evaluated by TUNEL. IGF1 treatment rescued GALC.LV transduced 
mHSPC from toxicity: a significant increase in the number o f colonies and in the VCN 
were observed, up to the values obtained on GFP/ARSA.LV transduced cells (Figure 
24A). The colonies grown from GALC.LV transduced, IG Fl-treated mHSPC showed an 
increase in size (Figure 24B), whereas the proportion o f myeloid and erythroid colonies 
was similar in all conditions (not shown). The rescue o f the clonogenic potential by 
IGF1 was associated to the protection of GALC over-expressing cells from apoptosis 
(Figure 24C). This data further confirmed the occurrence o f apoptosis upon GALC.LV 
transduction o f HSPC and the HSPC functional impairment being due to apoptotic cell
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death. Surprisingly, this rescue from apoptosis was not associated to an increase of 
GALC expression levels in IGF 1-treated GALC.LV transduced cells (Figure 24D). Once 
we had tested the anti-apoptotic activity of IGF1 treatment in vitro, GALC.LV 
transduced IGF 1-treated mHSPC were transplanted into irradiated +/- and -/- FVB/twi 
mice. The aim o f this experiment was on the one hand to confirm that the impairment o f 
the repopulation potential o f GALC over-expressing HSPC was due to their apoptosis, 
and on the other hand, to develop a feasible HSCT gene therapy approach for GLD. 
Indeed, IGF 1-treated GALC.LV transduced mHSPC were able to prevent recipient 
animals from early death. Transduced cells were detected in BM 20 days after the 
transplant at comparable levels (by VCN measurement) to those detected in mice 
transplanted with GFP.LV HSPC (Figure 25 and Table 3), thus confirming that 
apoptotic cell death o f GALC over-expressing HSPC was responsible for the observed 
in vivo functional impairment, and could be rescued by in vitro IGF1 treatment. In the 
long-term however, transduced cells were no longer detectable in -/- recipients, which 
consequently died due to GLD manifestations. It seems likely that the effect o f the brief 
in vitro treatment with IGF1 had been exhausted and was thus unable to protect the 
transduced HSPC from GALC de novo expression toxicity long-term (Figure 25 and 
Table 3). Indeed, +/- recipients survived long-term but showed absence of transduced 
cell engraftment, indicating successful reconstitution o f hematopoiesis only by either 
donor non transduced or autologous cells (Figure 25 and Table 3).
6. Investigating the mechanism of GALC de novo expression 
toxicity
6.1 Apoptosis of GALC expressing HSPC is associated to accumulation of bioactive 
GALC product
We then aimed at better understanding how GALC de novo expression could induce 
cell death in HSPC. Upon evaluation of the GALC metabolic pathway, we hypothesised 
that the apoptosis observed upon GALC.LV transduction could be due to a modification 
of the sphingolipid content of the cell. Indeed, Cer, the first product of GALC, plays a 
central role in sphingolipid metabolism (see introduction). Sphingomyelin (SM), Cer, 
So, S IP  and Psy are all involved in apoptosis, cell differentiation and survival, and a 
modification o f the balance between these molecules might explain the apoptotic death 
we observed. An intracellular sphingolipid profile was performed on control vector and 
GALC.LV transduced mHSPC at different intervals o f culture from gene transfer. SM, 
Cer, So, S IP  and Psy could be detected by gas chromatography and tandem mass 
spectrometry in the culture progeny o f both +/+ and -/- mHSPC (Figure 26A). At the 
beginning o f the in vitro culture (12h), the intracellular content o f SM, Cer and So was 
significantly higher in +/+ mHSPC than in mHSPC isolated from GLD mice (Figure 
26A), suggesting that GALC-dependent metabolism may represent one of the pathways 
regulating intracellular levels o f these sphingolipids in HSPC. The C:16 fractions o f SM 
and Cer were shown to be those most represented among the measured isoforms. 
Intracellular SM levels were substantially higher than those o f the other sphingolipids 
tested. Psy intracellular levels in mHSPC from GLD mice appeared to be slightly, but 
not significantly, increased as compared to cells from +/+ animals (Figure 26A).
Importantly, after 2 and 7 days of in vitro culture following GALC.LV transduction, 
we detected significant accumulation o f Cer both in -/- and +/+ HSPC, as compared to 
GFP.LV transduced controls (Figure 26B and data not shown). Moreover, a similar
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significant increase in the intracellular levels o f Cer downstream products So and SIP  
was observed (Figure 26C). No significant changes were detected in the intracellular 
content o f the other sphingolipids, although Psy content in GALC.LV transduced -/- 
mHSPC showed a tendency to decrease (data not shown).
In order to further confirm the presence o f Cer in mHSPC, we performed 
immunofluorescence stainings on GALC.LV transduced cells. We used commercial 
antibodies against Cer and against Lam pl (a well characterized lysosomal marker) to 
verify the intracellular localization o f Cer. For this experiment, PGK_DNGFR LV was 
used as control, in order to avoid a GFP direct fluorescence that would be deleterious for 
double immunofluorescent staining. At the same time, commercial antibodies for Delta- 
NGF Receptor (DNGFR) allowed us to verify by cytofluorimetry the frequency of 
transduction (data not shown). Cer signal co-localized more abundantly with the 
lysosomal marker Lam pl, as compared to HSPC transduced with a control vector 
(Figure 26D), suggesting that the intracellular Cer increase might be due to an increase 
o f lysosomally generated Cer.
6.2 Cathepsin D and PAR-4 are not involved in apoptosis of the transduced HSPC
The protease Cathepsin D has been proposed as a specific target for lysosomally 
generated Cer, and may couple the action o f lysosomal acid sphingomyelinase to the 
mitochondrial pathway o f apoptosis 278. We thus evaluated by western blot whether the 
apoptosis observed in GALC.LV transduced HSPC was due to the activation o f the 
Cathepsin D cascade. The monocytic cell line U937 was used as control, since it was not 
affected by de novo GALC expression (see section 7). Western blot analysis revealed a 
different basal content o f activated Cathepsin D in mHSPC: precursor and mature forms 
of Cathepsin D were almost undetectable in mHSPC at the beginning of the in vitro 
culture (GFP 12h) (Figure 27). No increase in the mature form o f Cathepsin D was 
observed after GALC gene transfer in mHSPC and their culture progeny (Figure 27).
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The precursor o f Cathepsin D accumulated in GFP-transduced cells after 7 days of 
culture (GFP.LV 7 days), while its accumulation was less pronounced in the presence of 
GALC (GALC 5 days), culminating with disappearance of both the precursor and 
mature forms after 7 days (Figure 27). Moreover, no secretion o f Cathepsin D was 
observed in the culture medium o f GFP.LV and GALC.LV transduced HSPC (not 
shown). We also evaluated the activation of caspases-9 and -3. Neither the inactive 
precursor form nor the active mature form of caspase-9 were detected in mHSPC in all 
conditions tested, nor accumulation of active caspase-3 was observed in the GALC.LV 
transduced HSPC (data not shown). Overall these findings confirmed that Cathepsin D 
pathway was not detectably involved in the apoptosis of GALC.LV transduced HSPC.
The prostate apoptosis response protein 4 (PAR4) is another key element among 
signaling pathways known to participate in ceramide-induced cell death in
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hematopoietic cells . W e thus evaluated the expression o f PAR4 upon GALC.LV 
transduction. PAR4 was undetectable in both GFP and GALC.LV transduced mHSPC 
both in basal conditions, ie. before the occurrence of transgene expression, as well as 5 
and 7 days after transduction, when apoptosis and sphingolipids accumulation occur 
(data not shown).
7. Sensitivity to GALC expression toxicity is dependent on 
differentiation and cell lineage
Macrophages and microglia represent the HSPC effector progeny reconstituting 
enzyme activity in affected tissues, including the nervous system, in HSPC gene therapy 
approaches for LSD (see peragraph 1.7.3 of the Introduction). We evaluated whether a 
prototypical monocytic cell line (U937), primary human monocytes, primary murine 
macrophages and microglia could experience GALC expression toxicity upon LV 
mediated gene transfer. Moreover, for further dissecting the specificity o f GALC- 
induced apoptosis along hematopoietic differentiation, we tested T and B lymphocytes. 
Eventually, we examined oligodendrocytes, which are the most relevant GALC recipient 
cells in the CNS, not derived from HSPC. To permit immunodetection of GALC and 
estimate transduction efficiency, in some experiments we used a C-terminally tagged 
transgene, in which the gene is fused in frame with the sequence encoding the HA 
peptide from the hemagglutinin protein o f the human influenza virus 208. The HA-tagged 
enzyme had a specific activity comparable with that o f the un-modified enzyme, and 
was properly sorted to the lysosomal compartment (data not shown). After transduction, 
we evaluated at different time points the occurrence o f apoptosis by TUNEL assay and 
GALC activity. As expected, all the cell types analyzed showed a different level o f basal 
GALC activity (Figure 28).
7.1 Monocytes, macrophages and microglia are not sensitive to GALC expression 
toxicity
Murine macrophages were obtained as the adherent fraction of peritoneal cell 
collection. Primary cultures of microglia were isolated from the brain of +/+ and -/- 
FVB/twi mice by established protocols . Further, we tested both primary
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monocytes and U937 monocytic cell line. Human monocytes were isolated from PBMC 
by positive selection for the CD 14 monocytic marker. Transduction conditions were set 
up using GFP.LV and analyzing the transduction efficiency by cytofluorimetry (when 
possible) or by confocal microscopy. Once the transduction protocol had been 
optimized, microglia and macrophages were efficiently transduced with 
GALC.LV/GALC-HA.LV and control vectors at MOI 50 and 200, respectively, and 
expressed GALC above basal levels (Figure 29). Even when high expression levels (up 
to 40 fold to wt level) were achieved, TUNEL assay demonstrated low frequency or no 
apoptosis following GALC.LV transduction and GALC over-expression in all tested 
cells (Figure 29). No difference was observed between +/+ and -/- microglia (Figure 29 
and other data not shown). These results demonstrate that HSC gene therapy effector 
cells are not sensitive to GALC toxicity, thus suggesting that, in order to develop a HSC 
gene therapy strategy for GLD, GALC expression should be avoided in HSPC, whereas 
it should be promoted in differentiated hematopoieic myeloid cells, capable o f targeting 
the enzyme to affected tissues.
7.2 Human T and B lymphocytes are not sensitive to GALC expression toxicity
Human T and B lymphocytes were obtained upon PH A-stimulation and EBV 
transformation of total PBMC, respectively. Similarly to the experiments with 
monocytes and macrophages, transduction was optimized by using GFP.LV and flow 
cytometry. B lymphocytes were efficiently transduced with GALC.LV/GALC-HA.LV 
and control vectors at MOI 100 while two hits at MOI 100 were used for T lymphocytes. 
Despite sustained increase on GALC activity upon transduction, no apoptosis was 
detected at all the examined time points (Figure 30), thus further supporting the notion 
that differentiated hematopoietic cells are not detectably sensitive to GALC over­
expression.
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7.3 Primary oligodendroglia are resistant to GALC-induced apoptosis
Oligodendrocytes are the cells mostly affected by GALC deficiency in GLD and are, 
as well, the primary target o f cross-correction in HSCT gene therapy. For this reason, we 
tested the sensitivity of oligodendroglia to GALC toxicity. Primary cultures o f 
oligodendoglia were generated from the brain o f +/+ and -/- FVB/twi mice by
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established protocols . The purity of the culture was evaluated by
immunofluorescence using the specific oligodendroglia markers NG2 and GalCer 281. 
Oligodendroglia constituted up to the 80% of the cells in culture, as estimated by the 
ratio between NG2+ plus GalCer+ cells, and the number o f total cells (nuclei were 
stained with ToPro3) (Figure 3 IB). Once the transduction protocol had been optimized 
using GFP.LV and confocal microscopy, oligodendroglia were efficiently transduced 
with GALC.LV/GALC-HA.LV and control vectors at MOI 50. No apoptotic cells were 
detected by TUNEL assay, despite an increase in GALC activity upon transduction 
(Figure 31A-B). These results demonstrate that oligodendroglia are resistant to GALC 
de novo expression apoptosis and could be a safe target o f GALC cross-correction in 
HSCT gene therapy. Moreover, this data suggests that GALC susceptibility is lineage- 
specific.
8. Regulation of GALC expression
Overall, our data thus far demonstrates that GALC de novo expression is responsible 
for apoptosis induction and functional impairment of HSPC, while differentiated 
hematopoietic cells and oligodendrocytes are not detectably sensitive to GALC 
overexpression. In order to develop an effective and safe gene therapy strategy for the 
treatment o f GLD we thus tried to overcome this limitation by regulating GALC 
expression. We pursued two strategies toward this goal . The first strategy is based on 
the use o f myeloid-specific promoters in order to restrict transgene expression only to 
differentiated macrophages and microglia, which represent the effector population in 
HSC gene therapy. A second strategy exploits HSC-specific microRNA regulation to 
suppress transgene expression only in HSPC, where GALC toxicity is higher, and to 
permit GALC over-expression in the differentiated cell progeny.
8.1 Trancriptional regulation of GALC expression
8.1.1 In vitro regulation of GALC expression by the CD1 lb  promoter
n-* 9R 9 9R9Three different promoters of myeloid-specific genes, cFes , Gp91phox and 
CD l i b  284 were tested in vitro and in vivo for the level and the specificity o f transgene 
expression, by using the reporter gene GFP. The promoter C D llb  was selected 
according to its low expression in HSC and its sustained expression in myeloid cells, as 
assessed by flow cytometry (data not shown). The specificity o f this promoter among the 
different hematopoietic lineages was quite low, as it was detectably expressed in B and 
T lymphocytes both in vitro and in vivo. However, since we demonstrated that GALC 
expression in these cells is not detrimental, we selected C D l l b  as our promoter of 
choice for future studies. In order to evaluate the effect of CD l ib-regulated GALC
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expression in HSPC, we generated C D llb_G A L C .L V  (Figure 32A). mHSPC were 
transduced with this new vector or with PGK_GFP.LV or PGK_ARSA.LV at MOI 100. 
After washing, cells were seeded for CFC assay or cultured in vitro for two weeks for 
GALC activity assay and Q-PCR analysis. Transduction with CD1 lb_GALC.LV 
allowed reconstitution of GALC activity in -/- HSPC progeny at physiological levels. 
Enzymatic activity measured in the CD1 lb_GALC.LV transduced mHSPC progeny was 
slight lower than the one measured in PGK_GALC.LV controls (Figure 32B). 
Interestingly, the number o f colonies obtained from mHSPC transduced with 
C D llb_G A L C .L V  was similar to controls and was 1.5 fold higher than the 
PGK_GALC.LV colonies (Figure 32C), thus suggesting that the use o f the C D l l b  
promoter to drive GALC expression protects the transduced HSPC from in vitro 
functional impairment.
We then evaluated the occurrence o f apoptosis in CD1 lb_GA LC.LV transduced 
mHSPC. After transduction, mHSPC were seeded on matrigel-coated coverslip and 
TUNEL assay was performed after 2 and 5 days of culture. The level o f apoptosis was 
evaluated by confocal microscopy. TUNEL assay on C D llb_G A LC .LV  transduced 
cells showed minor or no apoptosis at both time points (7%± 10 and 9%±2 at 2 and 5 
days respectively), similar to the one observed in cells transduced with control LV 
(Figure 33A-B), thus demonstrating that CD1 lb-regulation of GALC expression rescues 
mHSPC from GALC toxicity.
8.1.2 In vivo regulation of GALC expression by the CD1 lb  promoter
The effect o f CD lib-regulated  GALC expression on mHSPC repopulation potential 
was evaluated in FVB/twi heterozygous mice. Lethally irradiated 8 day old +/-FVB/twi 
mice were transplanted with CD1 lb_G A LC.LV  transduced mHSPC (n = 3) or with 
PGK_GALC.LV transduced cells (n = 5). Survival was evaluated both short- and long­
term. Untransplanted cells were cultured in vitro in order to perform Q-PCR. As 
expected, VCN measured on in vitro culture was higher in the CD1 lb_GALC.LV
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transduced mHSPC progeny as compared to the PGK_GALC.LV control (VCN = 12 for 
C D l l b  GALC and 2.4 for PGK_GALC). Remarkably, +/- FVB/twi mice transplanted 
with C D llb_G A L C .L V  transduced mHSPC were rescued from lethal conditioning and 
survived long-term, differently from PGK GALC.LV-transplanted mice that did not 
survive after conditioning and died approximately two weeks after HSCT (Figure 34). 
One out o f three mice transplanted with CD1 lb_GALC.LV transduced mHSPC was 
euthanized at the age of 80 days in order to harvest BM and perform Q-PCR analysis. 
We measured a VCN of 4.8, thus confirming the presence of transduced cells in the BM 
long-term after HSCT. Surprisingly, however, CD1 lb_GALC.LV transduced mHSPC 
failed to engraft into -/- FVB/twi mice (n = 5), which died two weeks after HSCT 
because o f lethal conditioning.
8.2 Post-transcriptional regulation of GALC expression
Recent studies in our Institute demonstrated the possibility of regulating transgene
9 9 8  9 8 S  9 8 £expression by endogenous microRNAs . We exploited a newly characterized
microRNA (miR126) which is selectively expressed in HSPC among hematopoietic 
cells (Gentner et al., manuscript in preparation). We thus generated a new LV expressing 
GALC under the PGK promoter, and containing four target sequences o f microRNA 126 
(GALC.miR126T.LV)(Figure 35A). The effective suppression of GALC expression by 
miRNA126 in HSPC, and the use o f the strong PGK promoter might allow reaching a 
higher level o f GALC expression in macrophages and microglia, as compared to the 
enzyme expression levels obtained using the CD l ib  promoter. We generated also a 
proper control vector, containing four miR126 target sequences down-stream of GFP 
(GFP.miR126T.LV).
8.2.1 In vitro regulation on GALC expression by miRNA126
In order to evaluate the effect of miRNA126-regulated GALC expression in HSPC, 
we transduced mHSPC with GALC.miR126T.LV or with GFP.miR126T.LV or 
GALC.LV at MOI 100. After washing, cells were seeded for CFC assay or cultured in 
vitro for two weeks for GALC activity assay and Q-PCR analysis. Transduction with 
G ALC.m iRl26T.LV allowed a reconstitution of GALC activity at supraphysiological 
levels in the differentiated mHSPC progeny, up to 2 fold over wild type levels (Figure 
35B). Importantly, the number o f colonies obtained from mHSPC transduced with 
G ALC.m iRl26T.LV was similar to controls and was almost 2-fold with respect to 
GALC.LV colonies (figure 35C), thus suggesting that regulation of GALC expression 
by miRNA126 allowed preserving the clonogenic potential o f transduced mHSPC. 
These encouraging results prompted us to evaluate if  the unaffected clonogenic potential 
was due to the rescue from apoptosis o f GALC.miR126T.LV transduced mHSPC. After 
transduction, mHSPC were seeded on matrigel-coated coverslip and TUNEL assay was 
performed after 2 and 5 days o f culture. The level of apoptosis was evaluated by 
confocal microscopy. TUNEL assay on GALC.m iRl26T.LV  transduced cells showed 
minor or no apoptosis at both the time points (1%±1 and 3%±2 at 2 and 5 days 
respectively), similarly to what was observed in cells transduced with the control LV 
(Figure 36A-B). This data demonstrated that suppression o f GALC expression by 
miRNA126 could rescue mHSPC from GALC-induced apoptosis.
8.2.2 In vivo regulation on GALC expression by miRNA126
The effect o f miRNA126-regulated GALC expression on mHSPC repopulation 
potential was evaluated in +/- and -/- FVB/twi mice. Lethally irradiated 8 day old mice 
were transplanted with GALC.m iRl26T.LV transduced -/- mHSPC (n = 3 for +/- and n 
= 8 for -/- FVB/twi mice) or with PGK_GALC.LV transduced cells (n = 3 for +/- and n 
= 5 for -/- FVB/twi mice) and survival was evaluated at both short- and long-term.
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Similarly to what observed with CD1 lb_GALC.LV, +/- FVB/twi mice transplanted with 
G ALC.m iRl26T.LV transduced mHSPC were rescued from lethality and survived long 
term (more than 3 months after HSCT), differently from PGK_GALC.LV-transplanted 
mice that did not survive after lethal conditioning (Figure 37). One out o f three mice 
transplanted with GALC.m iRl26T.LV transduced mHSPC was euthanized at the age of 
80 days and Q-PCR analysis was performed on BM. We found a VCN of 5, thus 
confirming the presence of transduced cells in the BM long-term after HSCT. However, 
also GALC.m iRl26T.LV transduced mHSPC were not able to rescue lethally irradiated 
-/-FVB/twi mice from lethal conditioning.
Overall, these results together to those observed with CD1 lb_G ALC.LV  transduced 
cells, show successful rescue o f the GALC deficiency and protection from de novo 
GALC expression in HSPC by our improved regulated gene therapy strategies. 
However, the failure o f the corrected cells to engraft in twi mice also suggest a non cell 
autonomous defect, which cannot be overcome by our gene replacement strategies and 
selectively challenges the engraftment o f gene-corrected twi cells.
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(A) CFC assay on m H SPC  transduced w ith  G A LC and control LV. The num ber (#) o f  
colonies/plate (Y left axis, colum ns) w as counted and the num ber o f  integrated LV 
copies/cell (V C N )(Y  right axis, dots) w as m easured. G A L C .L V  transduced -/- m H SPC 
(n = 12 independent experim ents) produced a significantly  low er num ber o f  colonies as 
com pared to G FP.L V  (n =  10) and A R SA .LV  (n =  8) transduced  cells. T his im pairm ent 
was not observed w hen m H SPC  w ere transduced w ith  the m ir l4 2 T  G A LC .LV  (n = 6). 
* p<0.001 at one-W ay A nova for both num ber o f  co lonies/p late and V CN . M ean 
values ± SD are show n. S im ilar results w ere obtained w ith -/- and + /+  m H SPC . (B) 
G A LC activity m easured on transduced m H SPC . A fter G A L C .L V  transduction GALC 
-/- (hereon -/-) (n =  5) and G A LC  +/+ (hereon +/+) (n =  5) m H SPC  show ed a 2 fold 
increase in G A LC  activ ity  above w ild type levels (+ /+  m H SPC  transduced w ith 
G FP.LV , n =  5). N o  increase in activity  w as detected in m H SPC  transduced w ith  a 
m ir l42 regulated G A L C .L V  (m irl4 2 T ) (n =  3).
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F igure 19. Im paired function o f  hum an H SPC  upon L V -m ediated  G A LC  
expression .
(A) CFC assay on hH SPC transduced w ith G A LC  and control LV. The num ber (#) o f  
co lonies/p late (Y  left axis, colum ns) w as counted and the num ber o f  integrated LV 
copies/cell (V C N )(Y  right axis, dots) w as m easured. G A LC .LV  transduced  n.d. (n =  4) 
and G LD  hH SPC (n = 4) show ed a sign ifican t im pairm ent in colony form ation as 
com pared to control cells (n =  5), w hich w as no t observed follow ing m ir l4 2 T  G A LC .LV  
transduction  (n =  4). C olonies obtained from  G A LC .LV  transduced hH SPC  show ed a 
sign ifican tly  low er vector content, w hen com pared to G F P /A R S A /G A L C m irl42T .L V  
controls. * p<0.001 at O ne-W ay A nova for both num ber o f  colonies/p late and VCN. 
M ean values ± SD are show n. (B) G A LC  activity  m easured on transduced hH SPC . 
G A L C .L V  transduction perm itted the reconstitu tion  o f  G A LC activ ity  at n.d. levels in 
G LD  hH SPC  (n = 3), w hile transduction  o f  n.d. hH SPC (n = 4 for CB and n =  3 for BM ) 
led to over-expression o f  the enzym e above G FP.LV  transduced levels (n =  3). N o 
increase in activity  was detected in hH SPC  transduced w ith a m ir l42 regulated 
G A L C .L V  (m irl4 2 T ) (n = 3).
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Figure 20. Survival o f  tw i m ice upon H SC T .
(A ) Schem atic representation o f  G FP.L V  and G A LC .LV . (B) M ean survival o f  tw i m ice 
receiving HSCT. Tw i m ice transp lan ted  w ith total BM  (TB M ) (n = 12) or w ith  G FP.LV  
transduced +/+ m H SPC and untransduced S e a l-  progenitors (G FP.L V  +/+  Lin- & +/+ 
S e a l- , n =  7) or w ith G FP.L V  transduced  + /+  m H SPC and G FP.L V  transduced S ca l-  
progenitors (G FP.LV  + /+  Lin- & G FP.L V  +/+ S ea l- , n =  5) achieved longer survival as 
com pared to untreated controls (U T) (n =  10). M ice receiving G A L C .L V  transduced -/- 
m H SPC  and +/+  S ea l - progenitors (n =  7) show ed a significantly  h igher lifespan respect 
to  TBM  or +/+ Lin- & S e a l-  transplanted m ice. On the contrary , transplantation  w ith 
G A LC .LV  transduced -/- L in- & -/- S e a l-  (n = 13) did not result in a prolonged lifespan. 
C ontrol groups: m ice transplanted w ith G FP.LV  transduced + /+  H SPC (+ /+  L in-) (n = 
10); m ice transplanted  w ith G FP.L V  transduced + /+  S e a l-  p rogenitors (n =  8). * p<0.01 
at one-W ay A nova test. (C ) R epresentative plot show ing the percentage o f  G FP+ 
engrafted cells in the peripheral blood o f  a tw i m ouse transp lan ted  w ith G FP.LV  
transduced + /+  m H SPC  and S eal - progenitors.
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Figure 21. Im paired in v ivo function o f  m H SPC  in F V B /tw i m ice. M ean survival o f  
m ice receiving m H SPC  transplantation , as indicated. -/- m ice transplanted  w ith G FP.LV  
transduced + /+  m H SPC  (n =  11) achieved longer survival as com pared to untreated 
controls (U T); on the contrary, -/- (n =  9) and +/- (°)(n =  5) m ice transplanted  w ith 
G A LC .LV  transduced  -/- m H SPC  did not survive after lethal irradiation.
Transplanted cells Host
VCN 
(20 days)
VCN 
(>120 days)
(°)G A L C  -/- H SPC  (§) + /- 0.01±0 -
G A LC  -/- H SPC  (§) -/- 0.02±0 -
G FP -/- H SPC  (§) -/- 2.3±1 2±0.5
Table 2. M ean V C N  ± SD detected in the BM o f  -/- or +/- m ice transplanted w ith the 
listed m H SPC  (transduced  w ith G A LC .LV  or G FP.L V ) at 20 and >120 days post 
transplant (n =  3 per  tim e point). (°)+/- host. (§) S im ilar results w ere obtained using +/+ 
m H SPC.
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Figure 22. hH SPC  en graftm ent and differentiation  in Rag2yc m ice.
(A -C ) Engraftment of hHSPC in bone marrow (A), thymus (B) and spleen (C) of Rag2yc 
mice, measured as the percentage of CD45+ cells, ten weeks after transplantation. (D-F) 
Human cell differentiation in bone marrow (D), thymus (E) and spleen (F) of Rag2yc 
mice. The percentage of lineage marker positive cells is reported in the chart. (G) 
Representative plot of human lymphocyte differentiation in thymus: human lymphocytes 
showed a normal differentiation pattern (H) Number of integrated vector copies (VCN) 
per genome in hematopoietic tissues of repopulated mice. No significant difference 
between GALC.LV and ARSA.LV transduced hHSPC engraftment and differentiation 
was reported.
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F igure 23. A poptosis o f G A L C  expressing  m urine and hum an H SPC .
(A -B ) TU N EL assay on -/- m H SPC  (left) and hH SPC  (righ t)(from  n.d. CB and GLD 
B M ) at 2 and 5 days after gene transfer. %  o f  T U N EL+ nuclei over the total num ber o f  
nucleated  cells is reported. >  8 fields and >  100 cells w ere counted per  condition. S im ilar 
results w ere obtained using  + /+  m H SPC . (A) The large m ajority  o f  G A LC .LV  
transduced m - and hH SPC  w ere T U N E L  positive both at 2 and at 5 days after 
transduction. (B) T U N E L  assay (red) and ToPro3 (TPIII, b lue) stain ing for nuclei on m- 
and hH SPC  at 2 and 5 (m H SPC ) days after transduction  w ith  the indicated LV: 
representative im ages (im ages w ere acquired  by three-laser confocal m icroscope - 
R adiance 2100, B ioR ad; fluorescent signals from  single optical sections were 
sequentially  acquired and analyzed by A dobe Photoshop CS softw are; m agnification 
lOOx). (C) C ytofluorim etric  analysis o f  A nnexin  V  staining on m - (top panels)(from  -/- 
donor m ice) and hH SPC  (bottom  panels)(from  n.d. CB). The fraction o f  apoptotic cells is 
h igher am ong G A LC .LV  transduced  m H SPC  and hH SPC  as com pared  to G FP- 
transduced controls. C M T = C am pto tecin  treated  positive control. A cquisition  was 
perform ed w ith  FA C S C alibur 2, B eckton D ickinson. A t least 10,000 events w ere scored 
and data w ere processed by  F low Jo 8.5.3 softw are. D ata from  -/- m H SPC  and n.d. CB 
(and GLD B M  for T U N EL) are show n, but sim ilar findings w ere obtained follow ing 
G A LC  transduction o f  +/+ m H SPC  as com pared to -/- cells and in n.d. BM  (T U N E L  and 
A nnexin  V) and G LD  BM  (A nnexin  V) hH SPC  as com pared to CB cells.
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Figure 24. IGF1 treatm ent prevents apoptosis o f  G A L C -expressing  H SPC .
(A) CFC  assay on G A L C .L V  and A R SA .L V  transduced m H SPC  treated  or not w ith 
IGF1. The num ber (#) o f  co lonies/p late (Y left axis, bars) w as counted  and the num ber 
o f  integrated lentiviral vector copies/cell (V C N )(Y  right axis, dots) w as m easured. IGF1 
treatm ent induced grow th o f  a h igher colony num ber, as com pared to G A LC .LV  
transduced untreated cells (n = 4 independent experim ents). U pon anti-apoptotic 
treatm ent, the V CN  o f  G A L C .L V  transduced cells approached that o f  A R SA .LV  
transduced control cells (for both CFC num ber and V CN  one-W ay A nova: * = pO .O O l 
for the com parison o f  treated  G A LC  transduced m H SPC  w ith untreated  G A LC .LV  
transduced cells; p>0.05 for the com parison o f  treated G A L C .L V  transduced m H SPC 
with A R SA .LV  transduced  cells). (B) The colonies grow n from  treated  m H SPC  also 
show ed an increase in size (pictures on the right, m agnification 5x). (C ) T U N E L  assay 
on G A LC .LV  and A R SA .L V -transduced  m H SPC  treated or not w ith IG F1. >  8 fields 
and >  100 cells w ere counted per  condition. The large m ajority  o f  treated  cells w ere 
negative for T U N EL (one-W ay A nova: pO .O O l for the com parison w ith  untreated 
G A LC .LV  transduced cells; p>0.05 for the com parison w ith  A R SA .L V  transduced 
cells). (D) G A LC activ ity  m easured on transduced m H SPC  from  -/- or + /+  m ice. IGF1 
treatm ent did no t sign ifican tly  affect G A LC expression levels (n = 3) w hen com pared to 
transduced untreated controls (n =  6). M ean values ± SD are show n.
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F igure 25. Survival o f  FV B /tw i m ice transplanted  w ith  IG F1- treated H SPC .
M ean survival o f  m ice transplanted w ith m H SPC  treated  or not w ith IGF1 after 
G A LC .LV  transduction , as reported in the graph. -/- and + /- m ice transplanted w ith IGF1 
treated, G A LC  transduced  -/- m H SPC survived to  lethal irradiation; -/- m ice (n =  3) 
transplanted w ith IGF1 treated, G A LC .LV  transduced died for G LD  m anifestation at the 
expected age, w hile transplanted  +/- (°) anim als (n =  3) reached long-term  survival.
Transplanted cells Host VCN  (20 days)
VCN
(lom g-term )
(°)G A LC  IGF1 -/- H SPC + /- 2 .7 ± 0 .7 0 .6 ±0 .3
G ALC  IGF1 -/- H SPC -/- 4 .3 ± 0 .5 0 .5 ±0 .2
(°)G A LC  -/- H SPC  (§) + /- 0 .0 1 ± 0 -
G A LC  -/- H SPC  (§) - /- 0 .0 2 ± 0 -
G FP  +/+  HSPC -/- 2 .3±1 2 ± 0 .5
Table 3. M ean V C N  ± SD detected in the BM  o f  -/- or +/- m ice transplanted w ith  the 
listed m H SPC (transduced  w ith G A LC .LV  or G FP.L V , treated  or not w ith IG F1) at 20 
and long-term  post transp lan t (42 days for G A L C .L V  IGF1 -/- HSPC in -/- recipients, 
120 days for the o thers) (n  =  3 per  tim e point). (°)+ /- host. (§) Sim ilar results w ere 
obtained using + /+  m H SPC .
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Figure 26. Sphingolip id  profile  o f m H SPC .
Tandem  m ass spectrom etry  quantification  o f  sphingolip ids perform ed on m H SPC  at 
different intervals after G A L C .L V  and control G FP.L V  gene transfer. G FP.LV  was 
preferred as contro l since A R SA  expression could alter sphingolip id  profile. (A) 
Sphingolipid in tracellu lar basal content (pm ol/10A6cells) in -/- (n =  6) and +/+ (n =  4) 
H SPC before the occurrence o f  transgene expression. C :16 SM , C :16 ceram ide and So 
content are reduced  in -/- cells. (B) C :16 ceram ide quantification  (pm ol/10A6cells) in 
G A LC and G FP.L V  transduced  -/- m H SPC  at d ifferen t in tervals after gene transfer. A 
significant accum ulation  o f  ceram ide occurs at 2 and 7 days after G A LC .LV  
transduction, as com pared  to G FP.L V  transduced cells (G A L C  7d versus G FP 7d) and to 
G A LC .LV  transduced  cells shortly  after gene transfer (G A LC  2d and 7d versus G A LC 
12h)(n=3). (C ) Q uantification  o f  So and S IP  in G A L C .L V  and G FP.L V  transduced -/- 
H SPC at d ifferent intervals after gene transfer. A  significant accum ulation  o f  So and S IP  
occurs at 7 days after G A L C .L V  transduction. (D) R epresentative im ages obtained after 
im m onofluorescence stain ing (for ceram ide and for the lysosom al m arker L a m p l)  and 
confocal analysis on the progeny o f  m H SPC  transduced w ith G A L C .L V  and control 
D eltaN G FR  (D N G FR ).L V  at 2 and 7 days after transduction  (as indicated). U pon GALC 
gene transfer, ceram ide signal co-localization  w ith L am p l is m ore pronounced, 
com pared to cells transduced  w ith the control vector. D N G FR  w as chosen as proper 
control to avoid  fluorescent signal interference by G FP. M ean values ± SD are shown. # 
= p<0.05 at unpaired  S tuden ts’ t Test; * =  pO .O O l and § = p<  0.05 at one-W ay A nova. 
In (B) and (C) data from  -/- H SPC are presented, bu t w e could  detect a sim ilar 
accum ulation o f  ceram ide, So and S IP  in +/+ H SPC. M agnification: lOOx in (D).
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Figure 27. A nalysis o f C athepsin  D activation  in transduced cells.
W estern blot analysis for C athepsin  D on G FP.L V  or G A LC .LV  transduced  m H SPC  and 
U 937 cells at d ifferent in tervals after gene transfer, as indicated. A ctivated  form 
corresponds to 30kD a m em brane bound isoform , as indicated by arrow . N o significant 
accum ulation o f  the active form  o f  C athepsin  D w as observed in G A L C .L V  transduced 
cells after gene transfer, com pared to G FP.LV  transduced cells. The precursor (48kD a, 
arrow ) accum ulated in G FP-transduced cells after 7 days o f  culture (G FP 7d), w hile its 
accum ulation w as less pronounced in the presence o f  G A LC (G A LC  5d), culm inating 
w ith  disappearance o f  both the precursor and m ature form s after 7 days. A n anti (3-actin 
w as used as control for protein loading.
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F igure 28. Basal G A LC  activ ity  in d ifferent cell types.
Basal G A LC  activity  norm alized to w ild  type m H SPC level. B oth prim ary w ild type 
o ligodendrocytes (n = 4) and m icroglia (n =  4) show ed a h igher G A LC  activity  as 
com pared to m H SPC.
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Figure 29. Sensitivity to G A LC  d e  n o v o  expression  in m yeloid cells.
R esults from  T U N EL assay (% T U N E L + cells over the total nucleated cells, on Y left 
axis, bars), G A LC activity determ ination  (on Y right axis, dots) and, w hen  possible, 
dedicated  stainings, perform ed on (A) hum an m onocytes, (B) the m onocytic hum an cell 
line U 937, (C) m urine m acrophages and D) m urine m icroglia, 5 days after transduction. 
In all tested conditions, T U N EL staining dem onstrated  the occurrence o f  m inor/no 
apoptosis (> 6 fields and >  250 cells w ere counted per  condition), despite  efficien t 
transduction  (evaluated by anti-H A  stain ing on m acrophages in (C )) and sustained 
G A LC  expression above basal levels in all the o ther sam ples (A R SA .L V - or G FP.LV - 
transduced  cells), w ere obtained. M ean values ± SD are show n. (C and D) 
R epresentative im ages o f  T U N E L  assay on G A L C /G A L C -H A .L V  or G FP.LV  
transduced  m acrophages (C) and m icroglia (D). Im ages w ere acquired by three-laser 
confocal m icroscope (R adiance 2100, B ioR ad). F luorescent signals from  single optical 
sections w ere sequentially acquired and analyzed by A dobe Photoshop CS softw are. 
M agnification: 80x in C, lOOx in D.
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Figure 30. Sensitivity to G A L C  d e  n o v o  expression  in lym phocytes.
R esults from  TU N EL assay (%  T U N E L + cells over the to tal nucleated  cells, on Y left 
axis, bars), G A LC activ ity  determ ination  (on Y right axis, dots), perform ed on T  and B 
lym phocytes, 5 days after transduction . T U N E L  staining dem onstrated  the occurrence o f  
m inor/no apoptosis (> 6 fields and >  250 cells w ere counted per  condition), despite 
efficien t transduction (see the sustained G A LC expression above basal levels). M ean 
values ± SD are show n.
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Figure 31. Sensitivity to G A L C  d e  n o v o  expression in o ligodendrocytes.
(A) TU N EL assay (%  T U N E L + cells over the total nucleated cells, on Y left axis, bars), 
G A LC activity determ ination  (on Y right axis, dots), perform ed 5 days after 
transduction. T U N EL stain ing dem onstrated  the occurrence o f  m inor/no apoptosis (> 6 
fields and > 250 cells w ere counted  per  condition), despite efficien t transduction  (see the 
sustained G A LC expression above basal levels). M ean values ± SD are show n. (B) 
R epresentative im ages o f  T U N E L  assay on G A LC .LV  or G FP.L V  transduced 
oligodendrocytes. The purity  o f  the oligodendrocyte preparation  w as verified by N G2 
and G al-C er staining on non-transduced cells (UT), w hile m icroglia w as stained w ith 
F4/80 on G A L C .L V -transduced cells; ToPro3 (TPIII) w as used to stain nuclei. Im ages 
w ere acquired by three-laser confocal m icroscope (R adiance 2100, B ioR ad). F luorescent 
signals from  single optical sections w ere sequentially  acquired  and analyzed by A dobe 
Photoshop CS softw are. M agnification: 40x.
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F igure 32. R egu lation  o f  G A LC  expression by C D l lb  prom oter. (A ) Schem atic 
representation o f  CD1 lb_G A L C .L V . (B) G A LC activ ity  assay perform ed on the in vitro 
progeny o f  -/- m H SPC  transduced w ith C D llb _ G A L C .L V  or w ith PG K _G A LC .LV . 
A ctivity  w as norm alized  respect to + /+  U ntransduced cells (first colum n). Cells 
transduced w ith  C D llb _ G A L C .L V  achieved a com plete reconstitu tion o f  enzym atic 
activity. (C) CFC assay perform ed on m H SPC  transduced  w ith CD1 lb_G A L C .L V , w ith 
PG K _G A L C .L V  or w ith  PG K _A R SA .L V  as a control. CD1 lb_G A L C .L V  transduced -/- 
m H SPC show ed an in tact clonongenic potential. * p<0.01 at one-W ay A nova test.
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Figure 33. C D l lb  prom oter-driven G A L C  expression  prevents apoptosis o f  
G A L C .L V  transduced  m H SPC .
(A) T U N E L  assay on C D llb _ G A L C .L V  or PG K _G A L C .L V  and PG K _A R SA .L V  - 
transduced m H SPC . >  8 fields and >  100 cells w ere counted per condition. The large 
m ajority  o f  CD1 lb_G A L C .L V  transduced cells w ere negative for TU N EL both at 2 
and 5 days after tranduction. (B ) TU N EL assay (red) and ToPro3 (TPIII, b lue) staining 
for nuclei on CD1 lb_G A L C .L V  or PG K  G A L C .L V -transduced  m H SPC -/- 5 days 
after transduction: representative im ages (im ages w ere acquired by three-laser confocal 
m icroscope - R adiance 2100, BioRad; fluorescen t signals from  single optical sections 
w ere sequentia lly  acquired and analyzed by A dobe Photoshop CS softw are; 
m agnification  40x).
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F igure 34. Survival o f  F V B /tw i m ice transplanted  w ith C D llb _ G A L C .L V  
transduced  m H SPC .
M ean survival o f  FV B /tw i m ice receiv ing m H SPC  transplantation. +/- FV B /tw i m ice (n 
=  3) transp lan ted  w ith CD1 lb_G A L C .L V  transduced m H SPC  achieved long-term  
survival, d ifferently  from  PG K _G A L C .L V  transp lan ted  +/- FV B /tw i m ice (n =  3). B oth - 
/- FV B /tw i m ice transplanted w ith  C D llb _ G A L C .L V  transduced m H SPC  (n =  5) and 
m ice transp lan ted  w ith P G K _G A L C .L V -transduced cells (n = 5) did not survive after 
lethal conditioning. U T  = untreated contro ls (n =  6).
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Figure 35. R egu lation  o f  G ALC expression  by m iR N A  126.
(A) Schem atic represen tation  o f  G A L C .m iR N A 126T ag.L V . (B -C ) G A LC activity assay 
and CFC assay perform ed on -/- m H SPC  transduced w ith G A L C .m iR N A 126T ag.L V  
(G A L C .126m iT ) or w ith  G A LC .LV  or G FP .m iR N A 126T ag.L V . (B ) A ctivity  w as 
norm alized respect to  +/+ levels (first colum n). C ells transduced w ith 
G A L C .m iR N A 126T ag.L V  over-express G A LC at supraphysiological levels. (C) The 
num ber (#) o f  co lonies/p late  (Y left axis, bars) w as counted and the num ber o f  integrated 
lentiviral v ec to r copies/cell (V C N )(Y  righ t axis, dots) w as m easured. R epression o f  
G A LC  expression by m iR N A  126 allow ed grow th o f  a higher colony num ber, as 
com pared to G A L C .L V  transduced cells (n = 4 independent experim ents). * p<0.01 at 
one-W ay A nova test.
152
A1 0 0
90
80
70
60
50
40
30
20
10
0
GALC.LV GALC.126miT.LV GFP.126miT.LV
B
GALC.LV
TUNEL^
TPIII
GALC.126miT.LV
m
Figure 36. m iR N A 126 regulation o f  G ALC expression  prevents apoptosis o f  
m H SPC .
(A) T U N E L  assay on G A L C .m iR N A 126T ag.L V  or G A LC .LV  and 
G FP.m iR N A 126T ag.L V  -transduced m H SPC . >  8 fields and >  100 cells w ere counted 
per  condition. The large m ajority  o f  G A L C .m iR N A 126T ag.L V  transduced cells w as 
negative for T U N EL. (B ) T U N EL assay (red) and ToPro3 (TPIII, blue) staining for 
nuclei on G A L C .m iR N A 126T ag.L V  or G A LC .LV  transduced  m H SPC -/- 5 days after 
transduction: represen tative im ages (im ages w ere acquired  by three-laser confocal 
m icroscope - R adiance 2100, BioRad; fluorescent signals from  single optical sections 
w ere sequentially  acquired  and analyzed by A dobe Photoshop CS softw are; 
m agnification 40x).
153
+/- FVB/twi 
GALC.LV
+/- FVB/twi 
GALC.miT126.LV
-/- FVB/twi 
GALC.LV
-/- FVB/twi 
GALC.miT126.LV
-/- FVB/twi UT
60 80 
days
100 120 140
F igure 37. Survival o f  FV B /tw i m ice transplanted w ith  G A L C .m iR N A 126T ag.L V - 
transduced m H SPC .
M ean survival o f  FV B /tw i m ice receiv ing m H SPC  transp lan tation . +/- FV B /tw i m ice (n 
= 3) transplanted  w ith  G A L C .m iR N A 126T ag.L V  transduced  m H SPC  achieved long­
term  survival, d ifferently  from  G A LC .LV  transplanted  +/- FV B /tw i m ice (n = 3). Both - 
/- FV B /tw i m ice transp lan ted  w ith  G A L C .m iR N A 126T ag.L V  transduced  m H SPC  (n = 
8) and those transplanted  w ith G A LC. LV cells (n = 5) did no t survive after lethal 
conditioning. U T  = untreated  contro ls (n = 6).
DISCUSSION
1. Toxicity of GALC de novo expression
non 9 0 0
Enzyme replacement and gene therapy applications in LSD patients and animal
9fiS 1 fl7 9QQ 9QA
models have generally demonstrated the lack of toxicity of lysosomal enzyme
administration and de novo expression above normal levels. In the case of Metachromatic 
Leukodystrophy (MLD), the safety of LV-mediated over-expression of ARSA, catalyzing 
the step upstream of GALC in sulfatide metabolism, was demonstrated in mHSPC, hHSPC, 
and transgenic mice 102 269, prompting clinical testing of HSPC gene therapy for this 
disease. Here, we report the unexpected finding of overt toxicity and in vitro and in vivo 
functional impairment of murine and human HSPC after LV-mediated GALC gene transfer 
and expression. GALC.LV transduced murine HSPC showed impaired clonogenic potential 
and failed to engraft and long-term repopulate myeloablated transplant recipients. This was 
associated to negative selection in vitro and in vivo and apoptosis of highly transduced 
HSPC. The lack of apoptosis and functional impairment observed in murine and human 
HSPC, transduced with a control vector in which GALC expression is regulated by the 
microRNA 142 (exclusively expressed in hematopoietic lineage cells) 228, confirmed the 
unique role of de novo expressed GALC in determining the death of transduced cells.
Host influence in GALC-expressing HSPC engraftment failure
Despite the impaired clonogenic potential and apoptosis observed in vitro on 
GALC.LV transduced human HSPC, these cells displayed intact repopulation and 
differentiation potential when transplanted into sub-lethally irradiated Rag2yc mice. This 
result is in contrast with what was observed in twi and FVB/twi mice, suggesting a
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fundamental role o f the HSCT recipient in determining engraftment failure of GALC.LV 
transduced HSPC. Recent studies reported a niche defect in ko mice for the diphosphate- 
galactose: ceramide galactosyltransferase (CGT) gene. CGT is responsible for the 
production o f GalCer from Cer and its deficit causes severe demyelination. In CGT ko 
mice, a defect in the hematopoietic niche trophism was observed, likely due to impaired 
sympathetic innervation. This seems to be responsible for an alteration of HSC 
mobilization from the niche 97. A similar defect was observed in the thymus of twi mice: 
defective autonomic innervation resulted in atrophy of the thymus with consequent 
impaired lymphocytic maturation 291. Specific studies of the hematopoietic bone marrow 
niche in twi mice are lacking. However, the engraftment failure of wild type lineage 
negative-selected HSPC, without the support of Seal - progenitors, suggests the existence of 
a niche defect in twi mice. If so, this may represent an additional factor detrimentally 
affecting GALC de novo expressing murine HSPC engraftment in twi or FVB/twi mice.
GALC.LV transduced murine HSPC also failed to repopulate heterozygous twi and 
FVB/twi recipient mice, which should not be affected by the hypothesized niche defect. 
This indicates that while GALC de novo expression has a strong detrimental effect on 
murine HSPC, it does not appear to be sufficient, per se, to impair the repopulation and 
differentiation potential of human HSPC. This issue could be highly relevant for the 
clinical translation of HSCT-based gene therapy for GLD.
Protective effect o f IGF1
The restored function of GALC.LV transduced HSPC upon treatment with the anti- 
apoptotic agent IGF1, confirmed that the GALC-induced functional impairment was due to 
apoptosis. IGF1 prevents cell death by activating the PI3K/Akt pathway, which is required
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for the survival of a number of cell types , including hematopoietic cells and
oligodendrocytes 29 294. Interestingly, by acting on this pathway, IGF1 protects
9 0oligodendrocytes from psychosine-induced apoptosis . Furthermore, ceramide, which can 
be synthesized from GalCer in the presence of functional GALC, exerts its pro-apoptotic 
activity, interacting with the same pathway but with an opposite effect, since it inhibits the 
phosphorylation and activation of Akt 295. The protective effect of IGF1 on GALC 
transduced cells suggests that the PI3K/Akt pathway and.possibly ceramide, may be 
involved in the apoptotic cell death of repopulating HSPC.
IGF1 treatment rescued mHSPC from GALC-induced functional impairment, both in 
vitro and in vivo, short-term after transplantation. However, the treatment was not sufficient 
to allow for long-term repopulation of the transplanted mice, by the transduced HSPC. This 
finding could either be due to the transient effect exerted by the brief ex vivo incubation of 
the transduced cells with IGF1 (only 40 minutes), or to the fact that this molecule may 
preferentially protect short-term repopulating committed progenitors from toxicity, but not 
long-term stem cells.
Interestingly, although IGF1 enabled an increase of the vector content in transduced 
HSPC progeny, no significant increase in GALC expression was detected in treated cells. 
This suggests the existence of a further regulation of GALC expression at the post- 
transcriptional or protein level, beyond the transcriptional control exerted by the atypical 
promoter and coding sequence 9 10.
Role o f bioactive sphingolipids in GALC toxicity
Recently, a novel role of Cer and other sphingolipids in regulating cell survival, 
senescence and apoptosis was demonstrated21. Hence, they have been defined as “bioactive 
lipids”. Importantly, Cer can be considered a metabolic hub because it occupies a central 
position in sphingolipid biosynthesis and catabolism. Interestingly, our data suggests that 
GALC, as well as having a role in other relevant metabolic pathways leading to Cer
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synthesis and metabolism 21, may also contribute to the regulation of the intracellular Cer 
levels in HSPC. In fact, lack of GALC activity in GLD HSPC is associated with a lower 
intracellular Cer level, compared to +/+ cells. Moreover, we observed a significant increase 
in the intracellular content of Cer in GALC.LV transduced versus GFP.LV transduced 
HSPC. Cer accumulation was accompanied by a significant increase in So and SIP 
intracellular levels. So appears to act in a similar fashion as Cer, while SIP appears to have 
the opposite effects to Cer in many of the pathways in which it is involved, particularly 
those relating to cell growth and survival. It has been suggested that the balance between 
survival and death of many cell types may be affected by the equilibrium between the 
intracellular levels of each of these inter-convertible sphingolipids. Enzymes that either 
produce or degrade sphingolipids, control this equilibrium. Thus, our findings suggest that 
an alteration of the intracellular content of Cer and other bioactive sphingolipids in HSPC 
following gene transfer and de novo GALC expression, may substantially affect this 
balance regulating cell survival. Indeed, the induced increase in So and Cer might exceed 
intracellular anti-apoptotic signals, like that of SIP, thus triggering apoptosis in both GLD 
and wild type, murine and human HSPC.
GALC substrates are present in HSPC
The first substrate of GALC is GalCer, which is produced in small quantities from 
catabolic pathways, i.e. from sulfo-GalCer by ARSA, or is synthesized by the inducible 
enzyme CGT. CGT is one of the key enzymes for the synthesis of galactocerebrosides 
(GCs), and is responsible for the galactosylation of Cer in the ER. While we previously 
measured basal ARSA activity in murine and human HSPC , no reports to date have 
demonstrated CGT activity in HSPC. However, using tandem mass spectrometry, we 
detected small quantities of both GalCer and GluCer in -/- HSPC in basal conditions, thus 
indicating the presence of GALC substrate in HSPC. We did not investigate whether
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GalCer present in HSPC is derived from ARSA activity, or whether it is a product of de 
novo synthesis. More importantly, the function of this molecule in HSPC remains unclear.
PAR4 and Cathepsin D  are not involved in GALC-induced apoptosis
The downstream molecular pathways activated by accumulated Cer and So, and the 
imbalance of Cer, So and SIP relative ratios, are not yet understood. Our data on IGF1 
indicates that the PI3K/Akt pathway might be involved in GALC-induced apoptosis in a 
fraction of HSPC. However, other pathways, which are probably affected by the variation 
of Cer, So and SIP intracellular content, may be relevant for regulating HSPC survival. We 
were not able to demonstrate that either PAR4 (one of pathways known to participate in 
Cer-induced death of hematopoietic cells 279, or mature Cathepsin D (a specific target for 
lysosomally generated ceramide) 278 accumulate in transduced cells, thus making it unlikely 
that these pathways cause apoptosis of HSPC. Furthermore, the variation in intracellular 
content of Cathepsin D precursor in the presence of GALC, suggests that the de novo 
expressed enzyme plays a role in altering the homeostasis of molecules involved in 
apoptosis. Studies performed on caspase 9 ko mice confirmed that the activation of 
apoptotic pathways changes according to different stimuli and cell types 296. Further studies 
are needed to analyze this phenomenon and the relative role of Cer and So accumulation in 
causing HSPC apoptosis.
Differentiated cells are less sensitive to GALC-related toxicity
We noticed that differentiated cells o f the hematopoietic lineage (lymphocytes, 
monocytes, macrophages and microglia) and cells from other lineages (oligodendrocytes, 
as well as neural progenitors) (Gritti et al., personal communication), are not affected by 
LV-mediated GALC over-expression. Therefore, HSPC appear to have a unique sensitivity
1 6 0
to GALC- and sphingolipid-mediated control of cell survival, which is apparently lost 
during differentiation into mature myeloid, T and B cells, and which is restricted to the 
hematopoietic lineage. A possible explanation for this, might be the very low basal GALC 
activity detected in HSPC, compared to other cell types, such as microglia or 
oligodendrocytes. Moreover, the role of sphingolipid metabolism and the consequences of 
an alteration in the content of Cer and derived molecules such as So and SIP, might vary 
according to cell types and differentiation stages. For example, the effect of intracellular 
Cer accumulation in oligodendrocytes was studied in depth, with conflicting findings. A 
recent study reported that induction of acid sphingomyelinase, which is responsible for Cer 
production from sphingomyelin degradation, resulted in Cer accumulation and induction of 
apoptosis 297. The same pathway seems to be involved in oligodendrocytic cell death 
induced by oxidative stress or by amyloid-beta peptide accumulation in Alzheimer’s 
disease 298 299. However, mature oligodendrocytes were also described as being resistant to 
some pro-apoptotic stimuli, inducing Cer accumulation. Similarly, a differential response to 
pro-apoptotic TNF-a stimulation was observed in oligodendrocytic precursors, where a 
high level o f apoptosis was observed and in mature oligodendrocytes, which appeared to be 
resistant to apoptotic stimulation 30°. Mature oligodendrocytes are also resistant to 
apoptosis induced by IL-1(3 administration 301. This suggests that the increase of 
intracellular Cer could be managed in different ways, according to the pathways activated 
in that particular cell type and at that particular differentiation stage. Supporting this 
hypothesis, it has been reported that the increase of intracellular Cer in neural tissue, is 
managed by the high activity of acid ceramidase 302. This enzyme catalyzes the degradation 
of Cer to So, which, in turn, is phosphorylated to SIP. SIP rescues cells from Cer-induced 
apoptosis 303 and induces proliferation in neural progenitor cells 304. It could be 
hypothesized that a similar mechanism was responsible for the reduced sensitivity of 
oligodendrocytes to GALC over-expression-related apoptosis. The sphingolipid metabolic 
pathway is also very active in oligodendrocytes, which are involved in myelination in order
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to produce the myelin glycosphingolipids (GalCer and Sulfatide). Moreover, these 
molecules participate in carbohydrate-carbohydrate interactions, forming glycosynapses 
(for a review see 305).
The reduced sensitivity to GALC de novo expression-induced apoptosis observed in 
monocytes and macrophages might be explained both by the activity of ceramidase and 
their secretory action. Reports show that in endothelial cells and cells of the immune 
system, Cer is rapidly converted to So and SIP, which are secreted. In the plasma, these 
molecules bind albumin and act as signals for specific receptors on lymphocytes (for a
21 306 307review see
Further studies will elucidate the actual mechanisms responsible for the peculiar 
sensitivity of HSPC to the toxic effect of GALC de novo expression.
2. Transcriptional and post-transcriptional regulation of GALC 
expression for safe and efficacious GLD gene therapy
CD 1 lb-regulated GALC expression
The regulation of GALC expression by the myeloid promoter CD lib , has shown 
promising results in vitro and in vivo. Transduction of -/- HSPC with CDllb_GALC.LV 
allowed for the reconstitution of enzymatic activity at physiological levels without 
impairing the clonogenic potential of multipotent progenitors, as assessed by the CFC 
assay. Moreover, HSPC expressing GALC under the control of the CD lib  promoter did 
not undergo apoptosis, despite the high VCN measured in this population. In vivo studies 
on heterozygous mice have shown that -/- HSPC expressing GALC under the CD lib  
promoter, could repopulate long-term, a lethally irradiated host. The absence of signs of 
bone marrow aplasia and pancytopenia ten weeks after bone marrow transplantation, 
suggests the absence of GALC-related toxicity in engrafted CDllb_GALC.LV transduced 
cells. The long-term presence o f hematopoietic cells with high VCN in the BM after 
transplantation, confirms the rescue of HSC from GALC toxicity, indicating that 
CD1 lb_GALC.LV transduced HSC could repopulate the host and sustain hematopoiesis.
Although we think that the rescue of HSPC from GALC-related apoptosis by the 
CD1 lb promoter was due to the specificity of expression in myeloid cells and the reduced 
expression in HSPC, we cannot exclude the possibility that this result might be due to the 
reduced strength of CD lib , as compared to PGK promoter. Indeed, the differentiated 
progeny of HSPC transduced with CDllb_GALC.LV, displayed a GALC activity equal to 
40% of that measured in PGK_GALC.LV transduced cells, approaching wild type levels.
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We do not know if these in vitro measurements are predictive of GALC expression in 
microglia and macrophages differentiated from the engrafted cells in vivo. Moreover, it is 
difficult to know whether this enzymatic level would be adequate enough to allow cross 
correction o f neighboring cells. The experience with the development of HSCT gene 
therapy for MLD, demonstrated that the therapeutic effect on the affected nervous system is 
directly proportional to the level of enzyme expression in HSPC and their progeny. In 
particular, we showed that over-expression of 4-5 fold with respect to wild type levels, is 
required to observe a therapeutic effect . However, allogeneic HSCT in MLD patients 
gave poor results when compared to what was observed in GLD patients. This data might 
indicate that the high CNS inflammation in GLD could contribute towards enhancing the 
benefit of HSCT and possibly, HSC gene therapy. Neuroinflammation was reported to 
accelerate microglia reconstitution by cells of donor origin 107. The neuroinflammatory 
environment that characterized the CNS of GLD patients and animal models, may enhance 
the reconstitution of brain microglia by donor-derived cells expressing GALC, thus 
increasing the amount of enzyme available for cross-correction. This phenomenon might 
result in a reduction of the enzymatic expression level per  cell, that is required to observe a 
clinical benefit in transplanted subjects.
miRNA126-regulated GALC expression
The regulation of transgene expression is of great interest in the field of gene therapy. 
In particular, the possibility of post-transcriptional regulation by micro RNA (miRNA), has 
recently open new perspectives for tuning the expression level of the transgene, according 
to cell type and to differentiation 285. In this study, we applied this innovative technology in 
order to suppress GALC expression in HSPC, which have been shown to be the most 
sensitive cells to GALC over-expression toxicity, while allowing enzyme over-expression 
in differentiated cells, which are responsible for GALC secretion and cross-correction of 
oligodendrocytes. In particular, we selected the microRNA126, which was reported to be
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more highly expressed in HSPC, as compared to peripheral blood mononuclear cells 308. 
Our data demonstrated that the regulation of GALC expression by the HSC-specific 
miRNA 126, protects HSPC from GALC de novo-induced apoptosis in vitro and in vivo. 
Transduction of GALC -/- HSPC with GALC.miR126T.LV permitted the reconstitution of 
enzymatic activity in their differentiated progeny at supra-physiological levels, without 
impairing the clonogenic potential of the multipotent progenitors, as assessed by the CFC 
assay. This data confirmed that miRNA 126 suppresses GALC expression only in HSPC 
and not in their differentiated progeny. The unaffected clonogenic potential may indicate 
that GALC expression is repressed not only in HSC, but also in multipotent progenitors 
responsible for the formation o f the hematopoietic colonies in CFC assay.
Moreover, transplantation of GALC.miR126T.LV-transduced HSPC into GALC +/- 
FVB/twi mice, resulted in long-term survival of treated animals. This data demonstrates 
that the suppression of GALC activity in the more primitive HSC by miRNA 126, allows 
their long-term repopulation and differentiation potential, to be preserved. The presence of 
highly transduced cells in the BM ten weeks after HSCT, further confirmed that long-term 
HSC were rescued from GALC over-expression apoptosis.
Importantly, the post-transcriptional regulation by HSC-specific miRNA, permitted the 
use of a strong promoter, such as PGK, thereby reaching the same expression level of the 
transgene in the differentiated HSPC progeny, as that obtained with unregulated 
PGK_GALC.LV. As discussed above, the level of GALC expression required for HSC 
gene therapy to be effective, is not known. However, even if a low enzyme expression level 
might be sufficient to obtain a clinical benefit, the use of a stronger promoter may allow the 
vector copy number(s) to be reduced, but reach the desired enzymatic expression. This 
issue could be relevant for the safety of clinical translation of HSC gene therapy.
Engraftment failure in GALC -/- FVB/twi mice
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Although the regulation of GALC expression, either by the myeloid-specific CD lib  
promoter or by HSC-specific miRNA, allowed for HSC rescue from the toxic effect of 
GALC de novo expression in vitro and in vivo in heterozygous mice, both 
CD1 lb_GALC.LV and GALC.miR126T.LV transduced HSPC failed to repopulate lethally 
irradiated GALC -/- FVB/twi mice. All -/- FVB/twi transplanted mice died due to 
engraftment failure, shortly after conditioning. This poor result might be explained by the 
existence of a niche defect in -/-FVB/twi mice (see above). Since both CDllb_GALC.LV 
and GALC.miRl26T.LV transduced HSPC successfully repopulated heterozygous mice 
long-term, the impaired repopulation observed in homozygous mice could not be 
exclusively cell-autonomous. Instead, is more likely that additional factors related to the 
BM niche affect the engraftment of CDllb_GALC.LV and GALC.miRl26T.LV 
transduced HSPC into -/- recipients. Moreover, the good engraftment of GFP.LV- 
transduced wild type HSPC observed in the majority of homozygous FVB/twi recipients 
and the prolonged survival of these treated animals, demonstrate that if a niche defect or 
any other non-permissive factor was present, it may be not sufficient per se, to totally 
hamper the engraftment of HSPC with a full repopulation potential. Further experiments 
are needed to elucidate this hypothesis.
CONCLUDING REMARKS
Our findings demonstrate that de novo GALC expression affects HSPC survival by 
altering the delicate intracellular bioactive sphingolipid balance, showing a possible novel 
regulatory role for this enzyme. Moreover, the observation of a unique sensitivity of HSPC 
to GALC de novo expression toxicity, suggests that there is a need for tight regulation of 
GALC expression in HSPC, to permit further advances in GLD gene therapy. To this 
purpose, we developed two approaches to regulate GALC expression, either by myeloid 
specific promoters, or by exploiting post-transcriptional microRNA regulation. Despite the
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poor engraftment of transduced HSPC in twi mice, we here provided the first evidence of 
successful application of HSPC-specific microRNA in HSC gene therapy for GLD. 
However, new strategies aimed at supporting the engraftment of transduced HSPC in a 
non-permissive host are needed.
ACKNOWLEDGEMENTS
I would like to thank Prof. Luigi Naldini and Alessandra Biffi, who supervised this 
project from A to Z.
Prof. Adrian Thrasher, who supervised this work and improved it with very helpful 
discussions and suggestions.
Dr. Sabata Martino and Dr. A. Merrill for their precious collaboration.
All the people in Biffi’s lab for their brilliant suggestions, discussions and friendship; 
Silvia, because she shared with me the bad and the good time in these years.
BIBLIOGRAPHY
Meikle, P. J., Hop wood, J.J., Clague, A.E. & Carey, W.F. Prevalence of lysosomal 
storage disorders. Jama 281, 249-254 (1999).
Collier, J. Prevention of Weak Legs in Experimental Chickens. Science 60, 42 
(1924).
Hagberg, B., Kollberg, H., Sourander, P. & Akesson, H.O. Infantile globoid cell 
leucodystrophy (Krabbe's disease). A clinical and genetic study O f 32 Swedish cases 
1953—1967. Neuropadiatrie 1, 74-88 (1969).
Wenger, D.A., Rafi, M.A. & Luzi, P. Molecular genetics of Krabbe disease (globoid 
cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 10, 268-279
(1997).
Loonen, M.C., Van Diggelen, O.P., Janse, H.C., Kleijer, W.J. & Arts, W.F. Late- 
onset globoid cell leucodystrophy (Krabbe's disease). Clinical and genetic 
delineation of two forms and their relation to the early-infantile form. 
Neuropediatrics 16, 137-142 (1985).
Kolodny, E.H., Raghavan, S. & Krivit, W. Late-onset Krabbe disease (globoid cell 
leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci 13, 
232-239 (1991).
Jardim, L.B. et al. Protracted course of Krabbe disease in an adult patient bearing a 
novel mutation. Arch Neurol 56, 1014-1017 (1999).
Luzi, P., Rafi, M.A. & Wenger, D. Structure and Organization of the Human 
Galactocerebrosidase (GALC) Gene. Genomics 26, 407-409 (1995).
Sakai, N. et al. Human galactocerebrosidase gene: promoter analysis of the 5'- 
flanking region and structural organization. Biochim Biophys Acta. 1395, 62-67
(1998).
Luzi, P., Rafi, M.A., Victoria, T., Baskin, G.B. & Wenger, D.A. Characterization of 
the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification
of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this 
primate. Genomics 42, 319-324 (1997).
11. Nagano, S. et al. Expression and processing of recombinant human 
galactosylceramidase. Clin ChimActa 276, 53-61 (1998).
12. Harzer, K. et al. Saposins (sap) A and C activate the degradation of 
galactosylceramide in living cells. FEBSLett 417, 270-274 (1997).
13. Wenger, D.A., Rafi, M.A., Luzi, P., Datto, J. & Costantino-Ceccarini, E. Krabbe 
disease: genetic aspects and progress toward therapy. Mol. Genet. Metab. 70, 1-9
(2000).
14. Norton, W.T. Some thoughts on the neurobiology of the leukodystrophies. 
Neuropediatrics 15 Suppl, 28-31 (1984).
15. Dyer, C.A. & Benjamins, J.A. Organization of oligodendroglial membrane sheets. I: 
Association of myelin basic protein and 2',3'-cyclic nucleotide 3'-phosphohydrolase 
with cytoskeleton. J  Neurosci Res 24, 201-211 (1989).
16. Marcus, J. & Popko, B. Galactolipids are molecular determinants of myelin 
development and axo-glial organization. Biochim Biophys Acta 1573, 406-413 
(2002).
17. Jung, E.M., Griner, R.D., Mann-Blakeney, R. & Bollag, W.B. A potential role for 
ceramide in the regulation of mouse epidermal keratinocyte proliferation and 
differentiation. J  Invest Dermatol 110, 318-323 (1998).
18. Uchida, N. et al. HIV, but not murine leukemia virus, vectors mediate high 
efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem 
cells. Proc Natl Acad Sci U SA  95, 11939-11944 (1998).
19. Sawada, M. et al. Molecular mechanisms of TNF-alpha-induced ceramide 
formation in human glioma cells: P53-mediated oxidant stress-dependent and - 
independent pathways. Cell Death Differ 11, 997-1008 (2004).
171
20. Tepper, A.D., de Vries, E., van Blitterswijk, W.J. & Borst, J. Ordering of ceramide 
formation, caspase activation, and mitochondrial changes during CD95- and DNA 
damage-induced apoptosis. J  Clin Invest 103, 971-978 (1999).
21. Hannun, Y.A. & Obeid, L.M. Principles of bioactive lipid signalling: lessons from 
sphingolipids. Nat Rev Mol Cell Biol 9, 139-150 (2008).
22. Spiegel, S. & Milstien, S. Exogenous and intracellularly generated sphingosine 1- 
phosphate can regulate cellular processes by divergent pathways. Biochem Soc 
Trans 31, 1216-1219(2003).
23. Austin, J. et al. Studies in globoid (Krabbe) leukodystrophy (GLD). V. Controlled 
enzymic studies in ten human cases. Arch Neurol 23, 502-512 (1970).
24. Suzuki, K. Ultrastructural study of experimental globoid cells. J  Neuropathol Exp 
Neurol 30, 145-146(1971).
25. Miyatake, T. & Suzuki, K. Globoid cell leukodystrophy: additional deficiency of 
psychosine galactosidase. Biochem Biophys Res Commun 48, 539-543 (1972).
26. Suzuki, K. Twenty five years of the "psychosine hypothesis": a personal perspective 
of its history and present status. Neurochem. Res. 23, 251-259 (1998).
27. Kobayashi, T., Shinnoh, N., Goto, I. & Kuroiwa, Y. Hydrolysis of 
galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases. 
JB iol Chem 260, 14982-14987 (1985).
28. Tapasi, S., Padma, P. & Setty, O.H. Effect of psychosine on mitochondrial function. 
Indian J  Biochem Biophys 35, 161-165 (1998).
29. Zaka, M., Rafi, M.A., Rao, H.Z., Luzi, P. & Wenger, D. Insulin-like growth factor- 
1 provides protection against psycosine-onduced apoptosis in cultured mouse 
oligodendrocyte progenitor cells using primarily the P13K/Akt pathway. Molecular 
and Cellular Neuroscience 30, 398-407 (2005).
172
30. Giri, S., Khan, M., Rattan, R., Singh, I. & Singh, A.K. Krabbe disease: psychosine- 
mediated activation of phospholipase A2 in oligodendrocyte cell death. J  Lipid Res 
47, 1478-1492(2006).
31. Giri, S., Khan, M., Nath, N., Singh, I. & Singh, A.K. The role of AMPK in 
psychosine mediated effects on oligodendrocytes and astrocytes: implication for 
Krabbe disease. JNeurochem 105, 1820-1833 (2008).
32. Haq, E., Contreras, M.A., Giri, S., Singh, I. & Singh, A.K. Dysfunction of 
peroxisomes in twitcher mice brain: a possible mechanism of psychosine-induced 
disease. Biochem Biophys Res Commun 343, 229-238 (2006).
33. Martin, J.J. et al. Fetal Krabbe leukodystrophy. A morphologic study of two cases. 
Acta Neuropathol 53, 87-91 (1981).
34. Itoh, M. et al. Immunohistological study of globoid cell leukodystrophy. Brain Dev 
24,284-290(2002).
35. Im, D.S., Heise, C.E., Nguyen, T., O'Dowd, B.F. & Lynch, K.R. Identification of a 
molecular target of psychosine and its role in globoid cell formation. J  Cell Biol 
153, 429-434 (2001).
36. Jesionek-Kupnicka, D. et al. Krabbe disease: an ultrastructural study of globoid 
cells and reactive astrocytes at the brain and optic nerves. Folia Neuropathol 35, 
155-162(1997).
37. Formichi, P. et al. Psychosine-induced apoptosis and cytokine activation in immune 
peripheral cells of Krabbe patients. J  Cell Physiolo. 212, 737-743 (2007).
38. Matsushima, G.K. et al. Absence of MHC class II molecules reduces CNS 
demyelination, microglial/macrophage infiltration, and twitching in murine globoid 
cell leukodystrophy. CelllS , 645-656 (1994).
39. Formichi, P. et al. Human fibroblasts undergo oxidative stress-induced apoptosis 
without intemucleosomal DNA fragmentation. J  Cell Physiol 208, 289-297 (2006).
173
40. Contreras, M.A., Haq, E., Uto, T., Singh, I. & Singh, A.K. Psychosine-induced 
alterations in peroxisomes of twitcher mouse liver. Arch Biochem Biophys 477, 211- 
218 (2008).
41. Farley, T.J., Ketonen, L.M., Bodensteiner, J.B. & Wang, D.D. Serial MRI and CT 
findings in infantile Krabbe disease. Pediatr Neurol 8, 455-458 (1992).
42. Loes, D.J., Peters, C. & Krivit, W. Globoid cell leukodystrophy: distinguishing 
early-onset from late-onset disease using a brain MR imaging scoring method. 
AJNR Am JNeuroradiol 20, 316-323 (1999).
43. Percy, A.K., Odrezin, G.T., Knowles, P.D., Rouah, E. & Armstrong, D.D. Globoid 
cell leukodystrophy: comparison of neuropathology with magnetic resonance 
imaging. Acta Neuropathol 88, 26-32 (1994).
44. Sabatelli, M. et al. Peripheral neuropathy with hypomyelinating features in adult- 
onset Krabbe's disease. NeuromusculDisord 12, 386-391 (2002).
45. Satoh, J.I. et al. Adult-onset Krabbe disease with homozygous T1853C mutation in 
the galactocerebrosidase gene. Unusual MRI findings of corticospinal tract 
demyelination. Neurology 49, 1392-1399 (1997).
46. Husain, A.M., Altuwaijri, M. & Aldosari, M. Krabbe disease: neurophysiologic 
studies and MRI correlations. Neurology 63, 617-620 (2004).
47. Callahan, J.W. & Skomorowski, M.A. Diagnosis of Krabbe disease by use of a 
natural substrate. Methods Mol Biol 347, 321-330 (2006).
48. Farina, L. et al. MR imaging and proton MR spectroscopy in adult Krabbe disease. 
AJNR Am J  Neur or adiol 21, 1478-1482 (2000).
49. Suzuki, K. Globoid cell leukodystrophy (Krabbe's disease): update. J  Child Neurol 
18, 595-603 (2003).
50. Kleijer, W.J. et al. Prevalent mutations in the GALC gene of patients with Krabbe 
disease of Dutch and other European origin. J  Inherit Metab Dis 20, 587-594 
(1997).
174
51. Henderson, R.D., MacMillan, J.C. & Bradfield, J.M. Adult onset Krabbe disease 
may mimic motor neurone disease. J  Clin Neurosci 10, 638-639 (2003).
52. Meikle, P.J. et al. Diagnosis of lysosomal storage disorders: evaluation of lysosome- 
associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 43, 1325- 
1335 (1997).
53. Chamoles, N.A., Blanco, M.B., Gaggioli, D. & Casentini, C. Hurler-like phenotype: 
enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 47, 2098-2102
(2001).
54. Chamoles, N.A., Blanco, M., Gaggioli, D. & Casentini, C. Tay-Sachs and Sandhoff 
diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective 
diagnoses in newborn-screening cards. Clin ChimActa 318, 133-137 (2002).
55. Umapathysivam, K., Hopwood, J.J. & Meikle, P.J. Determination of acid alpha- 
glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin 
Chem 47, 1378-1383 (2001).
56. Meikle, P.J., Fuller, M. & Hopwood, J.J. Mass spectrometry in the study of 
lysosomal storage disorders. Cell Mol Biol (Noisy-le-grand) 49, 769-777 (2003).
57. Li, Y. et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for
newborn screening. Clin Chem 50, 1785-1796 (2004).
58. Bach, G., Zeigler, M. & Zlotogora, J. Prevention of lysosomal storage disorders in
Israel. Mol Genet Metab 90, 353-357 (2007).
59. Kurtz, H.J. & Fletcher, T.F. The peripheral neuropathy of canine globoid-cell
leukodystrophy (krabbe-type). Acta Neuropathol 16, 226-232 (1970).
60. Victoria, T., Rafi, M.A. & Wenger, D.A. Cloning of the canine GALC cDNA and
identification of the mutation causing globoid cell leukodystrophy in West Highland 
White and Cairn terriers. Genomics 33, 457-462 (1996).
175
61. Kobayashi, T., Yamanaka, T., Jacobs, J.M., Teixeira, F, & Suzuki, K. The Twitcher 
mouse: an enzymatically authentic model of human globoid cell leukodystrophy 
(Krabbe disease). Brain Res 202, 479-483 (1980).
62. Luzi, P. et al. Generation of a mouse with low galactocerebrosidase activity by gene 
targeting: a new model of globoid cell leukodystrophy (Krabbe disease). M ol 
Genetics and Metab. 73, 211-223 (2001).
63. Pedchenko, T.V. & LeVine, S.M. IL-6 deficiency causes enhanced pathology in 
Twitcher (globoid cell leukodystrophy) mice. Exp Neurol 158, 459-468 (1999).
64. Tominaga, K. et al. Genetic background markedly influences vulnerability of the 
hippocampal neuronal organization in the "twitcher" mouse model of globoid cell 
leukodystrophy. J  Neurosci Res 77, 507-516 (2004).
65. Biswas, S., Biesiada, H., Williams, T.D. & LeVine, S.M. Delayed clinical and 
pathological signs in Twitcher (Globoid cell leukodystrophy) mice on a C57BL/6 x 
CAST/Ei background. Neurobiology o f Disease 10, 344-357 (2002).
66. Baskin, G.B. et al. Genetic galactocerebrosidase deficiency (globoid cell 
leukodystrophy, Krabbe disease) in rhesus monkeys (Macaca mulatta). Lab Anim 
Sci 48, 476-482 (1998).
67. Borda, J.T. et al. Clinical and immunopathologic alterations in rhesus macaques 
affected with globoid cell leukodystrophy. Am J  Pathol 172, 98-111 (2008).
68. Fratantoni, J.C., Hall, C.W. & Neufeld, E.F. Hurler and Hunter syndromes: mutual 
correction of the defect in cultured fibroblasts. Science 162, 570-572 (1968).
69. Hasilik, A., Klein, U., Waheed, A., Strecker, G. & von Figura, K. Phosphorylated
oligosaccharides in lysosomal enzymes: identification of alpha-N-
acetylglucosamine(l)phospho(6)mannose diester groups. Proc Natl Acad Sci U S A  
77, 7074-7078 (1980).
70. Orchard, P.J. et al. Hematopoietic cell therapy for metabolic disease. JPediatr 151, 
340-346 (2007).
176
71. Desnick, R.J. & Schuchman, E.H. Enzyme replacement and enhancement therapies: 
lessons from lysosomal disorders. Nat Rev Genet 3, 954-966 (2002).
72. Grabowski, G.A., Leslie, N. & Wenstrup, R. Enzyme therapy for Gaucher disease: 
the first 5 years. Blood Rev 12, 115-133 (1998).
73. Vellodi, A. et al. Management o f neuronopathic Gaucher disease: a European 
consensus. JInherit Metab Dis 24, 319-327 (2001).
74. Butters, T.D. Gaucher disease. Curr Opin Chem Biol 11, 412-418 (2007).
75. Burrow, T.A., Hopkin, R.J., Leslie, N.D., Tinkle, B.T. & Grabowski, G.A. Enzyme 
reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin 
Pediatr 19, 628-635 (2007).
76. Wenk, J., Hille, A. & von Figura, K. Quantitation of Mr 46000 and Mr 300000 
mannose 6-phosphate receptors in human cells and tissues. Biochem Int 23, 723-731 
(1991).
77. Kakkis, E.D. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. 
Engl J. M ed 344, 182-188 (2001).
78. Winkel, L.P. et al. Morphological changes in muscle tissue of patients with infantile 
Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 27, 743-751 
(2003).
79. Enns, G.M. & Huhn, S.L. Central nervous system therapy for lysosomal storage 
disorders. Neurosurg Focus 24, E12 (2008).
80. Vogler, C. et al. Overcoming the blood-brain barrier with high dose enzyme 
replacemnet therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S 
A, 14777-17782(2005).
81. Matzner, U. et al. Induction of tolerance to human arylsulfatase A in a mouse model 
of metachromatic leukodystrophy. Mol Med 13, 471-479 (2007).
177
82. Lee, W.C. et al. Enzyme replacement therapy results in substantial improvements in 
early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J  
19, 1549-1551 (2005).
83. Boado, R.J., Zhang, Y., Zhang, Y. & Pardridge, W.M. Humanization of anti-human 
insulin receptor antibody for drug targeting across the human blood-brain barrier. 
Biotechnol Bioeng 96,381-391 (2007).
84. Brooks, D.A., Kakavanos, R. & Hopwood, J.J. Significance of immune response to 
enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends 
Mol Med 9, 450-453 (2003).
85. Brady, R.O. et al. Management of neutralizing antibody to Ceredase in a patient 
with type 3 Gaucher disease. Pediatrics 100, El 1 (1997).
86. Baum, C.M., Weissman, I.L., Tsukamoto, A.S., Buckle, A.M. & Peault, B. Isolation 
of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U SA  
89,2804-2808(1992).
87. Strauss, L.C. et al. Antigenic analysis of hematopoiesis. IV. The My-11 
hematopoietic cell surface antigen is expressed by myelomonocytic and lymphoid, 
but not erythroid, progenitor cells. Exp Hematol 14, 935-945 (1986).
88. Morrison, S.J. & Weissman, I.L. The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1, 
661-673 (1994).
89. Meyerrose, T.E., Herrbrich, P., Hess, D.A. & Nolta, J.A. Immune-deficient mouse 
models for analysis of human stem cells. Biotechniques 35, 1262-1272 (2003).
90. Larochelle, A. et al. Identification of primitive human hematopoietic cells capable 
of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat 
Med 2, 1329-1337 (1996).
91. Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C. & Eaves, C.J. 
Functional characterization of individual human hematopoietic stem cells cultured
178
at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A  
87, 3584-3588 (1990).
92. Dick, J.E. Immune-deficient mice as models for human hematopoietic disease. Mol 
Genet Med 1, 77-115 (1991).
93. Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev 
Immunol 6, 93-106 (2006).
94. Adams, G.B. & Scadden, D.T. A niche opportunity for stem cell therapeutics. Gene 
Ther 15, 96-99 (2008).
95. Calvi, L.M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. 
Nature 425, 841-846 (2003).
96. Whetton, A.D. & Graham, G.J. Homing and mobilization in the stem cell niche. 
Trends Cell Biol 9, 233-238 (1999).
97. Katayama, Y. et al. Signals from the sympathetic nervous system regulate 
hematopoietic stem cell egress from bone marrow. Cell 124, 407-421 (2006).
98. Peled, A. et al. The chemokine SDF-1 stimulates integrin-mediated arrest of 
CD34(+) cells on vascular endothelium under shear flow. J  Clin Invest 104, 1199- 
1211 (1999).
99. Kollet, O. et al. Rapid and efficient homing of human CD34(+)CD38(- 
/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of 
NOD/SCID and NOD/SCID/B2m(null) mice. Blood 97, 3283-3291 (2001).
100. Eglitis, M.A. & Mezey, E. Hematopoietic cells differentiate into both microglia and 
macroglia in the brains of adult mice. Proc. Natl. Acad. Sci. USA 94, 4080-4085 
(1997).
101. Hoogerbrugge, P.M. et al. Effect of bone marrow transplantation on enzyme levels 
and clinical course in the neurologically affected twitcher mouse. J  Clin Invest 81, 
1790-1794(1988).
179
102. Biffi, A. et al. Correction of Metachromatic Leukodystrophy in the Mouse Model 
by Transplantation of Genetically Modified Hematopoietic Stem Cells. J. Clin. 
Invest. 113, 1118-1129(2004).
103. Simard, A.R., Soulet, D., Gowing, G., Julien, J.P. & Rivest, S. Bone marrow- 
derived microglia play a critical role in restricting senile plaque formation in 
Alzheimer's disease. Neuron 49, 489-502 (2006).
104. Malm, T.M. et al. Bone-marrow-derived cells contribute to the recruitment of 
microglial cells in response to beta-amyloid deposition in APP/PS1 double 
transgenic Alzheimer mice. Neurobiol Dis 18, 134-142 (2005).
105. Ponomarev, E.D., Shriver, L.P., Maresz, K. & Dittel, B.N. Microglial cell activation 
and proliferation precedes the onset of CNS auto immunity. JNeurosci Res 81, 374- 
389 (2005).
106. Rodriguez, M. et al. Bone-marrow-derived cell differentiation into microglia: a 
study in a progressive mouse model of Parkinson's disease. Neurobiol Dis 28, 316- 
325 (2007).
107. Sano, R., Tessitore, A., Ingrassia, A. & d'Azzo, A. Chemokine-induced recruitment 
of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis 
mice corrects neuronal pathology. Blood 106, 2259-2268 (2005).
108. Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W. & Rossi, F.M. Local self-renewal 
can sustain CNS microglia maintenance and function throughout adult life. Nat 
Neurosci 10, 1538-1543 (2007).
109. Li, Y., Liu, L., Barger, S.W. & Griffin, W.S. Interleukin-1 mediates pathological 
effects of microglia on tau phosphorylation and on synaptophysin synthesis in 
cortical neurons through a p38-MAPK pathway. JNeurosci 23, 1605-1611 (2003).
110. Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes 
only under defined host conditions. Nat Neurosci 10, 1544-1553 (2007).
1 8 0
111. Yeager, A.M., Shinn, C., Shinohara, M. & Pardoll, D.M. Hematopoietic cell 
transplantation in the twitcher mouse. The effects of pretransplant conditioning with 
graded doses of busulfan. Transplantation 5 6 ,185-190 (1993).
112. Krivit, W., Sung, J.H., Shapiro, E.G. & Lockman, L.A. Microglia: the effector cell 
for reconstitution of the central nervous system following bone marrow 
transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 4, 
385-392 (1995).
113. Boelens, J.J. et al. Outcomes of hematopoietic stem cell transplantation for Hurler's 
syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow 
Transplant 40, 225-233 (2007).
114. Kogler, G. et al. A new human somatic stem cell from placental cord blood with 
intrinsic pluripotent differentiation potential. J  Exp Med 200, 123-135 (2004).
115. Chen, H.K. et al. Combined cord blood stem cells and gene therapy enhances 
angiogenesis and improves cardiac performance in mouse after acute myocardial 
infarction. Eur J  Clin Invest 35, 677-686 (2005).
116. Hansen, M.D. et al. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's 
syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant 
41, 349-353 (2008).
117. Staba, S.L. et al. Cord-Blood Transplants from Unrelated Donors in Patients with 
Hurler’s Syndrome. NEnglJM ed. 350, 1960-1969 (2004).
118. Krivit, W. Stem cell bone marrow transplantation in patients with metabolic storage 
diseases. Adv Pediatr 49, 359-378 (2002).
119. Aubourg, P. et al. The red-green visual pigment gene region in 
adrenoleukodystrophy. Am J  Hum Genet 46, 459-469 (1990).
120. Peters, C. et al. Cerebral X-linked adrenoleukodystrophy: the international 
hematopoietic cell transplantation experience from 1982 to 1999. Blood 104, 881- 
888 (2004).
181
121. Krivit, W. Allogeneic stem cell transplantation for the treatment of lysosomal and 
peroxisomal metabolic diseases. Springer Semin Immunopathol 26, 119-132 (2004).
122. Tolar, J. et al. Combination of enzyme replacement and hematopoietic stem cell 
transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 41, 531- 
535 (2008).
123. Ichioka, T., Kishimoto, Y., Brennan, S., Santos, G.W. & Yeager, A.M. 
Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the 
twitcher mouse): effects on levels of galactosylceramidase, psychosine, and 
galactocerebrosides. Proc Natl Acad Sci U S A  84, 4259-4263 (1987).
124. Suzuki, K., Hoogerbrugge, P.M., Poorthuis, B.J., Bekkum, D.W. & Suzuki, K. The 
twitcher mouse. Central nervous system pathology after bone marrow 
transplantation. Lab Invest 58, 302-309 (1988).
125. Kondo, A. et al. Pathology of the peripheral nerve in the twitcher mouse following 
bone marrow transplantation. Brain Res 460, 178-183 (1988).
126. Yeager, A.M., Brennan, S., Tiffany, C., Moser, H.W. & Santos, G.W. Prolonged 
survival and remyelination after hematopoietic cell transplantation in the twitcher 
mouse. Science 225, 1052-1054 (1984).
127. Escolar, M.L. et al. Transplantation of Umbilical-Cord Blood in Babies with 
Infantile Krabbe’s Disease. N. Engl J. Med. 352, 2069-2081 (2005).
128. Krivit, W. et al. Hematopoietic stem-cell transplantation in globoid-cell 
leukodystrophy. N  Engl J  Med 338, 1119-1126 (1998).
129. Lim, Z.Y. et al. Sustained neurological improvement following reduced-intensity 
conditioning allogeneic haematopoietic stem cell transplantation for late-onset 
Krabbe disease. Bone Marrow Transplant 41, 831-832 (2008).
130. Pastores, G.M. & Barnett, N.L. Substrate reduction therapy: miglustat as a remedy 
for symptomatic patients with Gaucher disease type 1. Expert Opin Investig Drugs 
12,273-281 (2003).
182
131. Biswas, S., Biesiada, H., Williams, T.D. & LeVine, S.M. Substrate reduction 
intervention by L-cycloserine in twitcher mice (globoid cell leukodystrophy) on a 
B6;CAST/Ei background. Neurosci Lett 347, 33-36 (2003).
132. LeVine, S.M., Pedchenko, T.V., Bronshteyn, I.G. & Pinson, D.M. L-cycloserine 
slows the clinical and pathological course in mice with globoid cell leukodystrophy 
(twitcher mice). JNeurosci Res 60, 231-236 (2000).
133. Ozkara, H.A. Recent advances in the biochemistry and genetics of sphingolipidoses. 
Brain Dev 26, 497-505 (2004).
134. Platt, F.M., Neises, G.R., Karlsson, G.B., Dwek, R.A. & Butters, T.D. N- 
butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N- 
linked oligosaccharide processing. J  Biol Chem 269, 27108-27114 (1994).
135. Jeyakumar, M. et al. Delayed symptom onset and increased life expectancy in 
Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U 
SA  96, 6388-6393 (1999).
136. Ezoe, T. et al. Biochemistry and neuropathology of mice doubly deficient in 
synthesis and degradation of galactosylceramide. J  Neurosci Res 59, 170-178 
(2000).
137. Aerts, J.M., Hollak, C.E., Boot, R.G., Groener, J.E. & Maas, M. Substrate reduction 
therapy of glycosphingolipid storage disorders. J  Inherit Metab Dis 29, 449-456 
(2006).
138. Kay, M.A., Glorioso, J.C. & Naldini, L. Viral vectors for gene therapy: the art of 
turning infectious agents into vehicles of therapeutics. Nat Med 7, 33-40 (2001).
139. Hayes, M.E. et al. Genospheres: self-assembling nucleic acid-lipid nanoparticles 
suitable for targeted gene delivery. Gene Ther 13, 646-651 (2006).
140. Fuller, D.H. et al. DNA immunization in combination with effective antiretroviral 
drug therapy controls viral rebound and prevents simian AIDS after treatment is 
discontinued. Virology 348, 200-215 (2006).
183
141. Blomberg, P., Eskandarpour, M., Xia, S., Sylven, C. & Islam, K.B. Electroporation 
in combination with a plasmid vector containing SV40 enhancer elements results in 
increased and persistent gene expression in mouse muscle. Biochem Biophys Res 
Commun 298, 505-510 (2002).
142. Lechardeur, D. & Lukacs, G.L. Intracellular barriers to non-viral gene transfer. Curr 
Gene Ther 2, 183-194 (2002).
143. Hackett, P.B., Ekker, S.C., Largaespada, D.A. & Mclvor, R.S. Sleeping beauty 
transposon-mediated gene therapy for prolonged expression. Adv Genet 54, 189-232
(2005).
144. Wakabayashi, T. et al. A phase I clinical trial of interferon-beta gene therapy for 
high-grade glioma: novel findings from gene expression profiling and autopsy. J  
Gene Med 10, 329-339 (2008).
145. Boorjian, S.A. et al. Phase 1/2 clinical trial of interferon alpha2b and weekly 
liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell 
carcinoma. JImmunother 30, 655-662 (2007).
146. Verma, I.M. & Weitzman, M.D. Gene therapy: twenty-first century medicine. Annu 
Rev Biochem 74, 711-738 (2005).
147. Tomanin, R. & Scarpa, M. Why do we need new gene therapy viral vectors? 
Characteristics, limitations and future perspectives of viral vector transduction. Curr 
Gene Ther 4, 357-372 (2004).
148. Sandrin, V. et al. Lentiviral vectors pseudotyped with a modified RD114 envelope 
glycoprotein show increased stability in sera and augmented transduction of 
primary lymphocytes and CD34+ cells derived from human and nonhuman 
primates. Blood 100, 823-832 (2002).
149. Kelly, P.F., Vandergriff, J., Nathwani, A., Nienhuis, A.W. & Vanin, E.F. Highly 
efficient gene transfer into cord blood nonobese diabetic/severe combined 
immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped
184
with the feline endogenous retrovirus (RD114) envelope protein. Blood 96, 1206- 
1214 (2000).
150. Ailles, L. et al. Molecular evidence of lentiviral vector-mediated gene transfer into 
human self-renewing, multi-potent, long-term NOD/SCID repopulating 
hematopoietic cell. Mol Ther. 6, 615-626 (2002).
151. Movassagh, M. et al. High-level gene transfer to cord blood progenitors using 
gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically 
applicable protocol. Hum Gene Ther 9, 225-234 (1998).
152. Dick, J.E., Magli, M.C., Huszar, D., Phillips, R.A. & Bernstein, A. Introduction of a 
selectable gene into primitive stem cells capable of long-term reconstitution of the 
hemopoietic system of W/Wv mice. Cell 42, 71-79 (1985).
153. Keller, G., Paige, C., Gilboa, E. & Wagner, E.F. Expression of a foreign gene in 
myeloid and lymphoid cells derived from multipotent haematopoietic precursors. 
Nature 318, 149-154 (1985).
154. Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene 
therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. 
Nat Med 12, 401-409 (2006).
155. Schwarzwaelder, K. et al. Gammaretrovirus-mediated correction of SCID-X1 is 
associated with skewed vector integration site distribution in vivo. J  Clin Invest 
117,2241-2249(2007).
156. Aiuti, A. et al. Multilineage hematopoietic reconstitution without clonal selection in 
ADA-SCID patients treated with stem cell gene therapy. J  Clin Invest 117, 2233- 
2240 (2007).
157. Miller, D.G., Adam, M.A. & Miller, A.D. Gene transfer by retrovirus vectors occurs 
only in cells that are actively replicating at the time of infection. Mol Cell Biol 10, 
4239-4242 (1990).
185
158. Barquinero, J. et al. Efficient transduction of human hematopoietic repopulating 
cells generating stable engraftment of transgene-expressing cells in NOD/SCID 
mice. Blood 95, 3085-3093 (2000).
159. Dao, M.A., Hashino, K., Kato, I. & Nolta, J.A. Adhesion to fibronectin maintains
regenerative capacity during ex vivo culture and transduction of human
hematopoietic stem and progenitor cells. Blood 92, 4612-4621 (1998).
160. Glimm, H., Oh, I.H. & Eaves, C.J. Human hematopoietic stem cells stimulated to
proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do
not reenter G(0). Blood 96, 4185-4193 (2000).
161. Howe, S.J. et al. Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. J  Clin Invest 
118,3143-3150(2008).
162. Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy 
for X-linked severe combined immunodeficiency. N  Engl J  Med 348, 255-256 
(2003).
163. Hacein-Bey-Abina, S. et al. LM02-associated clonal T cell proliferation in two 
patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
164. Schweizer, M. et al. Markers of foamy virus infections in monkeys, apes, and 
accidentally infected humans: appropriate testing fails to confirm suspected foamy 
virus prevalence in humans. AIDS Res Hum Retroviruses 11, 161-170 (1995).
165. Russell, D.W. & Miller, A.D. Foamy virus vectors. J  Virol 70, 217-222 (1996).
166. Trobridge, G., Vassilopoulos, G., Josephson, N. & Russell, D.W. Gene transfer with 
foamy virus vectors. Methods Enzymol 346, 628-648 (2002).
167. Trobridge, G. & Russell, D.W. Cell cycle requirements for transduction by foamy 
virus vectors compared to those of oncovirus and lentivirus vectors. J  Virol 78, 
2327-2335 (2004).
186
168. Anderson, J.L. & Hope, T.J. HIV accessory proteins and surviving the host cell. 
Curr HIV/AIDS Rep 1, 47-53 (2004).
169. Peruzzi, F. The multiple functions of HIV-1 Tat: proliferation versus apoptosis. 
Front Biosci 11, 708-717 (2006).
170. von Schwedler, U., Song, J., Aiken, C. & Trono, D. V if is crucial for human 
immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J  Virol 67, 
4945-4955 (1993).
171. He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests 
cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J  Virol 69, 
6705-6711 (1995).
172. Mangasarian, A. et al. The HIV-1 N ef protein acts as a connector with sorting 
pathways in the Golgi and at the plasma membrane. Immunity 6, 67-77 (1997).
173. Aiken, C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the 
glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic 
pathway and suppresses both the requirement for N ef and the sensitivity to 
cyclosporin A. J  Virol 71, 5871-5877 (1997).
174. Aiken, C. & Trono, D. N ef stimulates human immunodeficiency virus type 1 
proviral DNA synthesis. J  Virol 69, 5048-5056 (1995).
175. Bour, S. & Strebel, K. The HIV-1 Vpu protein: a multifunctional enhancer of viral 
particle release. Microbes Infect 5, 1029-1039 (2003).
176. Weinberg, J.B., Matthews, T.J., Cullen, B.R. & Malim, M.H. Productive human 
immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human 
monocytes. J  Exp Med 174, 1477-1482 (1991).
177. Lewis, P.F. & Emerman, M. Passage through mitosis is required for 
oncoretroviruses but not for the human immunodeficiency virus. J  Virol 68, 510- 
516(1994).
187
178. Fassati, A. & Goff, S.P. Characterization of intracellular reverse transcription 
complexes o f human immunodeficiency virus type 1 .J  Virol 75, 3626-3635 (2001).
179. Bukrinskaya, A., Brichacek, B., Mann, A. & Stevenson, M. Establishment of a 
functional human immunodeficiency virus type 1 (HIV-1) reverse transcription 
complex involves the cytoskeleton. J  Exp Med 188, 2113-2125 (1998).
180. Piller, S.C., Caly, L. & Jans, D.A. Nuclear import of the pre-integration complex 
(PIC): the Achilles heel of HIV? Curr Drug Targets 4, 409-429 (2003).
181. Wu, X., Li, Y., Crise, B. & Burgess, S.M. Transcription start regions in the human 
genome are favored targets for MLV integration. Science 300, 1749-1751 (2003).
182. Cattoglio, C. et al. Hot spots of retroviral integration in human CD34+ 
hematopoietic cells. Blood 110, 1770-1778 (2007).
183. Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. 
Nature 381, 661-666 (1996).
184. Marcello, A. et al. Nuclear organization and the control of HIV-1 transcription. 
Gene 326, 1-11 (2004).
185. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells 
by a lentiviral vector. Science 272, 263-267 (1996).
186. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging 
system. J  Virol 72, 8463-8471 (1998).
187. Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo 
gene delivery. J  Virol 72, 9873-9880 (1998).
188. Cronin, J., Zhang, X.Y. & Reiser, J. Altering the tropism of lentiviral vectors 
through pseudotyping. Curr Gene Ther 5, 387-398 (2005).
189. Kahl, C.A., Marsh, J., Fyffe, J., Sanders, D.A. & Cometta, K. Human 
immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with 
envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J  
Virol 78, 1421-1430(2004).
188
190. Kobinger, G.P., Weiner, D.J., Yu, Q.C. & Wilson, J.M. Filovirus-pseudotyped 
lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat 
Biotechnol 19, 225-230 (2001).
191. Kappes, J.C. & Wu, X. Safety considerations in vector development. Somat Cell 
Mol Genet 26, 147-158 (2001).
192. Kaul, M., Yu, H., Ron, Y. & Dougherty, J.P. Regulated lentiviral packaging cell 
line devoid of most viral cis-acting sequences. Virology 249, 167-174 (1998).
193. Mautino, M.R., Ramsey, W.J., Reiser, J. & Morgan, R.A. Modified human 
immunodeficiency virus-based lentiviral vectors display decreased sensitivity to 
trans-dominant Rev. Hum Gene Ther 11, 895-908 (2000).
194. Follenzi, A. & Naldini, L. HIV-based vectors. Preparation and use. Methods M ol 
Med. 69, 259-274 (2002).
195. Kim, V.N., Mitrophanous, K., Kingsman, S.M. & Kingsman, A.J. Minimal 
requirement for a lentivirus vector based on human immunodeficiency virus type 1. 
J  Virol 72, 811-816(1998).
196. Delenda, C. Lentiviral vectors: optimization of packaging, transduction and gene 
expression. J  Gene Med 6 Suppl 1, S125-138 (2004).
197. Kraunus, J. et al. Self-inactivating retroviral vectors with improved RNA 
processing. Gene Ther 11, 1568-1578 (2004).
198. Bodine, D.M., Karlsson, S., Papayannopoulou, T. & Nienhuis, A.W. Introduction 
and expression of human beta globin genes into primitive murine hematopoietic 
progenitor cells by retrovirus mediated gene transfer. Prog Clin Biol Res 319, 589- 
599; discussion 600 (1989).
199. Piacibello, W. et al. Engraftment in nonobese diabetic severe combined 
immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: 
evidence for the amplification and self-renewal of repopulating stem cells. Blood 
93, 3736-3749 (1999).
189
200. McGuckin, C.P., Forraz, N., Allouard, Q. & Pettengell, R. Umbilical cord blood 
stem cells can expand hematopoietic and neuroglial progenitors in vitro. Exp Cell 
Res 295, 350-359 (2004).
201. Nolta, J.A., Smogorzewska, E.M. & Kohn, D.B. Analysis of optimal conditions for 
retroviral-mediated transduction of primitive human hematopoietic cells. Blood 86, 
101-110(1995).
202. Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific 
fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 
2, 876-882 (1996).
203. Moritz, T. & Williams, D.A. Gene transfer into the hematopoietic system. Curr 
Opin Hematol 1, 423-428 (1994).
204. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with 
nonmyeloablative conditioning. Science 296, 2410-2413 (2002).
205. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined 
immunodeficiency (SCID)-Xl disease. Science 288, 669-672 (2000).
206. Mazurier, F., Gan, O.I., McKenzie, J.L., Doedens, M. & Dick, J.E. Lentivector- 
mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic 
stem cell compartment and culture-induced stem cell impairment. Blood 103, 545- 
552 (2004).
207. Santoni de Sio, F.R., Cascio, P., Zingale, A., Gasparini, M. & Naldini, L. 
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells 
and is down-regulated by cytokines that enhance transduction. Blood 107, 4257- 
4265 (2006).
208. Biffi, A. et al. Gene therapy of metachromatic leukodystrophy reverses neurological 
damage and deficits in mice. J. Clin. Invest. 116, 3070-3082 (2006).
1 9 0
209. May, C., Rivella, S., Chadbum, A. & Sadelain, M. Successful treatment of murine 
beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 99, 
1902-1908 (2002).
210. Pawliuk, R. et al. Correction of sickle cell disease in transgenic mouse models by 
gene therapy. Science 294, 2368-2371 (2001).
211. Dupre, L. et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a 
WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum 
Gene Ther 17, 303-313 (2006).
212. Barese, C.N., Goebel, W.S. & Dinauer, M.C. Gene therapy for chronic 
granulomatous disease. Expert Opin Biol Ther 4, 1423-1434 (2004).
213. Bank, A., Dorazio, R. & Leboulch, P. A phase I/II clinical trial of beta-globin gene 
therapy for beta-thalassemia. Ann N Y  Acad Sci 1054, 308-316 (2005).
214. Schroder, A.R. et al. HIV-1 integration in the human genome favors active genes 
and local hotspots. Cell 110, 521-529 (2002).
215. Montini, E. et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse 
model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 
24,687-696(2006).
216. Sands, M.S. & Davidson, B.L. Gene therapy for lysosomal storage diseases. Mol 
Ther 13, 839-849 (2006).
217. Reddy, P.S. et al. Sustained human factor VIII expression in hemophilia A mice 
following systemic delivery of a gutless adenoviral vector. Mol Ther. 5, 63-73 
(2002).
218. Daly, T.M. AAV-mediated gene transfer to the liver. Methods Mol Biol 246, 195- 
199(2004).
219. Hartung, S.D. et al. Correction of metabolic, craniofacial, and neurologic 
abnormalities in MPSI mice treated at birth with adeno-associated virus vector 
transducing the human alpha-L-iduronidase gene. Mol Ther. 9, 866-875 (2004).
191
220. Sferra, T.J. et al. Widespread correction of lysosomal storage following intrahepatic 
injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol 
Ther. 10, 478-491 (2004).
221. McCormack, J.E. et al. Factors affecting long-term expression of a secreted 
transgene product after intravenous administration of a retroviral vector. Mol Ther. 
3,516-525 (2001).
222. Parker Ponder, K. et al. Therapeutical neonatal hepatic gene therapy in 
mucopolisaccharidosis VII dogs. Proc Natl Acad Sci U S A  99, 13102-13107 
(2002).
223. Mango, R.L. et al. Neonatal retroviral vector-mediated hepatic gene therapy reduces 
bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol 
Genet Metab 82, 4-19 (2004).
224. Nguyen, T.H. et al. Highly efficient lentiviral vector-mediated transduction of 
nondividing, fully reimplantable primary hepatocytes. MOL Ther. 6, 199-209 
(2002).
225. Cardone, M. et al. Correction of Hunter syndrome in the MPSII mouse model by 
AAV2/8-mediated gene delivery. Hum Mol Genet 15, 1225-1236 (2006).
226. Di Domenico, C. et al. Gene therapy for a mucopolysaccharidosis type I murine 
model with lentiviral-IDUA vector. HUm Gene Ther. 16, 81-90 (2005).
227. Follenzi, A. et al. Targeting lentiviral vector expression to hepatocytes limits 
transgene-specific immune response and establishes long-term expression of human 
antihemophilic factor IX in mice. BLood 103, 3700-3709 (2004).
228. Brown, B.D., Venneri, M.A., Zingale, A., Sergi Sergi, L. & Naldini, L. Endogenous 
microRNA regulation suppresses transgene expression in hematopoietic lineages 
and enables stable gene transfer. Nat Med 12, 585-591 (2006).
229. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells 
by a lentiviral vector. Science 272, 263-267 (1996).
192
230. Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L. & Trono, D. Multiply attenuated 
lentiviral vector achieves efficient gene delivery in vivo. NAT Biotechnol 15, 871- 
875 (1997).
231. Blomer, U. et al. Highly efficient and sustained gene transfer in adult neurons with a 
lentivirus vector. J  Virol 71, 6641-6649 (1997).
232. Kordower, J.H. et al. Lentiviral gene transfer to the nonhuman primate brain. Exp. 
Neurol 160, 1-16 (1999).
233. Consiglio, A. et al. In vivo gene therapy of metachromatic leukodystrophy by 
lentiviral vectors: correction of neuropathology and protection against learning 
impairment in affected mice. Nat Med 7, 310-316 (2001).
234. Desmaris, N. et al. Prevention of neuropathology in the mouse model o f Hurler 
syndrome. Ann Neurol 56, 68-76 (2004).
235. Ciron, C. et al. Gene therapy of the brain in the dog model of Hurler's syndrome. 
Ann Neurol 60, 204-213 (2006).
236. Passini, M.A. et al. Intracranial delivery of CLN2 reduces brain pathology in a 
mouse model of classical late infantile neuronal ceroid lipofuscinosis. J  Neurosci 
26,1334-1342(2006).
237. Cabrera-Salazar, M.A. et al. Timing of therapeutic intervention determines 
functional and survival outcomes in a mouse model of late infantile batten disease. 
Mol Ther 15, 1782-1788 (2007).
238. Crystal, R.G. et al. Clinical protocol. Administration of a replication-deficient 
adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to 
the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene 
Ther 15, 1131-1154(2004).
239. Worgall, S. et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS 
administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. 
Hum Gene Ther 19, 463-474 (2008).
193
240. Janson, C. et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector 
for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum 
Gene Ther 13, 1391-1412 (2002).
241. Luca, T. et al. Axons mediate the distribution of arylsulfatase A within the mouse 
hippocampus upon gene delivery. Mol Ther 12, 669-679 (2005).
242. Priller, J. et al. Targeting gene-modified hematopoietic cells to central nervous 
system; use of green fluorescent proteine uncovers microglial engraftment. Nat. 
Med. 7, 1356-1361 (2001).
243. Ohmi, K. et al. Activated microglia in cortex of mouse models of 
mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. USA 100, 1902-1907 
(2003).
244. Wada, R., Tifft, C.J. & Proia, R.L. Microglial activation precedes acute 
neurodegeneration in Sandhoff disease and is suppressed by bone marrow 
transplantation. Proc. Natl. Acad. Sci. USA 97, 10954-10959 (2000).
245. Zheng, Y. et al. Treatment of the mouse model of mucopolysaccharidosis I with 
retrovirally tyransduced bone marrow. Molecular Genetics and Metabolism 79, 
233-244 (2003).
246. Taupin, P. & Gage, F.H. Adult neurogenesis and neural stem cells of the central 
nervous system in mammals. J  Neurosci Res 69, 745-749 (2002).
247. Roy, N.S. et al. In vitro neurogenesis by progenitor cells isolated from the adult 
human hippocampus. Nat Med 6, 271-277 (2000).
248. Sanai, N. et al. Unique astrocyte ribbon in adult human brain contains neural stem 
cells but lacks chain migration. Nature 427, 740-744 (2004).
249. Lacorazza, H.D., Flax, J.D., Snyder, E.Y. & Jendoubi, M. Expression of human 
beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in 
mouse brains upon engraftment of transduced progenitor cells. Nat Med 2, 424-429 
(1996).
194
250. Buchet, D., Serguera, C., Zennou, V., Chameau, P. & Mallet, J. Long-term 
expression o f beta-glucuronidase by genetically modified human neural progenitor 
cells grafted into the mouse central nervous system. Mol Cell Neurosci 19, 389-401 
(2002).
251. Meng, X.L. et al. Brain transplantation of genetically engineered human neural stem 
cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J  
Neurosci Res 74, 266-277 (2003).
252. Gama Sosa, M.A. et al. Correction of the galactocerebrosidase deficiency in globoid 
cell leukodystrophy-cultured cells by SL3-3 retroviral-mediated gene transfer. 
Biochem Biophys Res Commun 218, 766-771 (1996).
253. Luddi, A. et al. Retrovirus-mediated gene transfer and galactocerebrosidase uptake 
into twitcher glial cells results in appropriate localization and phenotype correction. 
Neurobiol Dis 8, 600-610(2001).
254. Rafi, M.A. et al. Retroviral vector-mediated transfer o f the galactocerebrosidase 
(GALC) cDNA leads to overexpression and transfer of GALC activity to 
neighboring cells. Biochem Mol Med 58, 142-150 (1996).
255. Shen, J.S., Watabe, K., Ohashi, T. & Eto, Y. Intraventricular administration of 
recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological 
improvements. Gene Ther 8, 1081-1087 (2001).
256. Rafi, M.A. et al. AAV-mediated expression of galactocerebrosidase in brain results 
in attenuated symptoms and extended life span in murine models of globoid cell 
leukodystrophy. Mol Ther 11, 734-744 (2005).
257. Lin, D. et al. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS 
disease in the murine model of globoid-cell leukodystrophy more efficiently than 
AAV2. Mol Ther 12, 422-430 (2005).
195
258. Lin, D. et al. Central nervous system-directed AAV2/5-mediated gene therapy 
synergizes with bone marrow transplantation in the murine model of globoid-cell 
leukodystrophy. Mol Ther 15, 44-52 (2007).
259. Pellegatta, S. et al. The therapeutic potential of neural stem/progenitor cells in 
murine globoid cell leukodystrophy is conditioned by macrophage/microglia 
activation. Neurobiol Dis. 21, 314-323 (2006).
260. Pluchino, S. et al. Injection of adult neurospheres induces recovery in a chronic 
model of multiple sclerosis. Nature A ll, 688-694 (2003).
261. Pluchino, S., Furlan, R. & Martino, G. Cell-based remyelinating therapies in 
multiple sclerosis: evidence from experimental studies. Curr Opin Neurol 17, 247- 
255 (2004).
262. Taylor, R.M. et al. Intrinsic resistance of neural stem cells to toxic metabolites may 
make them well suited for cell non-autonomous disorders: evidence from a mouse 
model of Krabbe leukodystrophy. JNeuroehem 97, 1585-1599 (2006).
263. Luzi, P. et al. Biochemical and pathological evaluation of long-lived mice with 
globoid cell leukodystrophy after bone marrow transplantation. Mol Genetics and 
Metab 86, 150-159 (2005).
264. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M. & Naldini, L. Gene transfer by 
lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol 
sequences. Nat Genet 25, 217-222 (2000).
265. Sakai, N. et al. Molecular cloning and expression of cDNA for murine 
galactocerebrosidase and mutation analysis of the twitcher mouse, a model of 
Krabbe's disease. J  Neuroehem 66, 1118-1124 (1996).
266. Kumar, S., Mattan, N.S. & de Vellis, J. Canavan disease: a white matter disorder. 
Ment Retard Dev Disabil Res Rev. 12, 157-165 (2006).
267. Armstrong, R.C. Isolation and characterization of immature oligodendrocyte lineage 
cells. Methods 16, 282-292 (1998).
196
268. Gritti, A. et al. Multipotential stem cells from the adult mouse brain proliferate and 
self-renew in response to basic fibroblast growth factor. J  Neurosci 16, 1091-1100 
(1996).
269. Capotondo, A. et al. Safety of Arylsulfatase A Overexpression for Gene Therapy of 
Metachromatic Leukodystrophy. Hum Gene Ther [Epub ahead of print] PMID: 
17845130 (2007).
270. Dolcetta, D. et al. Design and optimization o f lentiviral vectors for transfer of 
GALC expression in Twitcher brain. J  Gene Med 8, 962-971 (2006).
271. Merrill, A.H., Jr., Sullards, M.C., Allegood, J.C., Kelly, S. <fc Wang, E. 
Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of 
sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 
207-224 (2005).
272. Martino, S., Emiliani, C., Orlacchio, A., Hosseini, R. & Stirling, J.L. Beta-N-
acetylhexosaminidases A and S have similar sub-cellular distributions in HL-60
cells. Biochim Biophys Acta 1243, 489-495 (1995).
273. Wu, Y.P., Matsuda, J., Kubota, A., Suzuki, K. & Suzuki, K. Infiltration of
hematogenous lineage cells into the demyelinating central nervous system of
twitcher mice. JNeuropathol Exp Neurol 59, 628-639 (2000).
274. Laviola, L., Natalicchio, A. & Giorgino, F. The IGF-I signaling pathway. Curr 
Pharm Des. 13, 663-669 (2007).
275. Kurmasheva, R.T. & Houghton, P. IGF-I mediated survival pathways in normal and 
malignant cells. Biochim Biophys Acta. 1766, 1-22 (2006).
276. Miyaji, M. et al. Role of membrane sphingomyelin and ceramide in platform 
formation for Fas-mediated apoptosis. JExp M ed ia l, 249-259 (2005).
277. Stoica, B.A., Movsesyan, V.A., Knoblach, S.M. & Faden, A.I. Ceramide induces 
neuronal apoptosis through mitogen-activated protein kinases and causes release of 
multiple mitochondrial proteins. Mol Cell Neurosci 29, 355-371 (2005).
197
278. Heinrich, M. et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid- 
mediated caspase-9 and -3 activation. Cell Death Differ 11, 550-563 (2004).
279. Bieberich, E., MacKinnon, S., Silva, J. & Yu, R.K. Regulation of apoptosis during 
neuronal differentiation by ceramide and b-series complex gangliosides. J  Biol 
Chem 276, 44396-44404 (2001).
280. Camandola, S. & Mattson, M.P. Pro-apoptotic action of PAR-4 involves inhibition 
of NF-kappaB activity and suppression o f BCL-2 expression. J  Neurosci Res 61, 
134-139 (2000).
281. Karram, K. et al. NG2-expressing cells in the nervous system revealed by the NG2- 
EYFP-knockin mouse. Genesis 46, 743-757 (2008).
282. Heydemann, A. et al. A minimal c-fes cassette directs myeloid-specific expression 
in transgenic mice. Blood 96, 3040-3048 (2000).
283. Marques, B. et al. Liposome-mediated cellular delivery of active gp91. PLoS ONE 
2, e856 (2007).
284. Yamada, Y. & Takakura, N. Physiological pathway of differentiation of 
hematopoietic stem cell population into mural cells. J  Exp Med 203, 1055-1065
(2006).
285. Gentner, B. et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat 
Methods (2008).
286. Brown, B.D. et al. Endogenous microRNA can be broadly exploited to regulate 
transgene expression according to tissue, lineage and differentiation state. Nat 
Biotechnol 25, 1457-1467 (2007).
287. Rohrbach, M. & Clarke, J.T. Treatment of lysosomal storage disorders : progress 
with enzyme replacement therapy. Drugs 67, 2697-2716 (2007).
288. Brady, R.O. & Schiffmann, R. Enzyme-replacement therapy for metabolic storage 
disorders. Lancet Neurol 3, 752-756 (2004).
198
289.
290.
291.
292.
293.
294.
295.
296.
297.
298.
Hofling, A.A., Devine, S., Vogler, C. & Sands, M.S. Human CD34+ hematopoietic 
progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation 
model of lysosomal storage disease. Mol Ther. 9, 856-865 (2004).
Sands, M.S. et al. Murine mucopolysaccharidosis type VII: long term therapeutic 
effects of enzyme replacement and enzyme replacement followed by bone marrow 
transplantation. J  Clin Invest 99, 1596-1605 (1997).
Galbiati, F. et al. Autonomic denervation of lymphoid organs leads to epigenetic 
immune atrophy in a mouse model of Krabbe disease. J  Neurosci. 27, 13730-13738
(2007).
Campana, W.M., Darin, S.J. & O'Brien, J.S- Phosphatidylinositol 3-kinase and Akt 
protein kinase mediate IGF-I- and prosaptide-induced survival in Schwann cells. . J  
Neurosci Res 57, 332-341 (1999).
Lichtenwalner, R.J., Forbes, M.E., Sonntag, W.E. & Riddle, D.R. Adult-onset 
deficiency in growth hormone and insulin-like growth factor-I decreases survival of 
dentate granule neurons: insights into the regulation of adult hippocampal 
neurogenesis. . JNeurosci Res 83, 199-210 (2006).
Shen, W.H. et al. Tumor necrosis factor alpha inhibits insulin-like growth factor I- 
induced hematopoietic cell survival and proliferation. . Endocrinology 145 (2004). 
Fox, T.E. et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) 
within structured membrane microdomains. JB iol Chem 282, 12450-12457 (2007). 
Hakem, R. et al. Differential requirement for caspase 9 in apoptotic pathways in 
vivo. Cell 94, 339-352 (1998).
Chudakova, D.A. et al. Integrin-associated Lyn kinase promotes cell survival by 
suppressing acid sphingomyelinase activity. J  Biol Chem 283, 28806-28816 (2008). 
Jana, A. & Pahan, K. Oxidative stress kills human primary oligodendrocytes via 
neutral sphingomyelinase: implications for multiple sclerosis. J  Neuroimmune 
Pharmacol 2, 184-193 (2007).
199
299. Lee, J.T. et al. Amyloid-beta peptide induces oligodendrocyte death by activating 
the neutral sphingomyelinase-ceramide pathway. J  Cell Biol 164, 123-131 (2004).
300. Scurlock, B. & Dawson, G. Differential responses of oligodendrocytes to tumor 
necrosis factor and other pro-apoptotic agents: role of ceramide in apoptosis. J  
Neurosci Res 55, 514-522 (1999).
301. Brogi, A., Strazza, M., Melli, M. & Costantino-Ceccarini, E. Induction of 
intracellular ceramide by interleukin-1 beta in oligodendrocytes. J  Cell Biochem 66, 
532-541 (1997).
302. Huang, Y. et al. Elevation of the level and activity of acid ceramidase in 
Alzheimer's disease brain. Eur J  Neurosci 20, 3489-3497 (2004).
303. Betito, S. & Cuvillier, O. Regulation by sphingosine 1-phosphate of Bax and Bad 
activities during apoptosis in a MEK-dependent manner. Biochem Biophys Res 
Commun 340, 1273-1277 (2006).
304. Harada, J., Foley, M., Moskowitz, M.A. & Waeber, C. Sphingosine-1-phosphate 
induces proliferation and morphological changes of neural progenitor cells. J  
Neuroehem 88, 1026-1039 (2004).
305. Boggs, J.M., Gao, W. & Hirahara, Y. Myelin glycosphingolipids, 
galactosylceramide and sulfatide, participate in carbohydrate-carbohydrate 
interactions between apposed membranes and may form glycosynapses between 
oligodendrocyte and/or myelin membranes. Biochim Biophys Acta 1780, 445-455
(2008).
306. Mechtcheriakova, D. et al. Sphingosine 1-phosphate phosphatase 2 is induced 
during inflammatory responses. Cell Signal 19, 748-760 (2007).
307. Rivera, J., Proia, R.L. & Olivera, A. The alliance of sphingosine-1-phosphate and 
its receptors in immunity. Nat Rev Immunol 8, 753-763 (2008).
308. Jin, P. et al. Differentiation of two types of mobilized peripheral blood stem cells by 
microRNA and cDNA expression analysis. J  Transl Med 6, 39 (2008).
2 0 0
ABBREVIATIONS
A A V  A d e n o - a s s o c i a t e d  v e c t o r s
AD A d u l t
ADA-SCID A d e n o s i n e  D e a m in a s e  S e v e r e  C o m b in e d
Im m u n o d e f i c i e n c y
Ad V  Ad e n o v i r a l  v e c t o r s
A L D  A d r e n o l e u k o d y s t r o p h y
A R S A  A r y l s u l f a t a s e  A
ASPA A s p a r t o a c y l a s e
B B B  BLOOD-BRAIN BARRIER
B M  B o n e  m a r r o w
CB C o r d  b l o o d
C e r  C e r a m i d e
CFC COLONY FORMING CELLS
CGD C h r o n i c  G r a n u l o m a t o u s  D i s e a s e
CGT C e r a m i d e - G a l a c t o s y l t r a n s f e r a s e
CHO C h in e s e  H a m s t e r  O v a r y
CNS C e n t r a l  n e r v o u s  s y s t e m
cPPT C e n t r a l  p o l y - p u r i n e  t r a c t
CTS C e n t r a l  t e r m i n a t i o n  s i t e
CXCR4 CXC CHEMOKINE RECEPTOR 4
E B V  EPSTEIN-BARR VIRUS
EEG ELECTROENCEPHALOGRAMS
E l E a r l y  in f a n t il e
ERT E n z y m e  r e p l a c e m e n t  t h e r a p y
F N  FIBRONECTIN
F V V  HFV-DERIVED VECTORS
GAGS G l y c o s a m i n o g l y c a n s
GALC G a l a c t o c e r e b r o s i d a s e
G a l C e r  G a l a c t o s y l c e r a m i d e
G C  G l o b o i d  c e l l s
GFAP GLIAL FIBRILLARY ACIDIC PROTEIN
GLD G l o b o i d  C e l l  L e u k o d y s t r o p h y
G USB ( 3 - g l u c u r o n i d a s e
G vH D  G r a f t - v e r s u s - h o s t  d i s e a s e
G vM  G r a f t - v e r s u s - m a r r o w
H F V  H u m a n  F o a m y  V i r u s
h H S P C  H u m a n  H e m a t o p o ie t ic  s t e m  a n d  p r o g e n it o r  c e l l s
H I V - l  H u m a n  i m m u n o d e f i c i e n c y  v i r u s  1
HSC H e m a t o p o i e t i c  S t e m  C e l l s
HSCT HEMATOPOIETIC STEM CELL TRANSPLANTATION
HSPC HEMATOPOIETIC STEM AND PROGENITOR CELLS
h TERT H u m a n  T e l o m e r a s e  R e v e r s e  T r a n s c r i p t a s e
IDS 2 IDURONATE 2 SULFATASE
ID U A  (X-L-lDURONIDASE
IGF1 I n s u l in e - L i k e  G r o w t h  F a c t o r  1
J Ju v e n il e
L a c C e r  L a c t o s y l c e r a m i d e
L A M P -1 LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN
LI La t e  in f a n t il e
L i n - L i n e a g e  n e g a t i v e
L IN C L  Ce r o id  l i p o f u s c i n o s i s
L SD s L y s o s o m a l  s t o r a g e  d i s o r d e r s
LTC-IC L o n g - t e r m  c u l t u r e - i n i t i a t i n g  c e l l s
LT-HSC LONG TERM HEMATOPOIETIC STEM CELLS
LTR LONG TERMINAL REPEATS
L V  L e n t iv ir a l  v e c t o r s
M 6 P -R  M a n n o s e -6 - p h o s p h a t e  r e c e p t o r
M A P K  AMP-ACTIVATED PROTEIN KINASE
M GD M o n o g a l a c t o s y l d i g l y c e r i d e
MHSPC M u r i n e  H e m a t o p o ie t ic  s t e m  a n d  p r o g e n it o r  c e l l s
MLD MET ACHROMATIC LEUKODYSTROPHY
MLV M o l o n e y  m u r in e  l e u k e m ia  v i r u s
MORV M L V -d e r i v e d  v e c t o r s
MPP MULTIPOTENT PROGENITORS
MPS M u c o p o l y s a c c h a r i d o s i s
MRI M a g n e t i c  r e s o n a n c e  im a g in g
NPC N i e m a n n -P ic k  t y p e  C
NSC N e u r a l  s t e m  c e l l s
PBMC PERIPHERAL BLOOD MONONUCLEAR CELLS
PIC PRE-INTEGRATION COMPLEX
PNS P e r ip h e r a l  n e r v o u s  s y s t e m
P s y P s y c h o s i n e
RFLP Re s t r i c t i o n  f r a g m e n t  l e n g t h  p o l y m o r p h i s m
RV Re t r o v i r u s -b a s e d  v e c t o r s
SIP S p h i n g o s i n e - 1 -P h o s p h a t e
SA S p l ic e  a c c e p t o r
S a p A S a p o s i n e  a
SD S p l ic e  d o n o r
SDF-1 S t r o m a l  c e l l  D e r iv e d  F a c t o r  1
SIN S e l f - I n a c t i v a t i n g
S M  S p h in g o m y e l in
S o  S p h in g o s in e
SOR O x y g e n - r e a c t i v e  s p e c i e s
SPLA2 S e c r e t o r y  p h o s p h o l i p a s e  A2
SRC SCID REPOPULATING CELLS
SRT S u b s t r a t e  r e d u c t i o n  t h e r a p y
ST-HSC S h o r t  t e r m  h e m a t o p o i e t i c  s t e m  c e l l s
TGN T r a n s  G o l g i  n e t w o r k
T P III T o P r o  3
T P P l TRIPEPTIDYL PEPTIDASE 1
T w i T w it c h e r
V C N  V e c t o r  c o p y  n u m b e r
V LA 4 VERY LATE ANTIGEN 4
V SV -G  VESICULAR STOMATITIS VIRUS GLYCOPROTEIN
WPRE WPRE (WOODCHUCK HEPATITIS POST-TRANSCRIPTIONAL
REGULATORY ELEMENT)
X  l i n k e d -S C ID  X -l in k e d  S e v e r e  C o m b i n e d  Im m u n o d e f i c i e n c y
